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ABSTRACT 
This thesis is concerned with image processing methods for multi-nuclear magnetic resonance 
lung images. Specifically, analysis of hyperpolarised gas (3He and 129Xe) and dynamic 
contrast-enhanced proton images is presented. This work is separated into four distinct themes: 
 
1. A semi-automated method of segmenting ventilation-weighted (hyperpolarised gas) 
and proton (anatomical) images is presented. This method is shown to improve 
agreement between observers compared to the current method of manual segmentation. 
 
2. The coefficient of variation is investigated as a marker of ventilation heterogeneity for 
separating healthy volunteers from patients with a range of obstructive disease. The 
effect of image signal-to-noise ratio, kernel size and kernel dimensionality on the 
measures are all investigated, along with the effect of the type of sequence used. 
Furthermore, the difference in metrics acquired from 3He and 129Xe datasets is 
assessed. 
 
3. The effect of inflation level on quantitative metrics of lung function and the 
repeatability of these measures is investigated in healthy volunteers. Additionally, data 
from a small cohort of patients with asthma and cystic fibrosis, acquired at functional 
residual capacity plus 1 litre and total lung capacity, are analysed to show the effect of 
inflation level on metrics in patients. It is shown that lung ventilated volume 
percentage is highly reproducible in healthy volunteers. 
 
4. An analysis pipeline is developed to investigate ventilation and perfusion matching 
using a combination of hyperpolarised gas and dynamic contrast-enhanced MRI. This 
methodology is validated on healthy volunteers and then applied to a small cohort of 
patients with asthma pre and post administration of a bronchodilator, and a small 
cohort of patients with chronic obstructive pulmonary disease. 
 
 
 
 
 
 
iii 
 
LIST OF ABBRVIATIONS 
Abbreviation Definition 
2D Two-dimensional 
3D Three-dimensional 
4D Four-dimensional 
1H Proton 
3He Helium-3 
129Xe Xenon-129 
AIF Arterial input function 
ASL Arterial Spin Labelling 
AUC Area under the curve 
BD Bronchodilator 
BH Breath hold 
BPleth Body plethysmography 
bSSFP Balanced steady state free precession 
CA Contrast agent 
CF Cystic fibrosis 
CNN Cellular neural network 
COPD Chronic obstructive pulmonary disease 
CoV Coefficient of Variation 
CT Computed tomography 
CTEPH Chronic thromboembolic pulmonary hypertension 
CV Coefficient of variation of signal intensity 
CVH Coefficient of variation of signal intensity histogram 
DCE-1H Dynamic contrast enhanced proton 
DLCO Diffusing capacity of the lungs for carbon monoxide 
DSC Dice similarity coefficient 
ERV Expiratory reserve volume 
FA Flip angle 
FB Free breathing 
FCM Fuzzy c-means 
FD Fourier decomposition 
FEV1 Forced expiratory volume in 1 second 
iv 
 
FID Free induction decay 
FOV Field of view 
FRC Functional residual capacity 
FRC+1L Functional residual capacity plus one litre 
FVC Forced vital capacity 
FV Fractional ventilation 
Gd Gadolinium 
GUI Graphical user interface 
HASTE Half-Fourier Acquisition Single-shot Turbo spin Echo imaging 
HA Healthy adults 
HC Healthy children 
HP Hyperpolarised 
HPV Hypoxic pulmonary vasoconstriciton 
HU Hounsfield units 
IC Inspiratory capacity 
ICC Intraclass correlation 
ILD Interstitial lung disease 
IPF Idiopathic pulmonary fibrosis 
IQR Interquartile range 
IRV Inspiratory reserve volume 
LCI Lung clearance index 
LOA Bland-Altman Limits of agreement 
MALF Multi-atlas label fusion 
MBW Multiple breath washout 
MIGET Multiple inert gas elimination technique !" Baseline (equilibrium) magnetisation 
MRI Magnetic resonance imaging 
MR Magnetic resonance 
MTT Mean transit time 
MI Mutual information 
NC Noise corrupted 
NMR Nuclear magnetic resonance 
NSCLC Non-small cell lung carcinoma 
Nslices Number of slices 
v 
 
NN Neural network 
N2 Nitrogen 
OE Oxygen enhanced 
PaO2/PO2 Partial pressure of oxygen 
PaCO2/PCO2 Partial pressure of carbon dioxide 
PBF Pulmonary blood flow 
PBV Pulmonary blood volume 
PE Pulmonary embolism 
PET Positron emission tomography 
PFT Pulmonary function test 
Q Perfusion 
Qvol Perfused volume 
RF Radio frequency 
ROI Region of interest 
R Pearson/Spearman correlation coefficient 
RV Residual volume 
S1/S2 Session 1 or Session 2 
Sacin Measure of ventilation heterogeneity in the acinar airway zone 
Scond Measure of ventilation heterogeneity in the conductive airway zone 
SD Standard deviation 
SENSE Sensitivity encoding 
SFCM Spatial Fuzzy c-means 
Shvol Shunt volume 
SNR Signal to noise ratio 
SPGR Spoiled gradient echo 
SPECT Single photon emission computed tomography 
SSFP Steady state free precession 
SV Specific ventilation 
SVD Singular value decomposition #$ Spin-lattice relaxation time #$," Baseline (equilibrium) spin-lattice relaxation #& Spin-spin relaxation time #&∗  Actual observed spin-spin relaxation time 
TE Echo time 
vi 
 
TLC Total lung capacity 
TLV Total lung volume 
T/R Transmit-Receive 
TRICKS Time resolved imaging of contrast kinetics 
TR Repetition time 
TV Tidal volume 
%VV Lung ventilated volume percentage 
VDP Ventilated defect percentage 
V Ventilation 
V/Q Ventilation-Perfusion ratio 
V⋂Q Ventilated and perfused (intersection) 
VV Ventilated volume 
Vvol Ventilated volume 
WVvol Wasted ventilation volume 
 
vii 
 
TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS ........................................................................................................ i	
ABSTRACT .............................................................................................................................. ii	
LIST OF ABBRVIATIONS ................................................................................................... iii	
TABLE OF CONTENTS ...................................................................................................... vii	
LIST OF TABLES .................................................................................................................. xi	
LIST OF FIGURES .............................................................................................................. xiv	
CHAPTER 1.	 Introduction .................................................................................................. 1	
1.1	 Motivation ............................................................................................................................. 1	
1.2	 Thesis outline ........................................................................................................................ 2	
CHAPTER 2.	 Background theory ...................................................................................... 4	
2.1	 Introduction .......................................................................................................................... 4	
2.2	 Lung physiology and pulmonary function testing ............................................................. 4	
2.2.1	 Lung physiology ................................................................................................................ 4	
2.2.2	 Introduction to lung diseases focused on in this work ....................................................... 7	
2.2.3	 Introduction to pulmonary function tests ........................................................................... 7	
2.3	 Nuclear magnetic resonance and magnetic resonance imaging ..................................... 10	
2.4	 Lung imaging methods ....................................................................................................... 17	
2.4.1	 Computed tomography ..................................................................................................... 17	
2.4.2	 Proton (1H) imaging ......................................................................................................... 19	
2.4.3	 Dynamic contrast enhanced 1H perfusion imaging .......................................................... 21	
2.4.4	 Hyperpolarised gas imaging ............................................................................................. 23	
2.5	 Image registration .............................................................................................................. 26	
CHAPTER 3.	 Development of an image processing pipeline For HP gas and 1H Lung 
Ventilation analysis ................................................................................................................ 29	
3.1	 Introduction ........................................................................................................................ 29	
3.1.1	 1H image segmentation .................................................................................................... 29	
3.1.2	 HP gas image segmentation ............................................................................................. 31	
3.1.3	 Neural networks and clustering methods ......................................................................... 32	
3.2	 Image processing algorithm development ........................................................................ 34	
3.2.1	 Filter choice ...................................................................................................................... 34	
3.2.2	 Spatial Fuzzy C-means methodology .............................................................................. 35	
3.2.3	 FCM or SFCM? ............................................................................................................... 36	
viii 
 
3.2.4	 Noise resilience ................................................................................................................ 38	
3.2.5	 Resilience to HP gas acquisition parameters ................................................................... 39	
3.2.6	 Filter and binary mask threshold values .......................................................................... 41	
3.2.7	 Registration method for breath-to-breath registration ..................................................... 43	
3.3	 Comparison with other methods ....................................................................................... 44	
3.3.1	 Materials and methods ..................................................................................................... 44	
3.3.2	 Image analysis .................................................................................................................. 46	
3.4	 Results .................................................................................................................................. 48	
3.4.1	 3He results ........................................................................................................................ 48	
3.4.2	 129Xe results ...................................................................................................................... 52	
3.5	 Discussion ............................................................................................................................ 55	
3.6	 Conclusion ........................................................................................................................... 56	
CHAPTER 4.	 Histogram-based analysis of ventilation heterogeneity measured by the 
coefficient of variation of signal intensity ............................................................................ 57	
4.1	 Introduction ........................................................................................................................ 57	
4.2	 Calculation of the coefficient of variation of signal intensity (CV) ................................ 60	
4.3	 Effect of image acquisition sequence, signal to noise ratio, kernel size and kernel 
dimensionality on CV ...................................................................................................................... 63	
4.3.1	 Overview .......................................................................................................................... 63	
4.3.2	 Participants and imaging .................................................................................................. 64	
4.3.3	 Imaging sequence effects on CV ..................................................................................... 65	
4.3.4	 SNR effect on CV ............................................................................................................ 66	
4.3.5	 Effect of kernel size on CV .............................................................................................. 74	
4.3.6	 2D vs 3D dimensionality - effect on CV .......................................................................... 79	
4.4	 CVH metrics as a tool to differentiate health from disease ............................................ 82	
4.4.1	 Participants and imaging .................................................................................................. 82	
4.4.2	 Analysis ............................................................................................................................ 82	
4.4.3	 Results .............................................................................................................................. 82	
4.5	 3He vs. 129Xe CVH metrics ................................................................................................. 99	
4.5.1	 Participants ....................................................................................................................... 99	
4.5.2	 Imaging ............................................................................................................................ 99	
4.5.3	 Analysis ............................................................................................................................ 99	
4.5.4	 Results .............................................................................................................................. 99	
4.6	 Discussion and conclusion ................................................................................................ 101	
4.6.1	 Effect of sequence and SNR on CV metrics .................................................................. 102	
4.6.2	 Effect of kernel size on CV metrics ............................................................................... 103	
4.6.3	 Effect of kernel dimensionality on CV metrics ............................................................. 103	
ix 
 
4.6.4	 CV metrics as a tool to differentiate groups .................................................................. 104	
4.6.5	 3He vs. 129Xe CVH metrics ............................................................................................ 106	
4.7	 Conclusion ......................................................................................................................... 106	
CHAPTER 5.	 Assessment of the influence of lung inflation state on the quantitative 
parameters derived from HP gas lung ventilation MRI ................................................... 107	
5.1	 Introduction ...................................................................................................................... 107	
5.1.1	 Review of HP gas methods to assess ventilation heterogeneity at different states of lung 
inflation ....................................................................................................................................... 108	
5.1.2	 Aims of the study ........................................................................................................... 110	
5.2	 Materials and methods ..................................................................................................... 111	
5.2.1	 Participants ..................................................................................................................... 111	
5.2.2	 Study protocol ................................................................................................................ 112	
5.2.3	 Image analysis ................................................................................................................ 114	
5.2.4	 Reproducibility and statistical analysis .......................................................................... 114	
5.3	 Results ................................................................................................................................ 115	
5.3.1	 Repeatability in healthy volunteers ................................................................................ 116	
5.3.2	 Comparison with body plethysmography values ........................................................... 127	
5.3.3	 Results of multiple inflation analysis using hyperpolarised 129Xe ................................. 129	
5.3.4	 The effect of inflation level on MRI-based measures of lung function demonstrated in 
patients with CF and asthma ....................................................................................................... 135	
5.4	 Discussion .......................................................................................................................... 141	
5.5	 Conclusion ......................................................................................................................... 143	
CHAPTER 6.	 Quantitative measurement of the Ventilation-Perfusion ratio using HP 
gas and DCE-1H lung MRI ................................................................................................. 144	
6.1	 Introduction ...................................................................................................................... 144	
6.1.1	 Review of PFT and imaging methods to analyse V/Q in the lung ................................. 145	
6.2	 Quantitative perfusion analysis theory ........................................................................... 150	
6.3	 Materials and methods ..................................................................................................... 157	
6.3.1	 Participant selection ....................................................................................................... 157	
6.3.2	 Imaging .......................................................................................................................... 158	
6.3.3	 Image analysis ................................................................................................................ 159	
6.4	 Results ................................................................................................................................ 163	
6.4.1	 Healthy volunteers ......................................................................................................... 163	
6.4.2	 Patients with asthma – pre and post bronchodilator administration .............................. 166	
6.4.3	 Patients with COPD ....................................................................................................... 170	
6.5	 Discussion .......................................................................................................................... 175	
6.6	 Conclusion ......................................................................................................................... 176	
x 
 
CHAPTER 7.	 Conclusions and future work .................................................................. 177	
7.1	 Summary of the thesis and conclusions .......................................................................... 177	
7.2	 Future work ...................................................................................................................... 178	
LIST OF PUBLICATIONS ................................................................................................. xxi	
REFERENCES ..................................................................................................................... xxv	
 
  
xi 
 
LIST OF TABLES 
Table 2.1 Properties of nuclei used in this work [137-140, 39, 141] ....................................... 11	
Table 3.1 Ventilated volume values obtained in 3He and 129Xe data using FCM and SFCM 
methods .................................................................................................................................... 37	
Table 3.2 Comparison of original and noise corrupted (NC) 3He image SNR ........................ 38	
Table 3.3 Comparison of original and noise corrupted (NC) 3He image masks using SFCM, 
FCM and K-means methods. ................................................................................................... 38	
Table 3.4 Imaging parameters for the data used to compare sequence type effect on the SFCM 
output ....................................................................................................................................... 40	
Table 3.5 Ventilated volume (L) values obtained from SPGR and SSFP sequences .............. 40	
Table 3.6 Filter values determined through experimentation .................................................. 41	
Table 3.7 Values used in the SFCM segmentation algorithm ................................................. 41	
Table 3.8 Imaging parameters for the scans used in this work. TR = Repetition time, TE = 
echo time, FA = flip angle ....................................................................................................... 45	
Table 3.9 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 3He data. 50	
Table 3.10 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 3He data 
(inter-method). ......................................................................................................................... 50	
Table 3.11 Friedman test results when comparing global %VV values for 3He data .............. 51	
Table 3.12 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 129Xe data 
(inter-method).  VV and TLV in litres ..................................................................................... 53	
Table 3.13 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 129Xe data 
(inter-method).  VV and TLV in litres ..................................................................................... 54	
Table 3.14 Friedman test results when comparing global %VV values for 129Xe data ........... 55	
Table 4.1 Subject overview ...................................................................................................... 64	
Table 4.2 Imaging parameters for the 3D and 2D scans used in this work. ............................ 64	
Table 4.3 P-values returned by the multiple comparisons of the Friedman test comparing each 
SNR level to the control (100% SNR) ..................................................................................... 68	
Table 4.4 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD 
groups, as well as Mann-Whitney results comparing the healthy children and CF group using 
CV metrics. Results are calculated using a kernel size of 3 voxels and the standard measure of 
lung function in pulmonary MRI, VDP ................................................................................... 83	
Table 4.5 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD 
groups and the Mann-Whitney results comparing the healthy children and CF group using CV 
metrics calculated using a kernel size of 5 voxels ................................................................... 85	
xii 
 
Table 4.6 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD 
groups and the Mann-Whitney results comparing the healthy children and CF group using CV 
metrics calculated using a kernel size of 7 voxels ................................................................... 86	
Table 4.7 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD 
groups and the Mann-Whitney results comparing the healthy children and CF group using CV 
metrics calculated using a kernel size of 9 voxels ................................................................... 88	
Table 4.8 Kruskal-Wallis test results comparing groups using 2D and 3D CV metrics ......... 90	
Table 4.9 Mean, median and 95th percentile values derived from mean histograms ............... 96	
Table 4.10 Kruskal-Wallis/One-way ANOVA test results comparing the healthy adults to the 
asthmatic and COPD groups and the unpaired t-test results comparing the healthy children 
and CF group using area under the curve of the CV histogram ............................................... 97	
Table 5.1 Patient demographics for the multiple inflation level study .................................. 111	
Table 5.2 Gas doses for 3He acquisitions ............................................................................... 112	
Table 5.3 Gas doses for 129Xe acquisitions ............................................................................ 113	
Table 5.4 Mean CoV for TLV, VV and %VV over all volunteers between each session ..... 119	
Table 5.5 CV metrics CoV over all volunteers between each session ................................... 119	
Table 5.6 %∆ of TLV, VV and %VV over both sessions for all volunteers ......................... 120	
Table 5.7 %∆ of CVH metrics generated from the VV mask ................................................ 121	
Table 5.8 %∆ of CVH metrics generated from the TLV mask .............................................. 121	
Table 5.9 Results of the inter-session voxel-wise Spearman correlation .............................. 121	
Table 5.10 Results of the voxel-wise correlation of all other inflation levels to FRC+1L from 
the first imaging session ......................................................................................................... 122	
Table 5.11 Results of the voxel-wise correlation of all other inflation levels to FRC+1L from 
the second imaging session .................................................................................................... 122	
Table 5.12 P-value comparing TLV, VV and %VV .............................................................. 123	
Table 5.13 P-value comparing CVH metrics generated from the VV mask between each 
session .................................................................................................................................... 123	
Table 5.14 P-values comparing CVH metrics generated from the TLV mask between each 
session .................................................................................................................................... 123	
Table 5.15 Mean absolute %∆ of median CV between FRC+1L and all other lung volumes
................................................................................................................................................ 124	
Table 5.16 Volume difference between MRI derived measures and body plethysmography 
measures ................................................................................................................................. 128	
Table 5.17 P-values comparing Body plethysmography and sessions 1 and 2 (S1/S2) lung 
volumes .................................................................................................................................. 128	
xiii 
 
Table 5.18 Mean CoV over all volunteers between each session .......................................... 131	
Table 5.19 CV metrics CoV over all volunteers between each session ................................. 131	
Table 5.20 Comparison of %∆ of TLV, VV and %VV calculated using 129Xe and 3He datasets
................................................................................................................................................ 132	
Table 5.21 %∆ of CVH metrics generated from the VV and TLV masks ............................. 133	
Table 5.22 Wilcoxon matched-pairs results of comparing metrics at FRC+1L and TLC in all 
cohorts analysed using CV metrics generated from both the VV and TLV masks ............... 139	
Table 5.23 Results of the Kruskal-Wallis test comparing healthy volunteers to the patient 
cohorts .................................................................................................................................... 140	
Table 6.1 Patient and volunteer demographics ...................................................................... 158	
Table 6.2 Imaging parameters for the sequences used in this work. ..................................... 158	
Table 6.3 Healthy volunteer V and Q metrics ....................................................................... 163	
Table 6.4 Mean values of PBV, FV and V/Q for the three healthy volunteers ..................... 164	
Table 6.5 MI and overlap area of histograms for healthy volunteers .................................... 165	
Table 6.6 Asthmatic V and Q metrics pre and post bronchodilator ....................................... 166	
Table 6.7 Mean values of PBV and FV for the asthmatic patients ........................................ 167	
Table 6.8 MI and overlap area of histograms for patients with asthma ................................. 169	
Table 6.9 COPD V and Q metrics ......................................................................................... 170	
Table 6.10 Mean values of PBV, FV and V/Q for the patients with COPD ......................... 171	
Table 6.11 MI and overlap area of histograms for patients with COPD ............................... 172	
Table 6.12 P-values from the Kruskal-Wallis multiple comparisons test comparing patient 
groups to healthy volunteers .................................................................................................. 174	
Table 6.13 Wilcoxon matched-pairs signed rank test results ................................................ 174	
 
 
 
 
 
 
 
xiv 
 
LIST OF FIGURES 
Figure 2.1 Basic illustrations of airway structure ...................................................................... 5	
Figure 2.2 Three-compartment model of perfusion shunt, gas exchange and wasted ventilation.
.................................................................................................................................................... 6	
Figure 2.3 Example normal spirogram demonstrating the lung volume subdivisions. ............. 8	
Figure 2.4 Example result of a multiple breath washout test in a child with cystic fibrosis. .... 9	
Figure 2.5 Basic illustration of expirogram acquired during a multiple breath washout test. . 10	
Figure 2.6 Graphical representation of the Zeeman splitting effect. ....................................... 12	
Figure 2.7 Simple graphical representation of RF excitation in the rotating frame of reference.
.................................................................................................................................................. 14	
Figure 2.8 (a) Example HP 3He ventilation slices from a healthy adults’ dataset and (b) 
example 1H slices from a patient with early stage cystic fibrosis datasets. ............................. 16	
Figure 2.9 Example CT images showing the high resolution capability and structural 
abnormalities in (a) a patient with IPF and (b) a patient with CF. ........................................... 17	
Figure 2.10 Example of CT images used to generate ventilation metrics. .............................. 18	
Figure 2.11 Example V, Q and V/Q quotient images from a SPECT image. .......................... 18	
Figure 2.12 Different examples of 1H images from patients ................................................... 20	
Figure 2.13 Basic illustration of a bolus passage of contrast agent in a single voxel and the 
image acquisition over time ..................................................................................................... 22	
Figure 2.14 Example slice and signal time course plots. ......................................................... 23	
Figure 2.15 Diagrammatic illustration of xenon solubility in tissue. ...................................... 24	
Figure 2.16 Example of the equipment used in this work. ...................................................... 24	
Figure 2.17 Example ventilation images from a patient with CF. ........................................... 26	
Figure 3.1 Example segmentation output from FCM and SFCM methods. ............................ 37	
Figure 3.2 Example slices from a HP 3He ventilation image with and without noise corruption 
and the overlap of their respective masks. ............................................................................... 39	
Figure 3.3 Example SPGR and SSFP images from a healthy volunteer. ................................ 40	
Figure 3.4 (a) Workflow for SFCM image segmentation; ....................................................... 42	
Figure 3.5 Registration workflow developed for breath-to-breath registration. ...................... 43	
Figure 3.6 Example K-means clustering algorithm output. ..................................................... 47	
Figure 3.7 Plot of global values of %VV for all 6 patients scanned with 3He ......................... 48	
Figure 3.8 Plot of global values of TLV for all 6 patients scanned with 3He .......................... 48	
Figure 3.9 Plot of global values of VV for all 6 patients scanned with 3He ............................ 49	
Figure 3.10 Bland-Altman analysis of 3He %VV on a slice-by-slice basis. ........................... 51	
xv 
 
Figure 3.11 Plot of global values of %VV for all 6 patients scanned with 129Xe .................... 52	
Figure 3.12 Plot of global values of TLV for all 6 patients scanned with 129Xe ..................... 52	
Figure 3.13 Plot of global values of VV for all 6 patients scanned with 129Xe ....................... 53	
Figure 3.14 Bland-Altman analysis of 129Xe %VV on a slice-by-slice basis. ......................... 54	
Figure 4.1 Graphical representation of (a) skewness, (b) kurtosis and (c) the IQR ................ 60	
Figure 4.2 Example histograms and CV maps from a healthy subjects 2D SPGR 3He image 
with (red) and without (blue) edge removal ............................................................................ 61	
Figure 4.3 Example images showing local heterogeneity not visible on the ventilated volume 
mask. ........................................................................................................................................ 62	
Figure 4.4 Example images showing regions included when calculating CV on the ventilated 
volume mask and the total lung volume mask from a patient with COPD. ............................. 62	
Figure 4.5 Example images from HA5 used to determine the effect of SNR on CV metrics. 67	
Figure 4.6 HA cohort average values CV metrics plotted as a function of SNR. ................... 67	
Figure 4.7 HA cohort average histograms for all 6 SNR levels generated from the (a) VV 
mask and (b) TLV mask .......................................................................................................... 68	
Figure 4.8 Example images from a patient with asthma used to determine the effect of SNR 
on CV metrics. ......................................................................................................................... 69	
Figure 4.9 Asthma_clinical cohort average values CV metrics plotted as a function of SNR. 70	
Figure 4.10 Asthma_clinical cohort average histograms for all 6 SNR levels generated from 
the (a) VV mask and (b) TLV mask ........................................................................................ 70	
Figure 4.11 Example images from a patient with COPD used to determine the effect of SNR 
on CV metrics. ......................................................................................................................... 71	
Figure 4.12 COPD cohort average values CV metrics plotted as a function of SNR. ............. 71	
Figure 4.13 COPD cohort average histograms for all 6 SNR levels levels generated from the 
(a) VV mask and (b) TLV mask .............................................................................................. 72	
Figure 4.14 Example images from a patient with CF used to determine the effect of SNR on 
CV metrics. .............................................................................................................................. 72	
Figure 4.15 CF cohort average values CV metrics plotted as a function of SNR. .................. 73	
Figure 4.16 CF cohort average histograms for all 6 SNR levels generated from the (a) VV 
mask and (b) TLV mask .......................................................................................................... 73	
Figure 4.17 Examples of the original image and CV maps after increasing the kernel size from 
a patient with COPD. ............................................................................................................... 74	
Figure 4.18 CV histograms generated using different kernel sizes from a patient with COPD 
generated using the (a) VV mask and (b) TLV mask .............................................................. 75	
xvi 
 
Figure 4.19 Plots of median CV for different kernel sizes for all groups generated from the 
VV mask. ................................................................................................................................. 75	
Figure 4.20 Plots of median CV for different kernel sizes for all groups generated from the 
TLV mask. ............................................................................................................................... 76	
Figure 4.21 Plots of CVH skewness at different kernel sizes for each of the groups of subjects 
imaged generated from the VV mask. ..................................................................................... 76	
Figure 4.22 Plots of CVH skewness at different kernel sizes for each of the groups of subjects 
imaged generated from the TLV mask. ................................................................................... 77	
Figure 4.23 Plots of CVH kurtosis at different kernel sizes for all groups generated from the 
VV mask. ................................................................................................................................. 77	
Figure 4.24 Plots of CVH kurtosis at different kernel sizes for all groups generated from the 
TLV mask. ............................................................................................................................... 78	
Figure 4.25 Plots of CVH IQR at different kernel sizes for each of the groups of subjects 
imaged generated from the VV mask. ..................................................................................... 78	
Figure 4.26 Plots of CVH IQR at different kernel sizes for each of the groups of subjects 
imaged generated from the TLV mask. ................................................................................... 79	
Figure 4.27 Example slices of a 3D ventilation image dataset and the corresponding CV maps 
generated from 2 and 3 dimensional kernels and the VV mask generated from a healthy 
volunteer (a-c) a patient with COPD (d-f) and a patient with asthma (g-i). ............................ 80	
Figure 4.28 Example histograms for the HA, asthma and COPD patients shown in Figure 4.27 
generated using the (a) VV mask and (b) the TLV mask ........................................................ 80	
Figure 4.29 Plots of CV metrics for 2D and 3D CV calculation for all groups analysed 
generated from VV (a-d) and TLV(e-h) masks. ...................................................................... 81	
Figure 4.30 Plots of CV metrics for all groups analysed generated using a kernel size of 3 
voxels generated from VV (a-d) and TLV(f-i) masks. ............................................................ 83	
Figure 4.31 Plots of CV metrics for all groups analysed generated using a kernel size of 5 
voxels generated from VV (a-d) and TLV(e-h) masks. ........................................................... 84	
Figure 4.32 Plots of CV metrics for all groups analysed generated using a kernel size of 7 
voxels generated from the VV (a-d) and TLV(e-h) masks. ..................................................... 86	
Figure 4.33 Plots of CV metrics for all groups analysed generated using a kernel size of 9 
voxels generated from the VV (a-d) and TLV(e-h) masks. ..................................................... 87	
Figure 4.34 Spearman correlations of coefficient of variation histogram metrics with LCI 
generated from VV (a-d) and TLV(e-h) masks. ...................................................................... 92	
Figure 4.35 Spearman correlations of coefficient of variation histogram metrics with Scond 
generated from VV (a-d) and TLV(e-h) masks. ...................................................................... 92	
xvii 
 
Figure 4.36 Spearman correlations of coefficient of variation histogram metrics with Sacin 
generated from VV (a-d) and TLV(e-h) masks. ...................................................................... 93	
Figure 4.37 Spearman correlations of coefficient of variation histogram metrics with FEV1 
generated from VV (a-d) and TLV(e-h) masks. ...................................................................... 93	
Figure 4.38 Spearman correlations of coefficient of variation histogram metrics with the 
FEV1/FVC ratio generated from VV (a-d) and TLV(e-h) masks. ........................................... 94	
Figure 4.39 Histograms of all healthy children analysed along with the mean histogram 
generated from the population distributions. ........................................................................... 95	
Figure 4.40 Histograms of all healthy adults analysed along with the mean histogram 
generated from the population distributions. ........................................................................... 95	
Figure 4.41 Plots of area under the histogram curve using the thresholds listed in Table 4.9 
generated from the VV mask (a-c) and TLV mask (d-f). ........................................................ 96	
Figure 4.42 Spearman correlations of the area under the curve of the CV histogram generated 
from the VV mask with (a) LCI, (b) Scond, (c) Sacin, (d) FEV1 % predicted and (e) FEV1/FVC 
ratio .......................................................................................................................................... 98	
Figure 4.43 Spearman correlations of the area under the curve of the CV histogram generated 
from the TLV mask with (a) LCI, (b) Scond, (c) Sacin, (d) FEV1 % predicted and (e) FEV1/FVC 
ratio .......................................................................................................................................... 98	
Figure 4.44 Plots of CV metrics for all NSCLC patients analysed generated from the VV 
mask (a-d) and TLV mask (e-h). ............................................................................................ 100	
Figure 4.45 Average histograms for NSCLC patients comparing 3He and 129Xe CVH values 
generated from the (a) VV mask and (b) TLV mask ............................................................. 100	
Figure 4.46 Plots of 3He and 129Xe SNR for NSCLC patients. .............................................. 101	
Figure 4.47 Example slices from an uncorrected 3He and bias field corrected image from a 
healthy volunteer. ................................................................................................................... 101	
Figure 4.48 Plots of SNR values for the three healthy adults scanned on the same day with 
SPGR and SSFP and the healthy adults scanned with a 2D SPGR sequence and the 
asthma_norm and asthma_abnorm cohorts. ........................................................................... 104	
Figure 4.49 Example CV maps generated using the (a) VV mask and (b) the TLV mask from 
a ptient with CF ...................................................................................................................... 105	
Figure 5.1 Breathing manoeuvres and acquisition volumes. ................................................. 112	
Figure 5.2 Workflow of image segmentation and CV metric calculation from the VV mask.
................................................................................................................................................ 114	
Figure 5.3 Example slices from all 6 healthy volunteers’ datasets (acquired with HP 3He). 116	
xviii 
 
Figure 5.4 Plot of total lung volume at each inflation level from the 6 healthy adults scanned 
here. ........................................................................................................................................ 117	
Figure 5.5 Plot of ventilated lung volume at each inflation level from the 6 healthy adults 
scanned here. .......................................................................................................................... 117	
Figure 5.6 Plot of %VV at each inflation level from the 6 healthy adults scanned here. ...... 118	
Figure 5.7 Plot of median CV at each inflation level from the 6 healthy adults scanned here 
generated using the (a) VV mask and (b) the TLV mask. ..................................................... 118	
Figure 5.8 Bland-Altman plots of (a) TLV, (b) VV and (c) %VV for all 6 volunteers ......... 119	
Figure 5.9 Bland-Altman plots of CVH metrics generated from the VV mask (a-d) and TLV 
mask (e-h). ............................................................................................................................. 120	
Figure 5.10 Example of differences seen in HP 3He images acquired at RV, RV+1L and 
FRC+1L (posterior slices). .................................................................................................... 124	
Figure 5.11 Plots of median CV per slice generated from the VV mask for all 6 healthy 
volunteers’ images obtained with HP 3He during imaging session 1. ................................... 125	
Figure 5.12 Plots of median CV per slice generated from the TLV mask for all 6 healthy 
volunteers’ images obtained with HP 3He during imaging session 1. ................................... 126	
Figure 5.13 Plots of SNR per slice for all 6 healthy volunteers’ images obtained with HP 3He 
during imaging session 1. ...................................................................................................... 126	
Figure 5.14 Plot of lung volumes measured using body plethysmography and MRI. ........... 127	
Figure 5.15 Example slices from all five inflation levels in all three healthy volunteers 
scanned with both HP 3He and HP 129Xe. .............................................................................. 129	
Figure 5.16 Plots comparing the SNR from each session using 129Xe and 3He for the three 
volunteers analysed using both gases. ................................................................................... 130	
Figure 5.17 Bland-Altman plots of (a) TLV, (b) VV and (c) %VV for all 3 volunteers ....... 131	
Figure 5.18 Bland-Altman plots of CVH metrics generated from the VV mask (a-d) and TLV 
mask (e-h). ............................................................................................................................. 132	
Figure 5.19 Plots of TLV, VV and %VV 129Xe and 3He datasets. (a) TLV, (b) VV and 
(c) %VV. ................................................................................................................................ 133	
Figure 5.20 Plots of median CV generated from the (a) VV mask and (b) TLV mask. ........ 133	
Figure 5.21 Scatter plots comparing (a) TLV, (b) VV and (c) %VV generated from images 
acquired with 129Xe and 3He .................................................................................................. 134	
Figure 5.22 Scatter plots comparing (a) median CV generated from the VV mask and (b) 
median CV generated from the TLV mask from images acquired with 129Xe and 3He ........ 134	
Figure 5.23 Plots of all metrics at both inflation levels analysed for all cohorts generated from 
the VV mask. ......................................................................................................................... 135	
xix 
 
Figure 5.24 Plots of all CV metrics analysed at both inflation levels analysed for all cohorts 
generated from the TLV mask. .............................................................................................. 136	
Figure 5.25 Example slices from datasets acquired at FRC+1L and TLC. ........................... 136	
Figure 5.26 Change in VDP for all cohorts analysed ............................................................ 137	
Figure 5.27 CVH Skewness change from FRC+1L to TLC for all cohorts generated from the 
(a) VV mask and (b) TLV mask ............................................................................................ 137	
Figure 5.28 Example histograms for the datasets shown in Figure 5.25. .............................. 138	
Figure 5.29 CV Kurtosis change from FRC+1L to TLC for all cohorts from the (a) VV mask 
and (b) TLV mask .................................................................................................................. 138	
Figure 5.30 CV IQR change from FRC+1L to TLC for all cohorts from the (a) VV mask and 
(b) TLV mask ......................................................................................................................... 139	
Figure 6.1 Simulated curves of relative signal enhancement as a function of concentration of 
contrast agent. ........................................................................................................................ 153	
Figure 6.2 Simulated curves showing the effect of including/excluding the T2* component (a) 
over a large range of contrast concentrations and (b) an enhanced view of concentrations of 0-
5 mmol/litre ............................................................................................................................ 153	
Figure 6.4 Basic representation of the workflow used to analyse V and Q images. ............. 160	
Figure 6.5 Example slices from a healthy volunteers (a) FV map, (b) PBV map and (c) V/Q 
map ......................................................................................................................................... 163	
Figure 6.6 Example axial slices from a HV1s FV and PBV maps. (a) FV slice and (b) PBV 
slice ........................................................................................................................................ 164	
Figure 6.7 FV and PBV histograms from all three healthy volunteers. ................................. 165	
Figure 6.8 Example images from an asthmatic (A1) pre and post bronchodilator 
administration. (a) FV pre, (b) PBV pre, (c) V/Q pre, (d) FV post, (e) PBV post and (f) V/Q 
post ......................................................................................................................................... 166	
Figure 6.9 Change in %Vvol, %Qvol and %V∩Q pre and post bronchodilator. (a) %Vvol, (b) %Qvol and (c) %V∩Q ........................................................................................................... 167	
Figure 6.10 Change in PBV, FV and V/Q pre and post bronchodilator. (a) FV, (b) PBV and (c) 
V/Q ......................................................................................................................................... 168	
Figure 6.11 Example axial slices form patient A1. (a) FV pre, (b) FV post, (c) PBV pre and (d) 
PBV post ................................................................................................................................ 168	
Figure 6.12 Example FV and PBV histograms for all patients with asthma. ........................ 169	
Figure 6.13 Example slices from a patient with COPD (COPD3) (a) FV map, (b) PBV map 
and (c) V/Q map ..................................................................................................................... 170	
xx 
 
Figure 6.14 Example axial slices from patient COPD3s FV and PBV maps. (a) FV slice and 
(b) PBV slice .......................................................................................................................... 171	
Figure 6.15 Example FV and PBV histograms for all patients with COPD. ......................... 172	
Figure 6.16 V and Q metrics for all cohorts analysed. .......................................................... 173	
Figure 6.17 %Shunt and %WVvol obtained from all cohorts analysed. ................................. 173	
Figure 6.18 Plots of mean FV, PBV and V/Q along with MI and overlap area for all cohorts 
analysed. ................................................................................................................................. 174	
 1 
CHAPTER 1. INTRODUCTION 
1.1 Motivation 
Respiratory diseases affect a large portion of the world’s population [1-4] and affect the lung 
in different ways through functional impairment. Many of these diseases are progressive (e.g. 
cystic fibrosis, idiopathic pulmonary fibrosis and cancer) and require longitudinal monitoring 
to evaluate response to treatment. Pulmonary function tests such as spirometry [5] and 
multiple breath washout [6, 7] are the clinical standards for analysing lung function, however 
these methods give only a global overview of the lung as does the gold standard of ventilation 
and perfusion analysis, the multiple inert gas elimination technique [8]. Clinical imaging to 
assess these diseases’ effect on ventilation and/or perfusion usually makes use of ionizing 
radiation (nuclear scintigraphy [9-15], computed tomography [16-26] or single photon 
emission computed tomography [27-32]) and is not desirable for these longitudinal 
assessments due to the radiation doses. Additionally, early detection and sensitivity to disease 
is important in a number of conditions, such as cystic fibrosis [33], and any technique 
developed for assessing the respiratory system needs to have this capability. 
 
Magnetic Resonance Imaging (MRI) is a non-ionizing imaging modality that is able to assess 
structure [34] and has been used in the clinic to analyse the brain [35] and abdomen [36] for 
many years. The main attraction is the excellent soft tissue contrast, ability to weight images 
differently and also for being able to detect the flow of blood or acquire diffusion-weighted 
images in a single protocol [37-42]. Lung function can also be measured using proton MRI, 
with the addition of a contrast agent, such as oxygen to generate ventilation images [43-45] or 
gadolinium-based contrast agents to assess perfusion [46-55].  
 
Lung function can also be assessed by using hyperpolarised gas MRI [56-71, 33] with 
numerous analysis techniques existing to derive different measures. With improvements in 
both sequences [72-74] and hardware [75, 76] for imaging with hyperpolarised gases this 
technique has recently been adopted into the clinic in Sheffield. The common method of 
analysing these images is by analysing lung ventilation volume percent; the ratio of ventilated 
volume (from hyperpolarised gas images) to total lung volume (from proton anatomical 
images) or its counterpart ventilation defect percent. These metrics have previously been used 
to detect early obstructive changes in the lungs of smokers [77], detect sub-clinical cystic 
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fibrosis [33], compare ventilation acquisitions pre and post treatment in asthmatics [63], 
assess exercise-induced bronchoconstriction [78] and assess treatment efficiency in cystic 
fibrosis patients [79]. Respiratory diseases may also affect the pulmonary vasculature leading 
to decreased perfusion and poor gas exchange [80, 81]. Using Dynamic contrast-enhanced 
proton MRI the distribution of blood volume and flow may be probed using quantitative 
modelling [82, 83] adding to the analysis of respiratory disease using MRI. 
1.2 Thesis outline 
The development and evaluation of image processing techniques for analysis of the lung is the 
focus of this thesis with the main modalities being anatomical proton imaging, hyperpolarised 
gas (Helium-3 and Xenon-129) ventilation imaging and dynamic contrast-enhanced proton 
imaging. This thesis will focus on the application of image registration [84], segmentation and 
development of novel image processing pipelines. The tools developed are evaluated with 
lung imaging data from healthy volunteers and patients and are also used to investigate 
physiological hypotheses. 
 
Chapter 2 introduces an overview of the basics of imaging using magnetic resonance and the 
underlying principles of nuclear magnetic resonance. A brief description of lung physiology 
and pulmonary function tests are presented. 
 
Chapter 3 presents the method developed for semi-automated lung ventilated volume 
percentage analysis during this PhD. The main focus of this chapter is the comparison of the 
developed method to manual segmentation and also to a well-known K-means method [62]. 
 
Chapter 4 investigates the use of the coefficient of variation of ventilation images as a 
possible biomarker in differentiating ventilation heterogeneity in healthy volunteers from 
patients. Additionally, markers from the coefficient of variation histograms usefulness in 
separating health from disease were investigated. Differences between two and three-
dimensional analysis are reported as well as differences caused by the kernel size, gas 
properties of Helium-3 and Xenon-129 and image signal to noise ratio. 
 
Chapter 5 investigates the reproducibility of quantitative metrics of lung function at different 
inflation levels in healthy volunteers using both Helium-3 and Xenon-129. Additionally, the 
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effect of the inflation level on quantitative regional metrics of lung function is investigated in 
diseased lungs. 
 
Chapter 6 introduces a method to analyse the ventilation-perfusion ratio using a combination 
and fusion of hyperpolarised gas and dynamic contrast-enhanced proton MRI. An image-
processing pipeline was developed to spatially register all images and allow for a voxel-by-
voxel comparison of ventilation and perfusion. Healthy volunteers, patients with asthma and 
patients with chronic obstructive pulmonary disease were then analysed using this 
methodology.  
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CHAPTER 2. BACKGROUND THEORY 
2.1 Introduction 
This chapter of the thesis provides a basic introduction into the fundamental principles 
underpinning this work. The basics of lung physiology, with some specific details on the 
diseases of patients analysed in this work, and pulmonary function tests (PFTs) are presented. 
A basic overview of nuclear magnetic resonance (NMR) and magnetic resonance imaging 
(MRI) theory is discussed along with the specific acquisition strategies used in this work for 
hyperpolarised (HP) gas ventilation and Dynamic contrast enhanced proton (DCE-1H) 
perfusion MRI. Methods of image registration are also discussed. 
2.2 Lung physiology and pulmonary function testing 
2.2.1 Lung physiology 
The lungs are located in the thoracic cavity. Each lung has its own pleural space and is 
protected by two pleurae (serous membranes; the parietal pleura, which covers the chest wall 
and mediastinum and the visceral pleura, which covers the lungs). In between the pleurae is a 
fluid that allows smooth movement when breathing [85, 86]. Generally the right lung will be 
larger than the left due to the fact that the heart is on the left side and occupies some of the 
space that would otherwise be taken up by the lung [86]. The lungs are supplied blood by the 
pulmonary and bronchial arteries, however it should be noted that gas exchange is only 
affected by the pulmonary arteries as the bronchial arteries generally do not take part in gas 
exchange [87, 88].  
 
Figure 2.1a shows how the trachea splits into bronchi, the bronchi into lobar bronchi and so 
on all the way down to the alveoli. The full respiratory tract can be considered as having two 
sections, the upper (conductive) and lower (transit and respiratory) section [89]. Figure 2.1b 
shows the terminal bronchioles (TB, the final section of the non-respiratory zone), 3 
generations of respiratory bronchioles (RB, bronchioles connecting TB to alveoli (Alv small 
air sacs)), a single alveolar duct (AD, small intralobular ducts), atrium (Atr, the end of an 
alveolar duct) and alveoli [90]. 
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Figure 2.1 Basic illustrations of airway structure (a) Airway generations (known as Weibels tree) and (b) 
an illustration of the respiratory zone. Reprinted with permission from [89] 
http://www.lww.co.uk/respiratory-physiology and (b) reprinted with permission from [90] TB = terminal 
bronchiole, RB = respiratory bronchiole, Alv = alveoli, AD = alveolar duct and Atr = ending of alveolar 
duct. 
 
The primary function of the lung is to facilitate gas exchange [89] which, in basic terms, 
allows oxygen (O2) from the air to move into the blood whilst carbon dioxide (CO2) is 
transferred to the exhaled air [89]. Gas exchange is controlled by the diffusion of the O2 and 
CO2 from an area of high pressure to an area of lower pressure [89]. The lungs’ anatomy 
allows for good gas exchange due to the extremely thin blood-gas barrier [89]. The matching 
of ventilation (V) and perfusion (Q) in the lungs is essential for good gas exchange in the lung. 
 
In the healthy lung, due to gravitational effects and the vascular and airway tree geometry it is 
reported that the ventilation-perfusion ratio (V/Q) will be in the range of 0.3-2.0 [81], in the 
upright position. In a healthy lung, the airways, pulmonary vasculature and membranes allow 
efficient gas exchange whereas pulmonary diseases will affect the lung in different ways. For 
example cystic fibrosis (CF) and asthma will increase the airway resistance resulting in 
obstructed airflow, whilst other diseases may affect the vasculature, reducing perfusion [91] 
and some diseases may have an effect on both the vasculature and airways, which in turn, 
means the ability to maintain efficient gas exchange is affected [92-94, 90, 68, 64, 95, 96, 81]. 
The reason behind this is that gas exchange relies on ventilation and perfusion, and having a 
ventilation and perfusion that is matched at the alveolar level (ideally V/Q = 1)[97]. Any 
detrimental change to V or Q therefore causes a mismatch in V/Q.  
Copyright	material	– see	reference
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Figure 2.2 shows the well-known three-compartment model used to represent the lung, 
describing perfusion shunt (left), a compartment where ventilation and perfusion take place 
(middle) and a compartment where there is no perfusion but ventilation. 
 
 
Figure 2.2 Three-compartment model of perfusion shunt, gas exchange and wasted ventilation. 
(Reproduced with permission of the European Respiratory Society © Eur Respir J October 2014 44:1023-
1041; published ahead of print July 25, 2014, doi:10.1183/09031936.00037014 
(dx.doi.org/10.1183/09031936.00037014)) 
 
Where: 456 – minute ventilation; 457  – alveolar ventilation; 859– total blood flow; 85:– blood flow in shunt; 45;  – dead space; <=>?5  – regional ratio of alveolar ventilation to 
perfusion 
 
One form of impaired gas exchange can be characterised by perfusion shunt and low V/Q, 
meaning that there is no ventilation reaching the alveoli but venous admixture is passing 
through. Low V/Q can lead to hypoxemia, a low arterial oxygen tension (PaO2<80mmHg) 
[98], but it must also be noted that diffusion limitation or hypoventilation can also cause 
hypoxemia [81]. Another form of V/Q mismatch is wasted ventilation or increased dead-
space, this is where there is no blood reaching the alveoli but there is fresh gas, one result of 
this is that minute ventilation, the volume of air passed into the lung per minute, increases 
causing an increase in the work of breathing [81]. 
Copyright	material	– see	reference
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2.2.2 Introduction to lung diseases focused on in this work 
Data from patients with a wide variety of diseases were analysed during the course of this 
PhD and therefore only a basic introduction to each of the lung diseases is given here. The 
diseases focused on in this work were asthma, chronic obstructive pulmonary disease (COPD), 
CF and non-small cell lung carcinoma (NSCLC). Asthma is an obstructive airways disease 
characterized by reversibility of bronchoconstriction following administration of a 
bronchodilator [99-102] and airway remodelling may take place if asthma is not detected 
early. COPD on the other hand is characterized by irreversible airflow caused by chronic 
bronchitis (narrowing of airways due to constant inflammation) and emphysematous elements 
(permanent airspace enlargement as a result of airway wall destruction leading to loss of 
elastic recoil and collapse on expiration) of the disease [103, 101]. CF is a genetic disorder 
that affects numerous organs including the lungs [104-109]. The disease affects how mucus 
and sweat are produced leading to mucus plugging and inflammation within the lung. Lung 
cancer is a disease which has numerous causes [110, 111] which result in uncontrolled growth 
of cells resulting in tumours. The lung cancer patients imaged in this work had non-small cell 
lung cancer which is usually grouped in to three main types; squamous cell carcinoma, large 
cell carcinoma and adenocarcinoma [110, 111]. 
2.2.3 Introduction to pulmonary function tests 
A basic introduction of the standard non-imaging methods used in clinic for assessing 
respiratory disease is presented here. For details of the methods please see the ERS-ATS 
standards given in [5, 112]. 
 
Pulmonary function testing is an important method in assessing pulmonary disease and is the 
most common non-imaging method of clinical classification of disease [113]. Spirometry is 
the most common method used in clinic with forced expiratory volume in 1 second (FEV1), 
forced vital capacity (FVC) and the ratio of the two (FEV1/FVC) being the most commonly 
used measures [113]. By comparing these values to standard normal values, disease severity 
may be assessed whilst also differentiating obstructive and restrictive diseases based on 
whether FEV1 is greater or smaller than FVC. Although spirometry has been used in the clinic 
for decades its main pitfall is the lack of regional information and the fact that it mainly 
represents the change in larger airways rather than the small airways, where some changes 
may occur first in certain diseases. Although the aforementioned values are still considered 
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insensitive to early-stage disease in the lung [114, 115] and also has some insensitivity to 
disease progression [116, 117]. Body plethysmography is another method in which lung 
function can be analysed. Participants are placed in an airtight box, with a small leak that 
stabilizes the internal pressure [118], and a pneumotachograph to record the respiratory flow 
rate. Two pressure transducers are used, one to measure the pressure within the box and 
another to measure the pressure at the mouth and it is the changes in pressure, caused by 
inspiratory/expiratory efforts which the participant carries out following instruction from the 
attending physiologist, that allow for the calculation of lung volumes and other metrics using 
this technique [118] (Figure 2.3). 
 
 
Figure 2.3 Example normal spirogram demonstrating the lung volume subdivisions. FRC = functional 
residual capacity, IC = inspiratory capacity, IRV = inspiratory reserve volume, ERV = expiratory reserve 
volume, TV = tidal volume, RV = residual volume, FVC = forced vital capacity and TLC = total lung 
capacity. Reprinted by permission from Macmillan Publishers Ltd: Bone marrow Transplantation, (2005) 
35, 429–435, © 2005 
 
Measuring lung volumes using inert gases has been used by pulmonary physiologists for 
many decades and has recently been used to assess ventilation heterogeneity within the lung 
using the multiple breath washout (MBW) technique [119] by deriving parameters such as the 
lung clearance index (LCI) [120, 6, 121]. By measuring the gas concentration washout over 
multiple exhalations and analysing the gas washout curves, LCI has been used successfully in 
detecting disease in patients [120, 6] (Figure 2.4).  
Copyright	material	– see	reference
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Figure 2.4 Example result of a multiple breath washout test in a child with cystic fibrosis.(a) and a healthy 
child (b). The black line represents the flow and the green line is the concentration of the tracer gas. The 
red and blue lines indicate the section used to calculate LCI and the dotted red line indicates the time 
point used to determine LCI. Reprinted from The Lancet Journal, Respiratory medicine, 1(2), Hartmut 
Grasemann and Felix Ratjen, Early lung disease in cystic fibrosis, 148-157, Copyright (2013), with 
permission from Elsevier 
 
This technique has been shown to be sensitive to early changes in the lung and to disease 
progression [114, 115, 120, 6, 122, 33]. However, these measures are global values of 
heterogeneity measured at the mouth and lack the regional information that is useful in 
assessing lung disease. This technique has the ability to assess the heterogeneity in the 
conducting and transitional zones of the airways (Figure 2.1) by analysing the phase 3 slope 
of the data (Figure 2.5).  
 
The expirogram shown in Figure 2.5 is derived from the curve generated by plotting the decay 
of the gas shown in Figure 2.4. Scond is then calculated by analysing the phase 3 slope of the 
decay of the tracer gas plotted as a function of lung turnover and this metric represents 
ventilation misplacement in the conductive respiratory zone. Sacin can then be calculated by 
subtracting Scond multiplied by the lung turnover in the first breath from the normalised slope 
of the first breath [121, 123]. 
Copyright	material	– see	reference
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Figure 2.5 Basic illustration of expirogram acquired during a multiple breath washout test. To assess the 
heterogeneity in the conducting and transitional the phase 3 area of the expirogram is used. Reprinted 
with permission from reference [124] © 2012 the American Physiological Society 
 
The multiple inert gas elimination technique (MIGET) developed by Wagner in the 1970s [8] 
is another pulmonary function test used in the clinic to assess the lung. This test is used as a 
way to measure the ventilation-perfusion ratio, shunt, physiological dead space and diffusion 
limitation. More detail is given in Chapter 6, section 6.1. Another test often used in the clinic 
when considering pulmonary diseases is one in which the diffusing capacity of the lungs for 
carbon monoxide (DLCO) is measured. To measure this the participant inhales gas with a small 
amount of carbon monoxide mixed in, and, following a breath hold, the gas is expired and the 
difference in partial pressures between inhaled and expired carbon monoxide is used to 
calculate DLCO [125, 126]. 
2.3 Nuclear magnetic resonance and magnetic resonance 
imaging 
Nuclear magnetic resonance was first observed in the early 1930s [127, 128] following which 
Bloch and Purcell [129, 130] quantified the effect of spin precession in a magnetic field. 
Following the observation of NMR numerous advances were made, including the discovery 
of the spin-echo phenomenon [131], the application of the Fourier Transform to NMR [132] 
Copyright	material	– see	reference
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and utilizing imaging gradients to spatially encode signal and form images, allowing the 
differentiation of soft tissues [133, 134].  
 
NMR utilizes the interaction of nuclear magnetic moment arising from spin with external 
magnetic fields, and unlike angular momentum, spin is an intrinsic property of the nuclei 
being examined. The nuclei have a dipolar magnetic moment (@) associated with their nuclear 
spin (A) and spin angular momentum (B) [135, 136] governed by equation 2.1: 
 
 @ = DB = DħFG	 (2.1) 
 
Where the gyromagnetic ratio D is a property of the nuclei (determined by a ratio of energy 
and mass), ħ is the reduced Planck constant, defined as ℎ/2J, and FG  is the spin quantum 
number which has a fixed number of values (2A + 1) ranging from −A to +A. Table 2.1 shows 
the properties of the nuclei used in this work (proton – 1H, Helium-3 – 3He and Xenon-129 – 
129Xe). As can be seen the net spin of these nuclei is non-zero (a requirement for NMR) and is 
a half-integer value, although other nuclei suitable for NMR may have integer values.  
 
Table 2.1 Properties of nuclei used in this work [137-140, 39, 141] 
 1H 129Xe 3He 
Gyromagnetic ratio (N) 
(MHz T-1) 
42.58 11.78 32.43 
Magnetic Moment (@) +2.79 -0.78 -2.13 
Larmor Frequency at 1.5T 
(MHz) 
63.9 17.7 48.6 
Natural abundance - 26.4% <<0.1% 
Net spin (A) ½ ½ ½ 
 
The interaction between an external magnetic field (B0) and the nuclear magnetic moment 
results in the nuclear energy levels being split (the Zeeman splitting effect) [136], according 
to equation 2.2: 
 O = −@P" = 	−	DFGħP" (2.2) 
 
For a spin-½ nucleus, this results in two energy states; one where the magnetic moment is 
parallel to the external field (low energy state) and one where it is anti-parallel (high energy 
state) (Figure 2.6). The energy difference between states is given by equation 2.3: 
 
 ∆O = Dħ P" = 	ħQR (2.3) 
 
Where the Larmor angular frequency QR is given by D P" . 
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Figure 2.6 Graphical representation of the Zeeman splitting effect. (a) the alignment of nuclei without an 
external magnetic field and (b) the Zeeman splitting effect and alignment due to an external magnetic 
field P" 
 
The polarization S is defined by equation 2.4, which represents the ratio of the difference 
between the number of nuclei on the lower (T↑) and higher (T↓) energy states in a spin-½ 
system to the total number of nuclei. 
 S = 	 |T↑ − T↓|T↑ + T↓  (2.4)  
 
Where T↑  (parallel to P") and T↓ (antiparallel) represent the number of spins per state as 
defined by the Boltzmann distribution (equation 2.5): 
 
 T↓T↑	 = 	 XY ∆6Z[9 = 	 XY\ħP"Z[9  (2.5)  
 
Where ]^ is the Boltzmann constant and _ is the temperature. Spin excess (SE), defined as 
the number of spins parallel to the magnetic field exceeding the number anti-parallel, is given 
by equation 2.6 [139]: 
 `O ≈ T ħQR2]^_ (2.6)  
 
where T is the total number of spins in the sample. Therefore, the polarization can then be 
written as: 
 SR ≅ |D|ħP"2]^_  (2.7)  
 
And the magnetization is denoted as (assuming P"	acts along the z axis): 
∆! 
!! 
I = 1/2
I = -1/2
!! = 0 !! ≠ 0 !! = 0 !! ≠ 0 (a) (b)
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 cd = 	e. S. @d (2.8) 
Or 
 cR = 	eDgħgP"4]^_  (2.9)  
 
Where e is the spin density and @d is the magnetic moment. It should be noted that e in the 
lungs is low (~0.1 g/cm3)[41] making 1H imaging of the lungs challenging as discussed in 
section 2.4. 
 
At body temperature the thermal energy is much greater than the energy difference between 
states caused by P" [140]. The thermal polarization of a spin system at body temperature and P" = 1.5T (standard clinical scanner strength) (T = Tesla) is 10-5, due to the small number of 
excess spin (equation 2.6) however in many structures, e.g. the brain, proton spin density is 
high which counteracts this small thermal polarization leading to a magnetization (equation 
2.7) sufficient for imaging. 
 
In order to detect a magnetic signal one must first tip the magnetization vector (excite) from 
the axis that the P" field is applied to in order to initiate precession. This precession produced 
by the aggregate proton spins causes a changing of flux, which is detected by the receiver 
coil(s). Excitation is accomplished via application of a radiofrequency (RF) pulse at the 
nuclear resonance frequency i" for a set transmission time j, which creates a small rotating 
magnetic field P$, perpendicular to the field P" resulting in the tilting of the magnetization 
vector. The magnetization vector is tilted at angle k (equation 2.10), the flip angle, from its 
alignment with the P" field into the transverse (l, m) plane.  
 
 k = DP$jR j . no (2.10)  
 
This tipping results in what is commonly referred to as transverse magnetization (cpq ) 
(equation 2.11) and this is the magnetization (signal) detected during NMR experiments: 
 
 cpq = !"sin	(k) (2.1§) 
 
Where !" is the equilibrium magnetization.  
 
Figure 2.7  is a simple graphical representation of the excitation process where a 
magnetization vector is at equilibrium (a) and the same system after excitation at the Larmor 
frequency (b).  
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Figure 2.7 Simple graphical representation of RF excitation in the rotating frame of reference. (a) 
magnetisation vector at equilibrium, (b) magnetisation vector after application of RF pulse with flip angle 
a resulting in a reduced !w and transverse magnetisation !xy 
 
As the magnetisation vector tips away from the z-axis it also precesses around the axis, which 
in the presence of a receiver coil tuned to the Larmor frequency, and with its area 
perpendicular to the transverse plane, induces an electrical current due to the variation of the 
transverse magnetization. This is the signal that is amplified and then detected in the NMR 
experiment and this phenomenon is known as free induction decay (FID) [139, 40]. 
 
Once the RF excitation pulse is stopped the magnetization vector will begin to tip back 
towards the z-axis whilst re-emitting the energy absorbed during the RF pulse as signal and 
via relaxation. This relaxation can be split into two different mechanisms: the longitudinal 
(also known as spin-lattice) relaxation of the cd component and transverse (also known as 
spin-spin) relaxation of the cpq component. Longitudinal decay time constant is denoted _z 
whilst transverse relaxation decay constant is denoted _g . Longitudinal magnetization will 
recover according to equation 2.12 and transverse magnetization will decay according to 
equation 2.13 [139, 40]: 
 
 cd j = cR 1 − XY{ 9| + cd " ∙ XY{ 9| (2.12)  
 
 cpq j = cpq(") XY{ 9~  (2.13)  
 _z is the mechanism by which signal is lost to the surrounding molecular environment/lattice 
and _g is the mechanism by which the signal is broadened, and more specifically is caused by 
the loss of phase coherence between spins. Additionally, magnetic field inhomogeneity will 
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cause dephasing and the combination of the effect of field inhomogeneity and _g decay is 
denoted _g∗  in MRI [139, 40]. _g∗  of the lung is very short (<2ms) [142, 143, 41] and 
combined with the low e makes 1H imaging of the lung even more difficult. 
 
To be able to create images from the signal generated due to these phenomena spatial 
information must be encoded. Spatial encoding is accomplished via gradient magnets (l, m, Ä)  that vary linearly in strength with position in the directions (l, m, Ä) . By 
superimposing the field from   with the external magnetic field P"  a modulation of the 
Larmor resonant frequency occurs as a function of the position within the field [139, 40].  
 
By switching on a gradient for a time _ the spins accumulate phase, dependent on the position 
along the static gradient field, and this signal is then related to the spatial frequency (]) by 
equation 2.14 [139, 40]: 
 
 Å(]) = e(Ç) ∙ XYÉ∙gÑ∙Z∙ÖnÇ (2.14)  
 
Where ] is defined as \gÑ (o) ∙ no9R . What this means is that ] varies as a function of the 
amount of time the gradient is applied, and that using these gradients, sampling of the spatial 
frequency domain (]-space) is possible. ]-space is the inverse Fourier transform of the image 
domain. The central locations of ]-space (low frequency components) denote contrast and 
brightness of the image and the edges of ]-space (high spatial frequency components) denote 
the details such as edges of the object being imaged. For 2D sequences a specific slice 
selection gradient is applied to only excite a specified area within the imaging sample, 
whereas for 3D images the whole sample is excited [139].  
 
As can be seen from the definitions of ] -space and NMR signal these are continuous 
functions, however they are discretely sampled during the digital acquisition process with the 
sampling period ∆]. To avoid aliasing the sampling frequency must be at least twice the 
maximum frequency of the object being imaged based on the Nyquist theorem (i.e. the field 
of view must be larger than the object being imaged). Image contrast can be manipulated by 
changing the flip angle, echo time (TE) and repetition time (TR). The ideal signal equation 
from a steady-state gradient echo experiment is defined by equation 2.15: 
 
 ÜBáàâ = cR 1 − XY9ä 9| ∙ sin(k)1 − cos(k) ∙ XY9ä 9| ∙ XY96 9~∗ (2.15)  
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Where TR is defined as the repetition time between two RF pulses (middle of pulse is used as 
the measurement point) and TE is the echo time (the time from the middle of the RF pulse to 
the acquisition of the centre of k-space). In most cases the XY96 9~∗ component is ignored due 
to negligible effects on the signal [144], however this effect is not negligible when imaging 
the lung because the _g∗ of 1H in the lung is short (<2ms at 1.5T [142, 145]) due to large 
susceptibility gradients. SSFP sequences differ from SPGR by recycling magnetisation 
through balancing gradients along all three axes leading to improved signal to noise ratio 
(SNR) over SPGR sequences [146].  
 
These two pulse sequences form the basis of the MRI methods used in this thesis. Figure 2.8a 
shows an example of SPGR (a(i)) and SSFP (a(ii)) hyperpolarised 3He ventilation images 
acquired from a healthy adult.  
 
Figure 2.8 (a) Example HP 3He ventilation slices from a healthy adults’ dataset and (b) example 1H slices 
from a patient with early stage cystic fibrosis datasets. a(i) SPGR, a(ii) SSFP, b(i) SSFP and b(ii) SPGR 
 
As can be seen the SNR is improved using the SSFP sequence compared to the SPGR 
sequence. Note that the HP gas images were acquired with the same dose of 3He (150ml) and 
the SPGR acquisition is 2D whilst the SSFP is 3D. Figure 2.8b shows an example slice from 
an SSFP (b(i)) and SPGR (b(ii)) 1H structural acquisition from a patient with early stage 
cystic fibrosis. As can be seen in Figure 2.8b the vessels appear less bright in the SPGR image 
compared to the SSFP image due to the different image contrasts between the two sequences. 
In addition to these factors spatial resolution also has an effect on the SNR, where decreasing 
the voxel size, by modification of the acquisition matrix and field of view, results in 
decreased SNR, due to less signals per pixel being received, and increasing the spatial 
resolution will result in improved image SNR. 
a(i)	 a(ii)	
b(i)	 b(ii)	
a(i)	 a(ii)	
b(i)	 b(ii)	
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2.4 Lung imaging methods 
This section of the thesis discusses the clinical gold standard for lung imaging, computed 
tomography (CT), before moving on to the focus of this thesis, lung imaging using MRI.  
2.4.1 Computed tomography 
CT has been used in the clinic for decades and has been used to detect emphysema [147-149], 
scoring and diagnoses of idiopathic pulmonary fibrosis (IPF) [150], scoring and diagnoses of 
CF [151] and detection of pulmonary nodules [152]. With the high resolution achievable with 
CT (in some cases <1mm isotropic resolution) it is possible to determine tissue, air and blood 
volumes [153]. A threshold usually defines emphysema, in most cases any voxels less than -
950 Hounsfield units (HU) is used in addition to visual scoring of the percentage of lung 
parenchyma affected by emphysema [154, 155]. These low attenuation areas are caused by 
the destruction of the tissue allowing for the photons produced by the CT scanner to pass 
freely through that area in contrast to the absorption of the photon in normal areas.  
 
IPF is usually characterised on CT by assessing the presence of reticulation, honeycombing 
and traction bronchiectasis (Figure 2.9a), although there are sometimes other issues seen on 
these high resolution scans [156]. Patients with CF scans usually contain a degree of mucus 
plugging, bronchiectasis, consolidation and bronchial wall thickening [157]. Figure 2.9b 
shows an example CT scan from a patient with CF where the white circle highlights airway 
obstruction (tree-in-bud phenomena), the white arrow shows bronchial wall thickening and 
the dashed white circle shows an area of bronchiectasis. 
 
Figure 2.9 Example CT images showing the high resolution capability and structural abnormalities in (a) 
a patient with IPF and (b) a patient with CF. (a) reproduced with permission from [158] and (b) 
reproduced with permission from [157] 
Copyright	material	– see	references
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Functional imaging has also been carried out with CT, specifically focusing on ventilation and 
perfusion measurements obtained using numerous methods [17, 21, 159, 160, 24, 31]. 
Ventilation can be assessed using non-contrast CT methods such as those developed by 
Guererro et al. and Castillo et al. [17, 18, 22]. The idea behind these methods is that high-
resolution images are acquired at either fixed points in the respiratory cycle, most commonly 
inspiration and expiration, or during free-breathing using 4DCT. One image is then selected 
as the target image to which all other images are registered using a non-rigid registration 
method. Finally, a metric representing ventilation is calculated using either change based on 
volume or HU in the voxels [17, 18, 22, 161]. Figure 2.10 shows an example inspiration (a) 
and expiration (b) CT image whilst Figure 2.10c shows the resulting ventilation metric map 
generated using the HU method overlaid on the inspiration CT image. 
 
Figure 2.10 Example of CT images used to generate ventilation metrics. (a) inspiration image, (b) 
expiration image and (c) ventilation metric map overlaid on the inspiration image. Courtesy of Dr Bilal 
Tahir 
 
The standard imaging method for assessing V and Q in the clinic is single photon emission 
computed tomography (SPECT) [27, 28, 162] or nuclear scintigraphy [9-15] as previously 
mentioned in chapter 1. These methods are generally low resolution, as shown in the SPECT 
example given in Figure 2.11, but provide clear information on defects.  
 
Figure 2.11 Example V, Q and V/Q quotient images from a SPECT image. Modified with permission from 
[162]. (a) ventilation images, (b) perfusion images and (c) ventilation/perfusion images 
(a)	 (b)	 (c)	
Copyright	material	– see	reference
 19 
Additionally, perfusion may be assessed using iodine CT, either by using dual-energy CT 
[163-165] or by acquiring a data set pre and post contrast and using a subtraction technique to 
generate maps of iodine concentration [166]. 
 
The main limitation of CT, SPECT and nuclear scintigraphy methods is the ionising radiation 
dose, however the international standards on analysing CT images and how to acquire them is 
an advantage which allows for more reproducible results than those obtained with MRI. CT 
also has the advantage of increased spatial resolution over MRI allowing for the assessment of 
smaller lung nodules for instance. MRI may have improved soft tissue contrast over CT, 
however both methods are susceptible to motion artifact. 
 
Although this is not a comprehensive review of the analyses possible with CT, it is important 
to note that both structure and function can be analysed using CT, with CT being considered 
the gold standard for structural imaging.  
2.4.2 Proton (1H) imaging 
As discussed in section 2.3 the proton spin density of the lung is low (0.1-0.2 g/cm3) and there 
are additional issues such as tissue-air interfaces causing field inhomogeneity that make 
imaging of the lungs challenging [167, 41]. These interfaces between tissues with different 
magnetic susceptibility cause local field gradients [168] and main field inhomogeneity over 
the lung. Due to this magnetic field inhomogeneity, the MR signal of the lung is dephased and 
therefore the lung has extremely short _g∗ [169, 168, 142] meaning that unless sequences with 
short echo time (TE) are used most of the signal will not be seen as it will have already 
decayed.  
 
Standard anatomical proton MRI results in images where the lung appears dark with vessels 
and most pathology, such as fibrosis, mucus, atelectasis and bronchiectasis appearing brighter 
(Figure 2.12). Three basic sequences are typically used for proton lung imaging; SPGR, SSFP 
and single-shot fast spin echo (HASTE), which all have short TEs and short acquisition times 
[170, 171, 41]. Ultra-short echo time (UTE) [172] imaging allows the signal to be acquired 
before it has decayed substantially due to _g∗ effects and shows great promise for anatomical 
lung imaging, but is challenging to implement and requires longer acquisition times for full 
lung coverage [173].  
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Figure 2.12 Different examples of 1H images from patients (a) CF patient anatomical image (bSSFP) with 
a collapsed lower lobe (circled) acquired using an 8-channel cardiac coil and (b) SPGR image from an 
asthmatic patient acquired using the system body coil 
 
Although proton MRI cannot match the spatial resolution of CT, MR images have been used 
previously to detect structural changes within the lung in patients with CF, emphysema and 
interstitial lung disease (ILD) [174-178, 33]. Recent advances with time resolved 1H 
techniques e.g. Fourier decomposition (FD) imaging [179-185], have allowed for functional 
1H imaging of the lung with no contrast agent required. Briefly, a set of balanced steady-state 
free precession images are acquired during free-breathing and analysed via signal separation 
to distinguish changes in intensity caused by respiration and the cardiac cycle [179-181, 185] 
and produce ventilation and perfusion weighted images. Associated methods have been 
developed including those proposed by Voskrebenzev et al. [186, 187] that make use of 
frequency-based filtering in the image analysis step and are modifications of the standard FD 
method. 
 
Arterial spin labelling (ASL) is another proton based imaging modality used in pulmonary 
MRI to measure perfusion with application in both pulmonary [188-191] and brain [192] MRI. 
Unlike contrast-enhanced techniques ASL ‘labels’ the inflowing arterial blood using a 
specialized preparatory RF pulse following which ‘labelled’ images are acquired. Control 
images without the magnetic labelling pulse are also acquired. During post-processing these 
control and labelled images are subtracted to remove background noise and produce an image 
proportional to the amount of arterial blood delivered to each voxel. 
 
Another proton-based imaging method used to assess function in the lung is oxygen-enhanced 
MRI (OE-MRI) [193-195, 43, 196-198]. This method makes use of the fact that the _z of the 
blood, plasma and lung tissue will decrease with inhalation of 100% pure oxygen, leading to a 
(a) (b) (c)(a)	 (b)	
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signal enhancement allowing for ventilation, perfusion and even partial pressure of oxygen 
measurements to be made with this technique [193-195, 43, 196, 41, 197, 198]. 
2.4.3 Dynamic contrast enhanced 1H perfusion imaging 
As mentioned in section 2.4.1 1H imaging of the lungs is challenging and contrast agents can 
be used to add functional information. In this work a paramagnetic Gadolinium (Gd) based 
agent was used as a contrast agent (CA) in order to assess pulmonary perfusion using 
dynamic contrast enhanced 1H MRI [199-201, 191, 202-206, 68, 53, 207, 198, 208, 209] 
(DCE1H-MRI). The dosage used in this work was 0.05ml/kg body weight, injected at a rate of 
4ml/s with a 20ml saline flush. Using this dose of CA should result in a change in relaxivity 
of around 5.7 L mmol-1 s-1 [210]. DCE1H-MRI has been shown to be able to detect pulmonary 
embolism (PE) [56, 211, 10] and altered perfusion in COPD [191]. Gd based contrast agents 
reduce the _z of the tissue hence increasing the signal observed (equation 2.16) [212]: 
 
 1_z(o) = 1_z,R + Çz[CA](t) (2.16)  
 
Where _z,R is the baseline longitudinal relaxation time measured prior to CA administration, _z(o) is the longitudinal relaxation time at time o in the dynamic acquisition and Çz  is the 
longitudinal relaxivity of the CA and [CA](t) is the contrast agent concentration at time o. The 
signal intensity observed in a voxel of a _z-weighted image therefore will be proportional to 
the amount of CA in that area (e.g. Gd mixed with blood for pulmonary perfusion imaging) 
[212] and the process of quantifying this as a concentration is discussed later in chapter 6. 
 
To image lung perfusion a DCE1H-MRI acquisition is often used where a number of image 
acquisitions (full lung volume) are acquired equispaced over time (usually ~25s). During 
DCE1H-MRI the contrast agent is administered as a bolus, whilst the patient holds their breath 
or breathes freely [213, 144, 203, 207, 206], and the first pass of the contrast agent through 
the lungs is monitored using a suitable fast gradient echo imaging sequence. Figure 2.13  is a 
simple representation of the acquisition, where at each time point a volumetric dataset is 
acquired. 
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Figure 2.13 Basic illustration of a bolus passage of contrast agent in a single voxel and the image 
acquisition over time 
 
Parallel imaging [214, 215] and other image acceleration techniques such as TRICKS (Time 
Resolved Imaging of Contrast KineticS) [216] are used in most cases as they provide high 
temporal resolution. As the sequences used usually employ parallel imaging, the SNR is 
affected not only by the regular contributors of noise in MRI but also by the acceleration and 
geometry factors [214]. Regular image denoising techniques will not provide satisfactory 
results as many assume non-spatially varying noise. Images acquired using parallel techniques 
have spatially varying noise [217] and therefore require specialized denoising techniques. 
 
An important factor to consider is that the level of inspiration will affect the perfusion of the 
lung [199], this is one reason why free-breathing (FB) DCE1H-MRI has recently been gaining 
more interest over the conventional breath-hold (BH) DCE1H-MRI. Another reason is patient 
compliance, which should be improved with FB DCE1H-MRI. A further consideration is the 
analysis of FB DCE1H-MRI, as the current studies have not corrected for breathing-related 
motion by registration, which would be a challenging post processing step due to the signal 
changes caused by vessel movement through voxels during the breathing cycle [203, 206].  
 
Perfusion is the extent to which blood travels through the capillaries which surround the 
alveoli [81] and Tracer-Kinetic theory is a method of quantifying the data acquired from 
DCE1H-MRI to obtain the primary hemodynamic parameters of pulmonary blood flow (PBF), 
pulmonary blood volume (PBV) and mean transit time (MTT). Qualitative assessment is also 
possible using metrics such as time to peak signal, area under the curve and relative signal 
enhancement [37, 207, 218, 219]. Figure 2.14  shows an example slice from a 4D perfusion 
dataset (a) with corresponding signal-time curves from the pulmonary artery (b) and the lung 
parenchyma (c). As can be seen the signal intensity in the pulmonary artery is higher than the 
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parenchyma, a factor of 10 in this instance. The signal-time curve from the pulmonary artery 
is referred to as the arterial input function and used to quantify pulmonary perfusion 
(discussed in detail in chapter 6, section 6.2). 
 
 
Figure 2.14 Example slice and signal time course plots. (a) slice from a 4D perfusion data set showing the 
region of interest for the pulmonary artery (red) and parenchyma (blue), (b) the arterial signal-time curve 
and (c) the parenchyma signal-time curve 
2.4.4 Hyperpolarised gas imaging 
Through the use of inhaled hyperpolarised (HP) noble gases, in this work Helium-3 (3He) and 
Xenon-129 (129Xe), functional imaging of the lung has been shown to be possible [220, 77, 
221]. In addition to breath-hold ventilation-weighted imaging numerous other methods have 
been developed to assess lung function including diffusion-weighted imaging using both 3He 
and 129Xe [222, 223, 50, 224, 225] to assess the microstructure of the lung, multiple breath 
washout and dynamic imaging to assess fractional ventilation and the flow of gas within the 
lung respectively [37, 226-228, 67, 69, 70] and partial pressure of oxygen imaging [229-231] 
to regionally assess the partial pressure of oxygen in the lungs. Additionally, 129Xe imaging 
methods have been developed to estimate pulmonary gas exchange and also to calculate ratios 
of tissue blood and plasma to red blood cells [232-236, 80, 237-242], where Figure 2.15  
shows diagrammatically the type of exchange during this imaging. 
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Figure 2.15 Diagrammatic illustration of xenon solubility in tissue. Reproduced with permission from 
reference Mugler and Altes Copyright © 2013 by John Wiley Sons, Inc. Reprinted by permission of John 
Wiley & Sons, Inc. 
 
In order to provide suitable polarisation (signal) for imaging, these gases are first 
hyperpolarised to increase the nuclear polarization up to 5 orders of magnitude and are 
inhaled acting as a gaseous contrast agent allowing the ventilated airspaces of the lung to be 
visualised. Details of the spin exchange optical pumping method used to polarize the gases in 
this work are not given here but can be found in references [243, 244, 76, 245]. In Sheffield 
commercial polarizers are used to hyperpolarize 3He (MITI, Durham, NC, USA and GE 
Healthcare, Amersham, UK) and a home-built polarizer is used for 129Xe [246] and were used 
in the projects presented here. For all imaging gases are collected in a Tedlar bag (Jensen 
Inert Products, Coral Springs, FL, USA) and mixed with N2 prior to inhalation by subjects.  
 
Figure 2.16 shows the homebuilt 129Xe polarizer (a), a Tedlar bag used to collect and 
administer gas (b), an RF coil for HP gas imaging (c) and the 1.5T scanner used for this work 
(d). 
 
Figure 2.16 Example of the equipment used in this work. (a) Home-built 129Xe polariser, (b) a Tedlar bag, 
(c) 3He RF coil tuned to 48.67 MHz and (d) 1.5T scanner 
Copyright	material	– see	
reference
Figure 2.2: A. Schematic diagram of the stopped-flow xenon polariser, including optical appa-
ratus: (1) Laser diode array; (2) Half-wave plate, for rotation of the plane of linear polarisation
from the laser; (3) polarisation beam splitter, with 13 transmission down the optic axis, and
2
3 reflection down the cell axis; (4) Holographic grating, for narrowing of the laser beam and
tuning of the operating wavelength; (5) Quarter-wave plate, for conversion of linear to circu-
lar light polarisation; (6) Helmholtz B0 coils, for Zeeman splitting of the atomic energy levels;
(7) Temperature-controlled oven, for vapourisation of rubidium; (8) Glass OP cell, containing
129Xe, 4He, 7N2 and  1g of 87Rb. Gas is flowed continuously through the cell, is polarised,
and is subsequently extracted via cryogenic methods. B. Photograph of the xenon polariser [3].
The optical array, OP cell, oven and Helmholtz B0 coils are clearly identifiable. C. Represen-
tative laser spectrum at room temperature, and 100 C (oven temperature), indicating the laser
emission profile, and the alteration of this profile during rubidium absorption, respectively.
2.2.1 Methodology for Quantifying Polarisation and ‘Spin-up’
Times
Polarisation
A procedure was developed to determine the polarisation of the 129Xe within the optical
pumping cell, by transferring small amounts of the gas mixture to a 1.5T (GE Signa HDx,
Milwaukee, WI) MRI scanner [3]. Samples of gas were collected directly from the cell,
which contained 3% 129Xe, 10% N2 and 87% 4He pressurised at 2bar and maintained at
100 C, after a steady-state polarisation had been achieved4. The samples were extracted
into a 1l Tedlar bag and subsequently conveyed to a previously-evacuated 10ml syringe
within the bore of the scanner (there were negligible polarisation losses in transport).
4This was monitored by an on-board NMR spectrometer, as described later.
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When imaging with HP gases it is important to remember the differences between HP gas and 
1H imaging. One key point is that once a gas is hyperpolarised the magnetization will begin to 
decay due to the spins relaxing to thermal equilibrium [245]. Furthermore RF pulses destroy 
magnetization and in contrast to 1H imaging this magnetization is not recoverable [247]. The 
decay means that the acquisition order of k-space affects the image appearance [248].The 
level of hyperpolarization achieved will affect the signal strength [140], as will the amount of 
gas inhaled into the lungs, whereas with 1H imaging signal strength is controlled by the 
external magnetic field [140]. Calibration of the flip angle must also be considered and this 
should be calculated for the coil and loading being used, as any miscalculation will cause a 
reduction in SNR. Specific receiver coils tuned to the Larmor frequency of the gas of interest 
and a broadband RF amplifier are also required and in Sheffield there are coils available for 
adults and children tuned to the resonant frequencies of both 3He and 129Xe.  
 
This work focuses on breath-hold ventilation-weighted images where the signal intensity is 
proportional to the HP gas volume within the voxel, but the effects of _z and _g∗ decay also 
contribute to the ventilation-weighted image signal intensity as well as the coil sensitivity. It 
is possible to acquire 2D or 3D images and these images are most commonly acquired using 
SPGR or bSSFP sequences. One drawback of 3D sequences is that any motion will affect all 
slices acquired, and cardiac motion is more likely to cause some artifact in the image, 
although 3D sequences do provide higher SNR than 2D sequences [220]. bSSFP sequences 
differ from SPGR sequences by recycling magnetisation through balancing gradients along all 
three axes leading to improved signal to noise ratio (SNR) over SPGR sequences [146]. The 
signal decay of an SPGR sequence, with a constant flip angle and TR<<_z, can be defined by 
equation 2.17: 
 
 cpq ë = 	cR sin(k) cosíYz(k) (2.17) 
 
 
Where ë is the RF pulse number and k is the RF excitation flip angle. Figure 2.17  shows an 
example 2D SPGR image and a 3D bSSFP image from the same CF patient, where the 
cardiac motion artifact is circled. Even with the smaller voxel volume (~12.2mm3) and 3He 
gas dose (100ml) of the bSSFP images compared to the SPGR image (~15.6mm3, 200ml) the 
SNR advantage of the 3D bSSFP sequence over the 2D SPGR sequence is evident. 
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Figure 2.17 Example ventilation images from a patient with CF. (a) a 2D SPGR image (200ml HP 3He, 
voxel size=1.25x1.25x10mm) and (b) a 3D bSSFP image (100ml HP 3He, voxel size=1.56x1.56x5mm) with 
the red circle marking an area of cardiac motion artifact. Note that the FOV for the SPGR image was 
32cm and the FOV for the bSSFP image was 40cm 
2.5 Image registration 
Image registration is well established in the medical imaging community with numerous 
reviews having taken place [249-252] for example. Image registration is used throughout this 
thesis to register images acquired using the same modality and to co-register images acquired 
using different modalities. Registration of lung MR images is difficult due to the fact that the 
lung is a large deformable organ. Further there are fewer features compared to other 
anatomical structures where registration is used, for example the brain. Furthermore, images 
with large contrast differences can be extremely difficult to register particularly when using 
intensity-based metrics.  
 
One use of image registration in the lung MR community to date is for lung ventilation 
volume percent (%VV) calculation where 1H anatomical images are registered to HP gas 
ventilation-weighted images. The registration technique used in [62] relied on landmark 
registration which was dependent on user selection of landmarks, although this is a proven 
method it introduces user-bias and can be time-consuming depending on the resolution of the 
images acquired. A more elegant solution would be to obtain 3He and 1H images in the same 
breath-hold [73] or to apply a registration algorithm based purely on similarity metrics or 
segmented images, rather than using landmarks, such as that used in [253-255, 66, 256, 257]. 
Horn et al. [66] compared same-breath %VV to registered separate breath %VV and found 
that these matched reasonably well, although the registration of 3He and 1H images is still a 
difficult process and using same-breath data is still the best option.  
(a) (b)
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There are numerous ways in which to describe image registration, however this literature 
review will be concerned only with the transformation types as listed in [249]: 
1 – Rigid 
2 – Affine 
3 – Projective 
4 – Curved (also known as non-rigid and deformable) 
  
Where a rigid transformation is only capable of rotation and translation of the image [252], an 
affine transformation is able to rotate, translate, scale and shear. This means that when 
registering a 3D image using a rigid transformation the model will be described by 3 rotations 
and 3 translations and can be described by a transformation matrix consisting of 3 parameters 
representing the rotations and a further 3 representing the translations. Affine transformations 
make use of all 9 parameters in the transformation matrix to carry out the operations 
mentioned previously whilst also maintaining the overall geometric relationships between 
points. 
 
Projective transformations will map any lines onto lines and curved transformations will map 
lines to curves [249]. Deformable image registration is an important technique for medical 
image registration as it is able to conserve topology and provides plausible solutions to the 
problems of multiple acquisitions over time or multiple modality acquisitions that would need 
registration [258, 259]. Deformable image registration can be carried out using a number of 
transformations [249, 260-265, 258, 259, 252], however the method used in this work was the 
Greedy Symmetric Normalisation algorithm (SyN) provided as part of the ANTs registration 
suite [84, 266] as this method was the best performing in the EMPIRE10 CT challenge [267]. 
The main aspect of the deformable registration method is that it makes use of a specific type 
of transformation known as a diffeomorphic transform [268, 266, 259], the mathematics of 
which are beyond the scope of this thesis. Briefly a dense transformation field (per voxel in 
the image) is calculated using the desired transformation and similarity metrics and the 
transformation to map one point to another point is calculated and constrained so that it is 
invertible [269, 84, 266, 259]. 
 
Projective registration is not commonly seen in the medical imaging community with many 
papers using rigid, affine, deformable or some combination of these three methods, with 
many publications using either elastix [270, 271] or ANTs [84, 266] due to the possibility of 
applying any combination of rigid, affine and deformable registrations with the use of a single 
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bash script. Rigid transformations are mainly used in the presence of rigid structures [272] or 
as the initial registration method prior to applying the more complex affine or deformable 
transformations [273].  
 
When registering two images, one image will be the reference image (or fixed image) to 
which the target image (or moving image) will be warped. The software from [84] is based on 
the well-known Insight tool kit [274] which uses intensity-based registration and has options 
for different optimisation strategies including mutual information (MI) and normalised cross 
correlation (NCC). That is a geometric transformation, to be applied to the moving image, 
will be found which will maximise the similarity measure based on the voxel intensity [252], 
and more generally will attempt to minimise/maximise an energy of the form shown in 
equation 2.18 [258] depending on the matching method chosen.  
 
 ℰ ℱ,ℳ ∘ó +ℛ ó  (2.18) 
 
Where the images are defined in the image domain Ω and: ℰ is the matching of the alignment 
of images; ℱ is the target image; ℳ is the moving image; ó is the transformation; ℛ is the 
regularisation term; ℳ ∘ó is applying the transform ó	to ℳ. The alignment is governed by 
the transformation term ó, and this transformation is a mapping in the image domain. The 
mapping of points ö  is determined by the addition of an identity transformation and the 
displacement õ and is in the general form of equation 2.19 [258]. 
 
 ó ö = 	ö + 	õ(ö) (2.19) 
 
The regularisation term will favour particular features depending on which type of 
regularisation is used. Image registration in the medical image community is still an 
interesting area of research and numerous algorithms and methodologies exist [249, 260-263, 
275, 250, 276, 255, 270, 266, 265, 258] to list but a few, and typically vary with the 
anatomical structures involved. 
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CHAPTER 3. DEVELOPMENT OF AN IMAGE 
PROCESSING PIPELINE FOR HP GAS AND 1H 
LUNG VENTILATION ANALYSIS1 
3.1 Introduction 
Previously quantitative indices of lung function have been obtained from hyperpolarised (HP) 
gas ventilation-weighted and proton anatomical (1H) lung MRI that detect early obstructive 
changes in the lung [277]. The common method of analysing these images is by calculating 
lung ventilation volume percent (%VV) the ratio of ventilated volume (VV - from 
hyperpolarised gas images) to total lung volume (TLV - from proton anatomical images) or its 
counterpart ventilation defect percent (VDP – defined as 100-%VV). The index focused on 
here was %VV, however the methods can equally be used to generate VDP. 
 
Manual segmentation has been commonly used to obtain the values of VV and TLV [277], 
however this can take over one hour depending on the image resolution and number of slices. 
Analysis of HP gas ventilation images is less challenging than the analysis of anatomical 
images in part due to the clearer contrast of HP gas images lending themselves to 
segmentation techniques. With the low proton density of the lung, partial volume effects and 
motion artifacts from the heart [73, 278] segmentation of the lung cavity is a challenging 
aspect of 1H image segmentation. 
 
The next sections of this chapter present an introduction to some related methods for lung 
MRI segmentation with a discussion of advantages and disadvantages that led to the 
motivation for this work. 
3.1.1 1H image segmentation  
The most basic method of segmenting 1H images is manual outlining of the lung [277]. 
However, this method is very dependent on the experience and interpretation of images of the 
user. Additionally, with the advances made in 3D imaging of the lung [34, 66, 221] a data set 
                                                
1 This chapter is based on an article published in the Journal of Magnetic Resonance Imaging: Spatial fuzzy c-means thresholding for 
semiautomated calculation of percentage lung ventilated volume from hyperpolarised gas and 1 H MRI. 
Hughes PJC1, Horn FC1, Collier GJ1, Biancardi A1,2, Marshall H1, Wild JM1,2;JMRI, 2017; doi:10.1002/jmri.25804 
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can consist of 40+ slices meaning manual outlining of the lung would take a considerable 
amount of time that is not acceptable in the clinic.  
 
Kirby and Imelinska proposed well-developed workflows [167, 62] for the segmentation of 
lung MR images. The semi-automatic method proposed by Kirby et al. [62] automates the 
segmentation of  the lung shape from 1H anatomical images by using a low-pass Gaussian 
filter to pre-process the 1H anatomical image and then applying a region-growing algorithm. 
This filtering reduces the chance of the region-growing algorithm leaking into areas of similar 
contrast [62]. One drawback of this method is the fact that finer detail is lost and that TLV 
may be underestimated due to the heavy Gaussian filtering of the images leading to the edge 
bleeding into the lung cavity. Region growing is commonly used in lung MR image 
segmentation [279, 62] as it is fairly straightforward to implement.  
 
Other methods have been suggested to segment 1H images including using active contours 
within a closed homogeneous region [279]. Although the results look promising in the 
publication, this method may not work well on all images. The main reason being some 
regions within the lung may be homogeneous while others may not and this will provide a 
poor segmentation, possibly including only certain parts of the total lung. Furthermore the 
active contours method implemented in [279] is limited to operating in a two-dimensional 
space, meaning that each slice of a data set must be processed individually. Applying active 
contours has also been used in other implementations including that of Tavares et al. [280], 
where they applied a modified Hough transform to identify a point cloud within the lung, 
which was then transformed to a contour via gravitational vector fields and Greedy contour 
creation [280]. One important consideration when reviewing that work was that the aim was 
not to evaluate the lung volume but to identify respiratory patterns from temporal acquisitions. 
 
Recent work by Tustison et al. [281] modified the multi-atlas label fusion (MALF) algorithm 
described in [282] by adding to the optimization. This was achieved by considering the error 
of the consensus voting between atlases and not only between the atlases and target image 
[281], resulting in lower correlative atlas error and improved segmentations. The atlas-based 
method described here used a large pool of data with patients at different inflation levels and a 
mix of healthy and diseased patients. This mix of inflation levels is advantageous as not all 
patients may be able to inhale to the same level meaning this atlas can be used across patient 
cohorts. Further the development of the registration algorithms on an open source software 
platform [84] means this method is able to be applied relatively simply. Processing time is 
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also reasonable with the authors commenting that for a single dataset processing time was 
approximately 36 minutes, which in the experience of this author, is around 50% of the time 
taken to manually segment low-quality anatomical images. 
 
Kohlmann et al. [53] also developed a 1H image segmentation strategy as part of their 
perfusion analysis workflow. They combined numerous low-level image-processing tasks to 
obtain seed points for a three-dimensional region growing algorithm to be applied. This 
method provided high quality results and as such were used as a comparison by Tustison et al. 
[281] to their method. One drawback of this method is the need to acquire coronal and axial 
images and then carry out an alignment for the airway segmentation presented. Although this 
would not greatly increase scan or processing time it may introduce errors into the final 
segmentation if registrations were not to a high standard.  
3.1.2 HP gas image segmentation 
Previous methods for HP gas ventilation image segmentation have been based on manual 
intensity thresholding [277], K-means clustering [62], multiple atlas labelling [283] and 
globally optimal graph cuts [284]. He et al. recently improved the K-means method of 
segmentation by characterizing the distribution of ventilation [285], whilst Zha et al. 
improved the K-means method by adding an adaptive aspect of the algorithm [78]. Most of 
these HP gas ventilation segmentation techniques [283, 62, 284, 285, 78] require little to no 
manual input, and the methods developed in [62] and [285] also grade ventilation. However, 
the K-means segmentation method [62, 285, 78] can fail with low SNR images due to its 
binary clustering nature and inability to differentiate noise from lung tissue. 
 
Prior to these more complex algorithms, thresholding, as used in [277] and as part of the 1H 
processing in [62] and [53], is a method which was popular, although this is time-consuming 
and user-biased. Basic thresholding, that selects a maximum or minimum value from the 
image that is known to be in the ROI and setting all values above or below this to 0 will vary 
between users, also thresholding values will vary between patients due to variations in image 
SNR between scans. A semi-automatic SNR-based method such as FXúë(Åùû) – 3∗Åon(ëüùÅX) 
[277] alleviates both of these problems but can still exclude regions of poor ventilation in 
some cases. Using ITK-SNAP, thresholding can be combined with active contour 
segmentation. The user first employs thresholding to define the regions where the contour 
may and may not grow and then places seed points. The contour’s parameters are modifiable 
and this is a good semi-automated approach to the problem. However due to the fact the user 
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selects the thresholding levels there is again an issue of time and user-bias. Furthermore, in 
most cases the contour will require manual removal of some of the larger blood vessels. 
 
Tustison et al. [283] created a workflow to segment 3He ventilation images which not only 
automates aspects of segmentation it also removes pulmonary vasculature as a source of error 
from the ventilation defect area. With the creation of a principal component analysis model of 
lung shape Tustison et al. overcome one of the major issues in segmenting 3He images, which 
is ventilation defects not being considered as part of the lung due to showing little or no signal. 
Principal component analysis is where a datasets dimensionality is reduced, that is a new set 
of variables is found which retains almost all of the information from the original dataset [94, 
286-288]. This is done by successively removing the variance in a dataset and converting the 
set of possibly correlated data to a set of linearly uncorrelated data. This methodology is 
clearly very useful and provides consistent data analysis [283]. The atlas-based methods are 
growing increasingly popular not only in lung MRI but also in other areas of MRI analysis 
[289], and although these methods are well established in MRI of the brain it has not yet been 
well developed in MRI of the lung. This method has many advantages but the main 
disadvantage is the amount of time necessary to create the atlas and registration algorithms. 
Further were a fully ventilated atlas registered to a patient with severely reduced ventilated 
volume then the technique may not be able to match the heterogeneous ventilation pattern.  
 
Recent improvements by He et al. and Virgincar et al. [290, 291] have allowed for not only 
ventilation defect percent calculation but also to demonstrate areas of different signal intensity 
within a 129Xe ventilation image. He et al. improved on the method presented by Virgincar et 
al. by scaling and classifying voxels into 4 clusters (void, low, medium and high) 
automatically. This does require extra pre-processing including removal of the blood vessels 
via a vesselness filter [292] and B1 correction [293] but the results can provide more 
information than a simple ventilated/non-ventilated comparison. Removal of the vessels via 
the 1H image may also introduce issues particularly if the registrations are not to a high 
standard, and as noted by the authors may remove far too much ventilated area if the 
vesselness filter is not properly applied.  
3.1.3 Neural networks and clustering methods 
Neural networks (NN) are a useful tool in signal processing and have been adapted in some 
publications to aid image segmentation [294-297]. Specifically a cellular neural network 
(CNN) was created using a specific network design template [296] for lung MR image 
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segmentation. This method also requires image filtering; however even with the smoothing of 
the Gaussian filter the method reportedly had improved accuracy over other common 
clustering techniques. CNN methods for image processing have been well reported [298] but 
remain heavily dependent on pre-processing steps, if the pre-processing steps do not improve 
image quality enough the final segmentation will be poor. A further drawback of this method 
is the complexity of designing a CNN and ensuring it is suitable for the particular task. 
 
K-means clustering attempts to find k	data points, given the integer k, in an n-dimensional 
space (R¢) given m data points. These k data points are known as centres/centroids and the 
aim is to minimise the distance from each data point (m) to its centre/centroid [299].  
 
K-means clustering was used in [62] to segment the 3He images and provide information 
about signal intensity rather than a binary decision of signal or no signal, this method of 
segmentation has been used in biomedical images before [300], but as implemented in this 
work attempts to emulate an expert radiologists to segment the signal intensity histogram [62] 
leading to improved segmentations. The k-means method employed by [62] also required 
extra computation due to the fact that one cluster contained both ventilation defects (signal =0) 
and background information, causing the need to again apply the same k-means algorithm to 
the first cluster, increasing computation time slightly, although this is still much shorter than 
manual analysis. 
 
Another clustering method available is that of Fuzzy c-means (FCM) clustering, first 
introduced by Bezdek [301], building on the introduction of Fuzzy logic by Zadeh [302], and 
it has also been adapted for image segmentation as shown in [303]. Fuzzy clustering allows 
pixels to belong to more than one class with varying degrees of membership [303], that is the 
membership value to a class will vary and the higher the membership the more likely that it 
belongs to that class [303]. This is in contrast to the hard clustering of k-means or the 
alternative hard clustering c-means [304] where a pixel belongs only in one class or another. 
This fuzzy membership can be advantageous as some pixels may not be clearly identifiable as 
hard clusters, but using Fuzzy clustering even pixels which may have a low membership (0.2 
for example) can be included into the segmentation if they are within the lung.  
 
In the work presented here the Spatial Fuzzy C-means (SFCM) method [305] was adapted for 
the segmentation of HP gas ventilation and 1H anatomical images of the lung, to create an 
image processing workflow that has high resilience to noise. The workflow was developed 
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within a graphical user interface (GUI) for semi-automatic %VV calculation. We 
hypothesised that the semi-automated method would reduce inter-observer variability when 
compared to the current approach of fully manual image segmentation (basic method 
described in section 3.3.4) and improve on the segmentation achieved using the K-means 
method developed in [62]. The performance of the different techniques was tested on patient 
data sets with a range of obstructive lung diseases and disease severity, with both 3He and 
129Xe HP gas ventilation images. 
3.2 Image processing algorithm development 
This section of the thesis describes the experiments carried out to develop the pipeline 
proposed for semi-automatic %VV calculation including the choice of filter and filter values 
and membership threshold for the creation of TLV/VV masks. 
3.2.1 Filter choice 
Hyperpolarised gas images of the lung can suffer from poor signal to noise ratio, as does any 
other image, due to coil uniformity or insufficient gas dose, particularly if a patient has 
trouble inhaling the gas dose provided. Whilst noise is normally not an issue for diagnostic 
images, in some cases it can corrupt an image to a point such that standard methods of 
processing are unable to differentiate lung tissue from noise. In order to develop a pipeline 
resilient to noise it was decided to incorporate filtering of the image to ensure even images 
with low SNR could be analysed.  
 
Standard filters used in image processing include the Gaussian [306], mean and median filters. 
One assumption made whilst using these filters is that the image being processed shall vary 
slowly in the spatial domain, which, in pulmonary MRI and more specifically at the edges of 
the ventilated lung, is not always true. Mean filtering is an example of simple linear filtering; 
a pixel in an image is replaced by an average of its neighbours (including itself) within a 
window of ë×ë pixels. Median filtering is a nonlinear filter approach that preserves edges to 
a higher level than mean filtering but is executed in the same way. Gaussian filtering is a 
more complex filtering approach which weights pixels spatially close to the centre of the 
window higher than those far away. 
 
Another filter considered to be added to the pipeline was Bias field correction (N4 correction) 
as described in [293]. This methodology corrects signal intensity based on the low spatial 
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frequencies of the image information only. However, it does not remove noise, and hence can 
be useful in normalising for any signal inhomogeneity introduced by the transmit and receive 
sensitivity profiles of the RF coil, but would make no difference to a low SNR image. 
 
One filtering method which does not rely on the assumption of slow variation in the spatial 
domain is the bilateral filter [307, 308]. This filter is a combination of range and domain 
filtering, that is the way in which a Gaussian filter weights pixels by distance the bilateral 
filter also weights pixels by photometric similarity, resulting in a nonlinear filter which 
removes noise and preserves edges well [307]. This combination will maintain edges and 
ventilation defects within pulmonary images, as there is high photometric dissimilarity 
between, for example, a defect and ventilated lung. Therefore, bilateral filtering was chosen 
for the image-processing pipeline. 
3.2.2 Spatial Fuzzy C-means methodology  
Spatial Fuzzy C-means (SFCM) was chosen for segmentation in the proposed pipeline. As 
previously mentioned rather than a hard clustering of data this approach applies membership 
to each data point [305]. The standard FCM algorithm assigns	T  pixels to •  clusters via 
Fuzzy memberships. The key assumption of the Spatial Fuzzy C-means is that pixels spatially 
close will have high correlation and hence have similarly high membership to the same cluster. 
This spatial information will modify the membership value only if, for example, the pixel is 
noisy and would have been incorrectly classified. For the standard FCM method the cost 
function to be minimized is given in equation 3.1 [309]: 
 
 J = 	 @ßí®©ß™z´í™z ùí − ¨ß g (3.1)  
 
Where the fuzziness modifier ≠ (>1) controls the fuzziness of the data. This transforms the 
scalar data to fuzzy data via the membership function;  @ indicates the membership of the ë-th object (T = number of objects = number of voxels in 
an image) to the F-th cluster;  • indicates the cluster number;  l  is any norm metric representing similarity between the measured data and the cluster 
centre; and ùí and ¨ß are the pixel and centroid of the F-th cluster respectively.  
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Equations 3.2 and 3.3 then describe how the membership and centroids are updated in the 
standard FCM method: 
 @ßí = 	 ùí − ¨ß Yg (®Yz)ùí − ¨Z Yg (®Yz)©Z™z  (3.2)  
 
 
 ¨É = 	 @ßí® ùíí´™z @ßí®í´™z  (3.3)  
 
Equations 3.2 and 3.3 are updated in an iterative manner in the FCM algorithm. The cost 
function is minimized when convergence to a saddle point of ¨É is found. MR images can be 
subject to noise and artifact that can lead to erroneous classification using standard FCM 
techniques, hence the need for spatial information. The modified SFCM methods membership 
function is described by equation 3.4: 
 @ßí5 = 	 @ßíÆ ℎßíØ@ZíÆ ℎZíØ©Z™z  (3.4)  
 
 ℎßí = 	 @íZZ	∞	´±  (3.5)  
 
 
This modifies the membership function by adding the spatial function ℎ (defined in equation 
3.5) and assigning importance to the contribution by the weighting variables ≤ and ≥. The 
standard FCM approach corresponds to ≥ = 0 and ≤ = 1, when ≥ > 0 the spatial information 
will be used to modify the cluster membership. Tí is a window centred on the pixel ë and for 
this work a window of size 5x5 was used. The user can modify the number of clusters used in 
the Fuzzy clustering, in order to ensure high quality segmentations are achieved. Spatial 
importance (≥) varies with SNR and for images with SNR>20 is 1 and for all others is 2. 
3.2.3 FCM or SFCM? 
Previously FCM segmentation has been used in HP gas images [310] and was reported to be a 
successful method for segmenting ventilated airspaces in this type of image. To decide 
whether to use the SFCM algorithm or FCM algorithm 6 HP gas datasets acquired with 3He 
and 6 acquired with 129Xe were segmented using both techniques. The initial ventilated 
volume mask, (the mask output by the Fuzzy clustering including airways) were compared 
visually and by volume. The same filter and binary mask threshold values were used in both 
FCM and SFCM segmentation. 
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Table 3.1 shows the volumes of the 3He data and 129Xe data. As can be seen the FCM 
volumes were higher than the SFCM volumes for all patients. By carrying out Wilcoxon 
matched-pairs signed-rank test to compare FCM to SFCM it was found that the FCM volumes 
were significantly (p=0.0312, for both 3He and 129Xe) larger than SFCM volumes.  
 
Table 3.1 Ventilated volume values obtained in 3He and 129Xe data using FCM and SFCM methods 
Patient VV FCM (L) VV SFCM (L) ∆% 
3He data 
P1 4.08 3.722 -8.78 
P2 4.80 4.285 -10.41 
P3 4.89 4.259 -12.86 
P4 5.14 4.474 -12.97 
P5 4.63 4.090 -11.74 
P6 4.95 3.764 -23.98 
129Xe data 
P1 4.721 4.616 -2.23 
P2 6.168 5.817 -5.68 
P3 6.220 4.846 -22.09 
P4 4.363 4.129 -5.38 
P5 4.017 3.633 -9.55 
P6 5.534 4.611 -16.69 
 
Figure 3.1 shows an example slice from a 3He dataset segmented using the FCM and SFCM 
approach. As can be seen the FCM method included areas that visually appear to be defects, 
this figure is representative of the pattern seen in all datasets analysed. Because of this the 
SFCM method was chosen. 
 
 
Figure 3.1 Example segmentation output from FCM and SFCM methods. (a) original image (3He), (b) 
FCM output and (c) SFCM output. The yellow circles highlight some of the areas where differences are 
seen between FCM and SFCM outputs. Reproduced with permission from [311]  
 
Original	image FCM SFCM(a)	 (c)	(b)	
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3.2.4 Noise resilience 
To ensure the combination of bilateral filtering and increase of the weight of the spatial function would 
function would provide segmentations of a high quality from poor SNR images six ventilation image 
image datasets were selected from a clinical database. White Gaussian noise was added to the original 
original images using the imnoise function in Matlab and the SNR values of the original and noise 
noise corrupted images are given in Table 3.2. The initial outputs (of the original and noise corrupted 
images) of the segmentation pipeline, the FCM method and a K-means method were compared ( 
Table 3.3) by volume and the Dice similarity coefficient (DSC) [312] equation 3.6 where A 
and B are the two images being compared. 
 
 DSC = 	 2|∏ ∩ π|∏ + |π| (3.6) 
 
The DSC gives a measure between 0 (no overlap) to 1 (complete overlap). For this work A 
and B were defined as the masks of each method. 
Table 3.2 Comparison of original and noise corrupted (NC) 3He image SNR  
 
 
Table 3.3 Comparison of original and noise corrupted (NC) 3He image masks using SFCM, FCM and K-
means methods. Note that for K-means the window, intensity and standard deviation of the bilateral filter 
were increased to 5, 3 and 0.5 respectively 
 
Patient Original SNR NC image SNR 
P1 47.77 8.4 
P2 63.14 5.35 
P3 50.79 5.44 
P4 53.17 7.06 
P5 70.52 3.48 
P6 72.64 7.72 
Mean 59.67 6.24 
 
Patient Original volume  
(L) 
NC volume  
(L) 
%Error  DSC  
SFCM data 
P1 3.8 3.68 -3.07 0.98 
P2 4.44 4.21 -5.35 0.97 
P3 4.04 3.31 -17.94 0.9 
P4 4.73 4.47 -5.51 0.97 
P5 4.28 4.04 -5.55 0.97 
P6 3.84 3.15 -17.91 0.9 
Mean 4.19 3.81 9.22 0.95 
FCM data 
P1 4.08 3.92 -4.03 0.97 
P2 4.78 4.6 -3.74 0.96 
P3 4.89 4.43 -9.44 0.9 
P4 5.14 4.9 -4.75 0.96 
P5 4.63 4.39 -5.14 0.96 
P6 4.95 5.24 5.82 0.83 
Mean 4.75 4.58 5.49 0.93 
K-means data 
P1 4.52 7.94 75.8 0.68 
P2 4.7 8.59 82.81 0.68 
P3 4.72 9.05 91.72 0.63 
P4 5.17 9.99 93.32 0.66 
P5 4.67 7.71 64.99 0.72 
P6 4.86 19.85 308.75 0.37 
Mean 4.77 10.52 119.57 0.62 
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The noise-corrupted images are an extreme case and, in reality diagnostic images would not 
likely have an SNR this poor, however as a test of the pipeline’s ability to handle data 
corrupted by noise extremely low simulated SNR values were chosen. The volumes produced 
from the noise-corrupted images were lower than those from the original images (Table 3.2). 
Mean Dice similarity increases using the SFCM method compared to the FCM and K-means 
based methods. One reason for the loss of volume using the SFCM method is that low signal 
areas of the lung (e.g. Figure 3.2) are excluded using the higher spatial weighting and filtering 
required. However as seen in Figure 3.2c the output mask from the noise-corrupted image is 
very similar to that of the original image and shows the pipeline’s resilience to noise. 
 
 
Figure 3.2 Example slices from a HP 3He ventilation image with and without noise corruption and the 
overlap of their respective masks.  (a) original image, (b) noise corrupted image, (c) overlap of the SFCM 
masks (green = original, red = noise corrupted), (d) overlap of the FCM masks (green = original, red = 
noise corrupted) and (e) overlap of the K-means masks (green = original, red = noise corrupted). Yellow 
indicates matching of the masks. 
3.2.5 Resilience to HP gas acquisition parameters 
To ensure that the SFCM method used was resilient to the effect of imaging parameters, field 
of view (FOV), echo time (TE) and repetition time (TR) three datasets (2 cystic fibrosis (CF) 
patients and one healthy volunteer (HV)) were analysed where an SPGR and bSSFP 3He scan 
were acquired in the same session. The SFCM method was then run using the same filter and 
threshold values for both sequence types. Imaging parameters are given in  
Table 3.4. 
 
(a)	
(c)	
(b)	
(d)	
(e)	
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Table 3.4 Imaging parameters for the data used to compare sequence type effect on the SFCM output 
Patient SPGR 
TR/TE/FOV 
SSFP 
TR/TE/FOV 
HV 3.6ms/1.06ms/35cm 3.05ms/0.86ms/35cm 
CF1 3.6ms/1.06ms/35cm 3.05ms/0.86ms/35cm 
CF2 3.6ms/1.06ms/35cm 3.0ms/0.84ms/35cm 
TR = repetition time, TE = echo time, FOV = field of view. 
 
Table 3.5 shows the results from this experiment, whilst Figure 3.3 shows an example slice 
from an SPGR and SSFP dataset with the corresponding segmentation output overlaid in pink. 
Table 3.5 Ventilated volume (L) values obtained from SPGR and SSFP sequences 
Patient VV SPGR 
(L) 
VV SSFP 
(L) 
∆% 
HV 2.539 2.515 -0.93% 
CF1 2.179 2.191 0.57% 
CF2 2.449 2.538 3.64% 
 
 
Figure 3.3 Example SPGR and SSFP images from a healthy volunteer. (a) original SPGR image, (b) 
SFCM mask overlaid on SPGR image, (c) original SSFP image and (d) SFCM mask overlaid on SSFP 
image 
 
As can be seen from Table 3.5 and Figure 3.3 there was very little difference in the output 
even with the different sequence, suggesting that the SFCM method has good resilience to TR, 
TE and FOV. 
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3.2.6 Filter and binary mask threshold values 
Weighting values for spatial and photometric similarity (Table 3.6) were determined 
empirically through experimentation on 12 data sets acquired using same-breath HP 3He 
ventilation and 1H anatomical imaging [66] from healthy volunteers and patients with COPD 
and 6 data sets acquired using separate-breath HP 129Xe and 1H anatomical imaging. 1H image 
filter values were determined that maintained edges of the lung, evaluated qualitatively by 
visual inspection, and ensured TLV was within an acceptable error margin (±5%) of manual 
segmentation. Additionally, filter values that maintained defect integrity, smoothed artifact 
and noise and maintained edges were determined for hyperpolarised gas images and were 
again compared quantitatively by volume and qualitatively by visual inspection. Values for 
intensity and spatial weighting within the SFCM segmentation (Table 3.7) were determined 
from the same data by evaluating the segmentations visually and comparing with the output 
obtained from manual segmentation. 
 
Table 3.6 Filter values determined through experimentation 
Image type Window size Spatial SD* Intensity SD* 
1H 5 3 0.1 
3He 3 3 0.15 
129Xe 3 3 0.2 
*SD = standard deviation 
 
Table 3.7 Values used in the SFCM segmentation algorithm 
Image type Intensity weight Spatial weight Binary mask threshold 
1H 1 1* 0.15 
3He 1 1* 0.1 
129Xe 1 1* 0.05 
*Spatial weight is increased when image SNR<20 
 
The number of clusters to be used was empirically determined from this data with 6 clusters 
providing TLV masks most similar to those produced manually and 3-4 clusters being the 
most suitable for HP gas images. Following these experiments the final pipeline (Figure 3.4) 
was created. The cluster selected for segmentation was the cluster with the minimum centroid, 
e.g. representing the noise. For calculation of VV, this cluster was transformed to the mask 
using the Matlab function imcomplement, following thresholding by the aforementioned 
values which removes those pixels with low membership values. 
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Figure 3.4 (a) Workflow for SFCM image segmentation; a(i) 1H anatomical image, single slice from 3D 
SPGR sequence, a(ii) 1H mask single slice including airways, a(iii) 1H mask single slice following removal 
of airways, a(iv) three dimensional representation of the 1H mask, a(v) HP gas ventilation image single 
slice from 3D bSSFP sequence, a(vi) HP gas ventilation mask single slice clustering output, a(vii) HP gas 
ventilation mask single slice following removal of airways and a(viii) 3D representation of the 3He mask. 
VV = (viii) and TLV = (iv). (b) Segmentation method overview; b(i) original image, b(ii) image following 
application of bilateral filter, b(iii) cluster images, b(iv) selected cluster and b(v) initial binary mask 
including airways. Reproduced with permission from [311] 
 
Section (a) of Figure 3.4 describes the outline of the workflow. Note that for both 3He and 1H 
images the same processing steps were used with differences only in values of the filter used 
and the final membership threshold. Section (b) describes the novel processing pipeline 
developed for this work. Areas of hypoventilation were included in the ventilation mask based 
on the interpretation of images by members of the multi-disciplinary research group, and by 
comparison with the results of the methodology of Kirby et al. [62], where areas of 
hypointense signal were included in the final ventilated volume reported. Additionally, in 
practice a threshold between ventilated and non-ventilated lung is a clearer definition than 
exists between hypoventilation and ‘normal’ ventilation, particularly in severe disease where 
‘normal’ ventilation is very difficult to determine. 
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3.2.7 Registration method for breath-to-breath registration 
This section of the thesis discusses a registration methodology developed for use when 
patients are unable to maintain a breath hold long enough to acquire a 1H image in the same 
breath and for registration of HP 129Xe images to the corresponding anatomical separate 
breath image. In many cases when a patient loses their breath during imaging the 
hyperpolarised gas image is larger than the corresponding anatomical image acquired 
subsequently. This is an issue for calculation of %VV as peripheral defects may be ignored 
providing false information on the lung volume.  
 
 
Figure 3.5 Registration workflow developed for breath-to-breath registration. (a) single slice of a 3D HP 
3He data set, (b) corresponding mask slice, (c) single slice of a 3D 1H data set, (d) corresponding mask slice, 
(e) ideal ventilation mask, (f) ideal ventilation image and (g) filtered, inverted and masked 1H image 
 
The workflow presented in Figure 3.5 was developed to automate creation of images that 
have similar intensity. The masks are combined by a logical AND operation followed by the 
imclose and imdilate functions within Matlab, this is the case when the HP gas image is larger 
than the 1H image to ensure all ventilated lung is included within the 1H segmentation. These 
functions remove any small defects within the masks and also are adjustable should there be a 
significant difference between lung inflation state of the HP gas and 1H images. In most cases 
the error at the edges of the lungs, particularly the diaphragm, are only 3-5 pixels. Following 
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the creation of this mask areas of defect within the HP gas image that correspond to an area of 
the mask that is 1 are replaced by an artificial voxel with an intensity equal to the mean of the 
image to create an image of ideal ventilation – that is an image with no defects. The 1H image 
is then masked and filtered via the bilateral filter and the lung parenchyma intensity inverted. 
The number of slices is then increased by 5-20% depending on the difference in lung inflation 
state. 
 
Effective registration was required to overcome the aforementioned issues. To achieve this 
the workflow seen in Figure 3.5 was integrated into the aforementioned segmentation pipeline. 
Typically, 1H images were registered to the HP gas images, as these are the images that are 
generally considered the ground truth of lung ventilation and size, however it is also capable 
of registering a hyperpolarised gas image to an anatomical image if desired. Registrations are 
carried out using the ANTs registration software [84]. 
3.3 Comparison with other methods 
To quantify the algorithm’s performance the outputs of this novel semi-automated approach 
was compared to that of the current basic segmentation and a K-means based method 
for %VV calculation.  
3.3.1  Materials and methods 
All studies were performed with local research ethics committee approval and informed 
consent given for 129Xe scans. 
3.3.1.1 Observers 
Three observers (O1, O2 and O3) with previous experience in lung image analysis were 
selected. O1 had 6 years’ experience in lung image segmentation whilst O2 and O3 had 1 and 
5 years’ experience respectively. O1, O2 and O3 analysed 3He scans and O2 and O3 analysed 
129Xe scans, with manual segmentation (basic method), and the semi-automated method 
developed here. Observers analysed all images independently. All observers were physicists. 
3.3.1.2 Participants 
Scans were selected by O1 and O2 from a database of clinical lung imaging data of patients 
with respiratory conditions of various severities. The work was performed with research 
governance approval from the local NHS trust for retrospective research using clinical lung 
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imaging data. The inclusion criterion for the scans was that the patients had held their breath 
for the duration of the back-to-back HP gas and 1H imaging sequence. One patient suffered 
from horseshoe lung, one patient had asthma and four patients had COPD. In addition, images 
from six patients with lung cancer were analysed to test the applicability of the method to 
ventilation images acquired with HP 129Xe. Patients’ forced expiratory volume in 1 second (% 
predicted) ranged from 24% to 94% and age ranged from 23 to 68 years (6 male, 6 female). 
3.3.1.3 Imaging 
All imaging was carried out on a GE HDx 1.5T MR scanner (GE Healthcare, Milwaukee, IL, 
USA) and images were acquired at functional residual capacity + 1L. Patients were coached 
on the breath hold manoeuvres. Imaging parameters can be seen in Table 3.8. 
 
Table 3.8 Imaging parameters for the scans used in this work. TR = Repetition time, TE = echo time, FA = 
flip angle 
 
Note that slice number and field of view was adjusted per patient to ensure full lung coverage 
3.3.1.3.1 3He imaging 
Three-dimensional 1H anatomical (SPGR) and HP gas ventilation-weighted (bSSFP) images 
were acquired during the same breath hold following the methods in [73, 66]. HP gas 
ventilation-weighted images were acquired using HP 3He polarized on site to approximately 
25% using a rubidium spin exchange polarizer (GE Healthcare, Amersham, UK). Images 
were acquired using a 3He transmit-receive flexible vest coil tuned to 48.62 MHz (Clinical 
MR Solutions, Brookfield, WI, USA) and the 1H system body coil. HP gas ventilation-
weighted images were acquired followed immediately by 1H anatomical images. Patients 
inhaled 200mL HP 3He mixed with 800mL N2 from a Tedlar bag (Jensen Inert Products, 
Coral Springs, FL, USA) prior to the scan.  
3.3.1.3.2 129Xe imaging 
HP gas ventilation-weighted images were acquired using HP 129Xe polarized on site [313]. 
Images were acquired using a 129Xe transmit-receive flexible vest coil (Clinical MR Solutions, 
Acquisition TR 
(ms) 
TE 
(ms) 
FA 
(°) 
Matrix size 
(frequency x phase) 
Voxel size 
(mm) 
Slice thickness 
(mm) 
Slices 
1H (3D SPGR) 1.5 0.6 5 100x100 3.6x3.6-4x4 5 40-48 
3He (3D bSSFP) 1.9 0.6 10 100x80 3.6x3.6-4x4 5 40-48 
1H (3D SPGR) 1.9 0.6 5 100x100 3.4x3.4-4.2x4.2 10 20-24 
129Xe (3D bSSFP) 6.7 2.2 10 100x80 3.4x3.4-4.2x4.2 10 20-24 
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Brookfield, WI, USA) and the 1H system body coil [221]. 1H anatomical images were 
acquired in a separate breath prior to the HP gas ventilation images. Patients inhaled 550mL 
HP 129Xe mixed with 450mL N2 from a Tedlar bag (Jensen Inert Products, Coral Springs, FL, 
USA) prior to the ventilation scan. 
3.3.2 Image analysis 
The main outcome measure was %VV defined as ventilated volume (VV, from HP gas 
ventilation images) divided by total lung volume (TLV, from 1H anatomical images) [277] 
(equation 3.7). 
 
 %44 =	 44_ª4 ×100 
 
(3.7) 
 
The total lung volume masked the ventilated volume so that only voxels included in the TLV 
contributed to the calculated VV.  
3.3.2.1 Basic method 
Basic method segmentations were carried out using software written in MATLAB (The 
MathWorks, Inc., Natick, MA, United States). To segment ventilation images a threshold 
approach was used, the user chose a threshold that separated ventilated lung from background. 
For 1H anatomical images the ventilation image was overlaid on the anatomical image with 
opacity of 30% and the user delineated the total lung volume for each slice, using the 
ventilation-weighted image as ground truth and the anatomical image as a guide on the shape 
of the lung. 
3.3.2.2 K-means method 
For a comparison to a well-known automated method the k-means segmentation presented by 
Kirby et al. [62] was implemented and modified for the images used in this study. The size of 
the window used in the Gaussian filter for 1H anatomical image segmentation was reduced 
from 15x15 to 3x3 and the standard deviation reduced to 0.01, the radius of the closing 
structuring element was reduced from 15 to 7, and data outside the lung region was removed 
by a border clearing algorithm. No filtering of HP gas images was applied as per [62]. 
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3.3.2.2.1 Ventilation image segmentation 
As previously discussed this method uses a hierarchical k-means segmentation to classify the 
ventilation image into five clusters (C1 – background to C5 – hyperintense signal). To 
achieve this the image is normalized in the range 0-255. From this range four cluster ranges 
are defined (0–63, 64–127, 128–191 and 192–255) with the initial centroids being the centre 
of the ranges [62]. Following initial clustering all data in C1 is reanalysed to separate 
background and hypointense (C2) signal, this leads to a final image with 5 clusters [62] (e.g. 
Figure 3.6). 
 
 
Figure 3.6 Example K-means clustering algorithm output. (a) 3He ventilation-weighted image, (b) result of 
first clustering stage and (c) final clustering result 
3.3.2.2.2 1H anatomical segmentation 
1H anatomical image segmentation is carried out by first Gaussian filtering the image and then 
thresholding the image by half the maximum value obtained from the lowest intensity cluster 
by k-means clustering [62]. Following this seed points for the region growing algorithm are 
selected as those with only 20 vertical adjacent neighbours and the region-growing algorithm 
is applied followed by morphological operations (imclose – Matlab function) to close any 
small holes within the image [62].  
3.3.2.3 Semi-automated approach based on Spatial Fuzzy C-means 
The pipeline described in Figure 3.4 was used for segmentation. 
3.3.2.4 Performance evaluation 
Quantitative performance analysis was carried out on the computed values for TLV, VV 
and %VV as expressed previously in equation (3.7). Intra-class correlation (ICC), Bland-
Altman analysis and Pearson’s / Spearman’s correlation of the segmentation methods was 
carried out on a slice-by-slice basis using GraphPad Prism (GraphPad Software, La Jolla, CA, 
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US). In addition, the limits of agreement (LOA) provided by the Bland-Altman analysis were 
also analysed to test for an improvement in the consistency of results when using the semi-
automated method when compared to the manual method. Spatial similarity analysis was 
carried out on VV and TLV masks using the DSC [312]. Friedman’s test was used to test for 
statistical significance in global %VV values.  
3.4 Results 
3.4.1 3He results 
Figures 3.7 to 3.9 show the results of the global values of %VV, TLV and VV respectively, as 
measured by the pipeline proposed here (semi-auto), the basic method and the k-means 
method. As can be seen the k-means method overestimated %VV compared to all other 
methods.  
 
Figure 3.7 Plot of global values of %VV for all 6 patients scanned with 3He 
 
Figure 3.8 Plot of global values of TLV for all 6 patients scanned with 3He 
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Figure 3.9 Plot of global values of VV for all 6 patients scanned with 3He 
 
Correlation improved (p=0.25) between observers when using the semi-automated method 
(%VV mean R = 0.984) when compared to the basic method (%VV mean R = 0.863) whilst 
mean ICC also increased (p=0.25) from 0.873 using the basic method to 0.980 using the semi-
automated method.  LOA (p=0.50) and %VV bias magnitude (p=0.25) were reduced when 
using the semi-automated method (%VV mean LOA = 7.5%, mean |bias| = 2.3%) when 
compared to the basic method (%VV mean LOA = 14.2%, mean |bias| = 4.6%). These 
improvements were also seen in the VV and TLV measures. DSC significantly improved 
using the semi-automated method (VV mean DSC = 0.973, TLV mean DSC = 0.980) when 
compared to the basic method (VV mean DSC = 0.947, TLV mean DSC = 0.957) (p<0.01 for 
both VV and TLV DSC).  
 
The K-means method underestimated TLV when compared to both other methods. %VV was 
overestimated when compared to the basic (mean bias = 5.0%) and semi-automated (mean 
bias = 9.7%) methods. The Bland-Altman plot in Figure 3.10a(iii) shows poor agreement of 
the K-means method %VV with the basic method for O2 and is representative of the pattern 
seen when comparing K-means with both the basic (%VV mean LOA = 29.8%) and semi-
automated (%VV mean LOA = 28.2%) methods for all observers. 
 
On average the semi-automated method underestimated %VV by 4.6% compared to the basic 
method carried out by the same observer, with a mean LOA of 19.7%. The semi-automated 
method reduced average segmentation time from 1 hour (basic) to 25 minutes.  
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Table 3.9 shows the correlation, Intraclass correlation (ICC), DSC and LOA for TLV and VV 
and %VV on a slice-by-slice basis for 3He data. Table 3.10 shows the same analysis for each 
observer inter-method (basic, semi-automated) values. 
 
Table 3.9 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 3He data. VV and TLV 
in litres 
  
 
Table 3.10 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 3He data (inter-
method). VV and TLV in litres 
 
Parameter O1 v O2 O1 v O3 O2 v O3 O1 v K-means O2 v K-means O3 v K-means 
TLV Basic method 
R 0.904 0.998 0.907 0.913 0.983 0.914 
ICC 0.906 0.989 0.905 0.883 0.960 0.906 
bias + LOA  0.003±0.062 0.009±0.010 -0.006±0.061 0.019±0.060 0.016±0.030 0.009±0.030 
DSC 0.960 0.960 0.950 0.918 0.920 0.949 
TLV Semi-automated method 
R 0.999 0.994 0.993 0.994 0.994 0.996 
ICC 0.999 0.992 0.992 0.975 0.980 0.985 
bias + LOA  0.002±0.007    0.003±0.017    -0.002±0.018 0.013±0.020 0.012±0.020 0.010±0.010 
DSC 0.990 0.980 0.970 0.942 0.941 0.953 
VV Basic method 
R 0.829 0.991 0.824 0.830 0.980 0.828 
ICC 0.845 0.985 0.820 0.843 0.965 0.837 
bias + LOA    -0.007±0.060 0.006±0.014 -0.013±0.061 0.002±0.060 0.009±0.020 -0.004±0.060 
DSC 0.950 0.960 0.930 0.896 0.918 0.906 
VV Semi-automated method 
R 0.997 0.993 0.993 0.940 0.950 0.961 
ICC 0.998 0.992 0.993 0.930 0.940 0.960 
bias + LOA    -0.0004±0.007    -0.002±0.012    0.002±0.012 -0.007±0.040 -0.007±0.030 -0.005±0.030 
DSC 0.980 0.970 0.970 0.887 0.897 0.911 
%VV Basic method 
R 0.909 0.859 0.819 0.905 0.850 0.894 
ICC 0.850 0.920 0.850 0.726 0.660 0.670 
bias + LOA -6.9%±12.9% -1.7%±14.2% -5.3%±15.5% -8.0%±27.4% -11.2%±30.0% -0.8%±32.0% 
%VV Semi-automated method 
R 0.988 0.981 0.978 0.901 0.905 0.926 
ICC 0.990 0.970 0.980 0.702 0.730 0.788 
bias + LOA -1.1%±5.6% -3.5%±8.3% 2.4%±8.7% -11.2%±29.6% -10.1%±28.4% -7.7%26.5% 
Parameter 
O1 basic v            
O1 semi-automatic 
O2 basic v                   
O2 semi-automatic 
O3 basic v            
O3 semi-automatic 
TLV 
R 0.918 0.991 0.914 
ICC 0.987 0.918 0.914 
bias + LOA 0.006±0.060 0.005±0.020 -0.0002±0.059 
DSC 0.956 0.947 0.966 
VV 
R 0.814 0.972 0.821 
ICC 0.825 0.931 0.839 
bias + LOA 0.010±0.060 0.016±0.026 0.002±0.059 
DSC 0.946 0.913 0.944 
%VV 
R 0.938 0.864 0.898 
ICC 0.900 0.730 0.860 
bias + LOA 3.4%±16.6% 9.3%±23.2% 1.5%±21.3% 
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Figure 3.10a(iv) shows the inter-method agreement for O1 and is representative of the inter-
method agreement seen between all observers.  
 
Figure 3.10 Bland-Altman analysis of 3He %VV on a slice-by-slice basis. a(i) O1vO2 basic, a(ii) O1vO2 
semi-automatic, a(iii) O1 basic v K-means, a(iv) O1 semi-automatic v K-means 
 
Table 3.11 shows the results of the Friedman test when comparing global %VV values. As 
can be seen the K-means method result is significantly different to the basic segmentation 
values of O1 and O3 and the semi-automatic method results of O1 and O2. No significant 
differences were found between observers using either method (basic or semi-automatic) and 
no intermethod statistical difference was found. 
Table 3.11 Friedman test results when comparing global %VV values for 3He data 
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3.4.2 129Xe results 
Figures 3.11 to 3.13 show the distribution of global values of %VV, TLV and VV for both 
observers and the K-means method. 
 
 
Figure 3.11 Plot of global values of %VV for all 6 patients scanned with 129Xe 
 
Figure 3.12 Plot of global values of TLV for all 6 patients scanned with 129Xe 
O2
_s
em
i-a
uto
O2
_b
as
ic
O3
_s
em
i-a
uto
O3
_b
as
ic
K-
me
an
s
0
50
100
Observer
%
VV
%VV global
O2
_s
em
i-a
uto
O2
_b
as
ic
O3
_s
em
i-a
uto
O3
_b
as
ic
K-
me
an
s
2
4
6
8
Observer
TL
V 
(L
)
TLV global
O2
_s
em
i-a
uto
O2
_b
as
ic
O3
_s
em
i-a
uto
O3
_b
as
ic
K-
me
an
s
2
3
4
5
6
Observer
VV
 (L
)
VV global
O2
_s
em
i-a
uto
O2
_b
as
ic
O3
_s
em
i-a
uto
O3
_b
as
ic
K-
me
an
s
0
50
100
Observer
%
VV
%VV global
O2
_s
em
i-a
uto
O2
_b
as
ic
O3
_s
em
i-a
uto
O3
_b
as
ic
K-
me
an
s
2
4
6
8
Observer
TL
V 
(L
)
TLV global
O2
_s
em
i-a
uto
O2
_b
as
ic
O3
_s
em
i-a
uto
O3
_b
as
ic
K-
me
an
s
2
3
4
5
6
Observer
VV
 (L
)
VV global
 53 
 
Figure 3.13 Plot of global values of VV for all 6 patients scanned with 129Xe 
 
Correlation, LOA, bias magnitude and DSC improved between observers when using the 
semi-automated method compared to the basic method (Figure 3.14a(i, ii), Table 3.12). The 
K-means method underestimated TLV and overestimated %VV compared to the other 
methods to a greater extent than for the 3He data. The semi-automatic method 
underestimated %VV by 2.3% compared to the basic method for O2 (Figure 3.14 a(iv)) and 
overestimated %VV by 18.6% for O3. The mean LOA for %VV calculated by the same 
observer between the basic and semi-automatic methods was 26.4%. 
Table 3.12 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 129Xe data (inter-
method).  VV and TLV in litres 
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Parameter O2 v O3 O2 v K-means O3 v K-means Parameter O2 v O3 O2 v K-means O3 v K-means 
TLV basic method TLV semi-automated method 
R 0.981 0.896 0.904 R 0.984 0.930 0.930 
ICC 0.930 0.950 0.638 ICC 0.950 0.897 0.899 
bias±LOA 0.014±0.103 0.035±0.056 0.021±0.106 bias±LOA 0.007±0.088 0.022±0.050 0.015±0.102 
DSC 0.960 0.920 0.923 DSC 0.980 0.947 0.935 
VV basic method VV semi-automated method 
R 0.977 0.892 0.893 R 0.977 0.922 0.930 
ICC 0.710 0.950 0.915 ICC 0.890 0.970 0.926 
bias±LOA 0.016±0.093 -0.005±0.072 -0.020±0.098 bias±LOA 0.052±0.080 -0.020±0.095 -0.072±0.136 
DSC 0.838 0.888 0.782 DSC 0.928 0.892 0.895 
%VV basic method %VV semi-automated method 
R 0.884 0.836 0.740 R 0.929 0.860 0.883 
ICC 0.579 0.610 0.356 ICC 0.905 0.589 0.660 
bias±LOA 20.0%±24.3% -10.9%±30.4% -31.0%±34.6% bias±LOA -0.9%±19.1% -13.3%±33.8% -12.4%±28.5% 
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Table 3.13 Correlation, Bland-Altman and DSC analysis of TLV, VV and %VV of 129Xe data (inter-
method).  VV and TLV in litres 
 
 
Figure 3.14 shows Bland-Altman plots for 129Xe %VV on a slice-by-slice basis. As can be 
seen there was improved agreement between O2 and O3 using the semi-automated method 
and also for the inter-method plot for O2. 
 
 
Figure 3.14 Bland-Altman analysis of 129Xe %VV on a slice-by-slice basis. a(i) O2vO3 basic, a(ii) O2vO3 
semi-automatic, a(iii) O2 basic v K-means and a(iv) O2 semi-automatic v K-means 
Parameter 
O2 basic v  
O2 semi-automatic 
O3 basic v  
O3 semi-automatic 
TLV 
R 0.959 0.966 
ICC 0.989 0.995 
bias + LOA 0.013±0.030 0.007±0.034 
DSC 0.948 0.965 
VV 
R 0.956 0.956 
ICC 0.962 0.781 
bias + LOA 0.015±0.052 0.051±0.100 
DSC 0.917 0.831 
%VV 
R 0.862 0.824 
ICC 0.877 0.661 
bias + LOA 2.3%±20.0% -18.6%±21.78% 
0 10 20 30 40 50 60 70 80 90 100
0
10
20
30
40
50
60
70
80
90
100
y=0.676x+37.3
r2=0.732
SSE=9.8
n=115
0 20 40 60 80 100
Mean %VV values
-50
-40
-30
-20
-10
0
10
20
30
40
50
"
 %
VV
 O
2B
as
ic
-O
3B
as
ic
44
20
-4.3
0 10 20 30 40 50 60 70 80 90 100
0
10
20
30
40
50
60
70
80
90
100
y=0.959x+2.06
r2=0.8216
SSE=9.7
n=115
0 20 40 60 80 100
Mean %VV values
-50
-40
-30
-20
-10
0
10
20
30
40
50
"
 %
VV
 O
2s
em
i-a
ut
om
at
ic
-O
3s
em
i-a
ut
om
at
ic
18
-0.88
-20
0 10 20 30 40 50 60 70 80 90 100
0
10
20
30
40
50
60
70
80
90
100
y=0.512x+30.5
r2=0.4135
SSE=14
n=115
0 20 40 60 80 100
Mean %VV values
-50
-40
-30
-20
-10
0
10
20
30
40
50
"
 %
VV
 O
2B
as
ic
-K
-m
ea
ns 26
-10
-46
0 10 20 30 40 50 60 70 80 90 100
0
10
20
30
40
50
60
70
80
90
100
y=0.737x+21
r2=0.8086
SSE=8.3
n=115
0 20 40 60 80 100
Mean %VV values
-50
-40
-30
-20
-10
0
10
20
30
40
50
"
 %
VV
 O
2B
as
ic
-O
2s
em
i-a
ut
om
at
ic
22
2.3
-18
a(i)	
a(iii)	
a(ii)	
a(iv)	
 55 
Table 3.14 shows the results of the Friedman test when comparing global values of %VV 
derived from the 129Xe data. As can be seen the K-means method is significantly different to 
O2’s semi-automatic segmentation results and the basic segmentation result of O3. No 
significant intermethod difference was found for O2, and no significant difference was seen 
when comparing the results between users for the basic and semi-automatic segmentation 
methods. O3 had a significant intermethod difference in global %VV values. 
 
Table 3.14 Friedman test results when comparing global %VV values for 129Xe data 
 
 
3.5 Discussion 
The focus of this study was the development and evaluation of a graphical tool for semi-
automated %VV calculation. The tool developed reduces inter-observer variability and also 
provides similar results to the manual segmentation output. With longitudinal and multiple 
centre studies becoming more commonplace, developing novel and reproducible semi/fully-
automatic analysis techniques are becoming the focus of many research groups.  
 
The use of a co-registered multinuclear image acquisition [66] removes the need for image 
registration, which is commonly used for %VV analysis in other publications [62, 291, 285]. 
However, this software was written to be fully compatible with image registration software 
(section 3.2.7) if needed for breath-to-breath registration as shown here with the 3D 129Xe 
ventilation images. This tool also has the ability to include bias field correction for image 
processing however due to issues discussed in Chapter 4 it was not used in this work. 
 
Results obtained using the semi-automated approach proposed here were more similar to 
manual segmentation results than those obtained using the K-means method [62]. This is 
partially due to underestimation of TLV via heavy Gaussian filtering of the K-means method 
Comparison %VV p value 
O2 basic vs. O2 semi-auto >0.9999 
O3 basic vs. O3 semi-auto 0.0219 
  
O2 basic vs. O3 basic 0.2498 
  
O2 semi-auto vs. O3 semi-auto >0.9999 
  
O2 basic vs. K-means 0.2498 
O3 basic vs. K-means 0.0016 
  
O2 semi-auto vs. K-means 0.0117 
O3 semi-auto vs. K-means 0.0628 
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and also due to the inclusion of areas of noise as ventilated lung (e.g. Figure 3.6c). The 
remaining differences between the semi-automated and manual segmentation results could be 
explained by a few factors, among which is the treatment of partial volume effects at the lung 
border. Whilst the manual method would include neighbouring pixels corresponding to tissue 
where 3He signal is present in the 1H mask the method developed here would exclude these 
areas and consider the edge of the lung from the 1H image as the ground truth. 
 
However, this method is not without its drawbacks, principally the need for manual editing. 
Although segmentations are usually to a high standard as seen in Figure 3.4, there is still a 
need for airway removal and large vessel removal. Vessel removal may be overcome by the 
addition of a vesselness filter to the processing pipeline [314], whilst airway removal could be 
achieved with a region growing algorithm. Additionally, manual selection of clusters is a 
possible source of user bias that needs to be automated. This could be based on the range of 
the data being analysed or possibly SNR, however in practice there is rarely need to change 
the number of clusters from those found empirically. 
 
The limitations of this technical development study are the small numbers of patients 
analysed as well as the reduced number of observers who segmented the 129Xe images and the 
lack of comparison to other established techniques for %VV calculation.  
3.6 Conclusion 
In conclusion, the semi-automated method proposed here reduced image segmentation time 
for the author from 1 hour to less than 25 minutes on average. A semi-automatic segmentation 
robust to noise was demonstrated on both 3He and 129Xe ventilation images. Improvements 
were seen in agreement between users’ values of TLV, VV and %VV using the semi-
automatic method compared to the basic method, and the limitations of the K-means method 
were discussed. 
 
The semi-automated method presented is encapsulated in a custom-built graphical interface 
that is easily portable between sites and easy to use. This software also allows for data which 
is misregistered to be analysed by interfacing with the well-known registration software 
ANTS [84]. This tool may be a step towards moving HP gas ventilation MRI into routine 
clinical use however further work for automation is needed before this can tool can be 
considered clinically useful. 
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CHAPTER 4. HISTOGRAM-BASED ANALYSIS 
OF VENTILATION HETEROGENEITY 
MEASURED BY THE COEFFICIENT OF 
VARIATION OF SIGNAL INTENSITY2 
4.1 Introduction 
As outlined in Chapter 3 the measurement of %VV (or its counterpart VDP) are well known 
and often used methods of evaluating lung ventilation that can be derived from HP gas MRI 
[315-318, 283, 62, 60, 63, 66, 284]. They are however binary measures derived from 
segmenting images that contain rich functional and spatial information about the lung. In this 
chapter, other metrics derived from HP gas ventilation images that provide information on 
ventilation heterogeneity in the lungs are explored. 
 
The signal in ventilation-weighted HP gas images acquired with an SPGR or SSFP sequence 
is directly proportional to the gas spin density, which in turn is directly proportional to the 
ventilation in that voxel and thus these images provide information on ventilation on a 
continuous scale. Images are also weighted by the square of the coil sensitivity profile 
(Transmit (T) and receive (R) using a T/R coil, equation 4.1), whilst coils for HP gas imaging 
would ideally have a uniform πz field there is some inevitable coil inhomogeneity [319-321, 
75].  
 ` Ç ∝ 4 Ç ∙ πz9(Ç) ∙ πzä(Ç) ∙ XY 969~∗(Ö) ∙ XY9Ωæø(Ö)9|(Ö)  (4.1) 
 
Where	` Ç  is the signal in a voxel, 4 Ç  is the ‘ventilation’, the volume of gas within the 
voxel/breath hold, πz9 and πzä are the transmit and receive fields, _O is the echo time of the 
acquisition, _g∗ and _z are intrinsic properties of the gas in the lung voxel at the magnetic field 
used and _¿¡Ø is the time at which the centre of k-space is acquired post gas inhalation for the 
pulse sequence used. In most applications of ventilation image analysis [322, 283, 291, 285, 
78] coil bias is corrected using either a flip angle map [323] or the popular N3 or N4 bias field 
correction methods [324, 293] which require no prior information on the acquisition and 
calculate the bias field in a non-parametric way. 
                                                
2 I would like to acknowledge the efforts of Dr Helen Marshall for segmenting the images from healthy children, 
mild cystic fibrosis and asthma patients scanned with a 2D sequence. 
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One method to analyse ventilation image signal heterogeneity is the coefficient of variation of 
signal intensity (CV), a measure which describes the amount of variability relative to the 
mean of the sample being analysed and is calculated as the ratio of the standard deviation to 
the mean value of the sample [325]. This measure has previously been used to describe the 
ventilation heterogeneity in patients with asthma and healthy subjects, pre and post 
methacholine challenge and after a series of deep inspirations [326]. In this work the final 
heterogeneity score was generated by averaging all non-zero values within the heterogeneity 
map. The heterogeneity map was generated by first calculating a length scale to define as the 
neighbourhood for CV calculation, this neighbourhood was defined as 10% of the average of 
the maximum width of the left and right lungs. A sliding window was then applied over the 
fractional ventilation image, centred on each voxel within the lung ROI and excluding voxels 
dominated by defects with SNR<2. 
 
Ventilation heterogeneity may also be assessed via imaging fractional ventilation using wash-
in [327] or wash-out [67, 69, 70] MRI. These methods of acquisition measure the build-up 
(wash-in) or decay (wash-out) of MR signal in the lungs. An advantage to these methods are 
the dynamic nature of the acquisitions allowing a more complete picture of ventilation 
heterogeneity to be measured rather than a single static breath hold. However, the acquisitions 
are generally complicated and require good patient compliance, with post-processing 
techniques also being fairly complex although these techniques may be more easily 
implemented using fluorinated gases as they do not need to be hyperpolarised before use 
[328-332].  
 
He et al. also quantified the pulmonary ventilation distribution [285] compared to a reference 
of healthy volunteers’ distributions using the normalised ventilation signal, and also 
calculated the CV of the rescaled distribution. This method made use of histogram bins, 
defined from a set of 10 healthy volunteers, and then applied the same bin width to patient 
cohorts. The difference in the standard deviation and mean of the distributions was compared 
with the healthy reference values. 
 
Sa et al. [333] made use of proton MRI to estimate the heterogeneity of the specific 
ventilation measured in humans and carried out a comparison with MBW metrics. The 
heterogeneity here was described as the width of the fitted log(Gaussian) function to the 
distribution of the specific ventilation values. 
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Additionally metrics using SPECT ventilation imaging have been suggested [334, 30]. 
Norberg [30] developed a metric known as CVT which is the area under the curve of the CV 
histogram at a particular threshold, represented as a percentage of the total area under the 
curve whilst Walsh et al. [335] calculated CV locally using SPECT images in patients with 
asthma. 
 
The MBW pulmonary function test has recently become more established for analysing 
ventilation heterogeneity by deriving the measures of lung clearance index (LCI) [120, 33] 
Scond, and Sacin [123]. During the MBW pulmonary function test, which uses inert extrinsic 
gases, there is a wash-in phase where a known concentration of the test gas is administered 
and this phase is completed when the expired gas concentration reaches the level of the 
delivered gas concentration [122]. The wash-out phase then begins with the subject breathing 
room air until the gas concentration is 1/40th the initial concentration for at least 3 consecutive 
breaths [7]. Following this LCI is calculated using FRC and the cumulative expired volume 
from the MBW data [6]. Scond and Sacin are then calculated as described in Chapter 2, section 
2.2.3, and these metrics represent the heterogeneity in the conducting and transitional zones of 
the airway tree respectively. 
 
The aim of this work was to utilise the spatial ventilation heterogeneity information provided 
by the coefficient of variation of signal intensity from HP gas ventilation images by analysing 
CV histogram metrics including skewness (Å), kurtosis (]) and the interquartile range (IQR). 
We go on to compare these metrics of image derived ventilation heterogeneity with those 
derived from the MBW test. 
 
Skewness is a measure of the asymmetry of the data around the mean (sample mean) and a 
normal distribution has Å=0. The more left skewed a data distribution the more negative Å and 
the more right skewed the more positive Å will be [325]. The Skewness of data is defined by 
equation 4.2: 
 Å	 = 	O(l − @)√ƒ√  (4.2) 
 
Where O(c) is the expected value of the quantity c,	@ is the mean and ƒ is the standard 
deviation of the data l. Kurtosis on the other hand is a measure of how outlier prone the data 
is, where the normal distribution has ]=3. Data that is less outlier prone have ]<3 while data 
which is more outlier prone have ]>3 [325]. Kurtosis is defined by equation 4.3: 
 
 60 
 ] = 	O(l − @)≈ƒ≈  (4.3) 
 
Finally the IQR of data is defined as the lower quartile of the data subtracted from the upper 
quartile of the data [325]. Figure 4.1 represents skewness (a), kurtosis (b) and the interquartile 
range (c) visually with distributions generated using MATLAB.  
 
 
Figure 4.1 Graphical representation of (a) skewness, (b) kurtosis and (c) the IQR 
 
The next sections of this chapter discuss the experimentation carried out in order to determine 
the final analysis pipeline for coefficient of variation histogram (CVH) calculation. 
4.2 Calculation of the coefficient of variation of signal 
intensity (CV) 
The coefficient of variation of signal intensity of a spatially variant image data set can be 
calculated in two or three dimensions (in-plane over a square region or in-plane and through-
plane as a cube) and also over different length scales. The length scale is the size of the kernel 
used to cluster data and calculate the local CV. In addition, partial volume effects at the edges 
of the lungs and low SNR will increase the CV and alter the distribution of CV values. It is 
therefore important to understand the effect of the kernel size, dimension and the effect of 
image SNR on the measures being reported.  In this work the CV was calculated using two 
different techniques, both of which are described below. 
 
For calculating CV over the ventilated lung, defined by the ventilated volume mask, both HP 
gas ventilation and 1H anatomical images were segmented. The segmentation method 
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developed in Chapter 3 was used for the 3D imaging data and the manual segmentation 
method was used for the older 2D imaging data. The 1H anatomical image mask was then 
eroded by 1 pixel to account for the partial volume effects at the edge of the lung and to 
ensure no high values of CV at the edges (see Figure 4.2 for an example).  The ventilated 
volume mask, generated from the HP gas image, was then multiplied by the total lung volume 
mask, generated from the 1H anatomical image, to ensure that CV was calculated only within 
the lung cavity. Following segmentation, the HP gas ventilation image, HP gas ventilation 
mask and 1H anatomical masks were downsampled from 256x256xNslices to 128x128xNslices 
for 2D CV calculation or 86x86xNslices for 3D CV calculation. This downsampling was 
chosen so that the smallest possible kernel used for experimentation, 3x3 or 3x3x3 voxels, 
would still encompass multiple acini in the CV measure based on previously reported values 
for the size (path length, the distance from the terminal bronchiole to the end of the acinus) of 
acini (ranging from ~4mm to 8mm depending on inflation level) [336-338]. Also, 
downsampling is performed to ensure that the subsampled image is closer to the actual 
acquisition matrix size. CV is then calculated by dividing the standard deviation of the voxels 
within the neighbourhood with the mean of the voxels within the neighbourhood and 
generating an image where the voxel on which the sliding window is centred is replaced by 
the CV value. The sliding window then only operates on voxels defined as ventilated by the 
ventilated volume mask. For CV metrics generated over the ventilated lung histograms were 
generated using 100 equispaced bins ranging from 0-1. 
 
 
Figure 4.2 Example histograms and CV maps from a healthy subjects 2D SPGR 3He image with (red) and 
without (blue) edge removal 
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Figure 4.2 demonstrates increased histogram skewness and a decreased peak with no edge 
removal when compared to the CV histogram generated following edge removal. The aim of 
the measurement of CV in these neighbourhoods was to attempt to capture the heterogeneity 
present in mild disease that using the standard metric of VDP would not be visualised as it 
would simply be included as ventilated lung e.g. Figure 4.3. 
 
 
Figure 4.3 Example images showing local heterogeneity not visible on the ventilated volume mask. (a) 
original 3He image, a(i) focused area of original image, (b) ventilated volume mask, (c) CV map and c(i) 
focused area of the CV map 
 
For calculating CV over the total lung volume the method by Tzeng et al. [326] was 
implemented where only voxels with an SNR<2 and/or mean neighbourhood SNR<2 were 
excluded e.g. Figure 5.4.  
 
 
Figure 4.4 Example images showing regions included when calculating CV on the ventilated volume mask 
and the total lung volume mask from a patient with COPD. (a) original image, (b) ventilated volume mask, 
(c) ventilated volume mask generated using the SNR threshold and (d) voxels included in the CV 
calculation using the ventilated volume mask (white) and regions with SNR>2 (pink) 
 
(a)	 (b)	 (c)	
a(i)	 c(i)	
(a) (b) (c) (d)
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SNR was calculated using the colfilt routine in MATLAB and a sliding window of 3x3 voxels, 
where the SNR was calculated on the central voxel as well as the mean SNR of the 
neighbourhood and voxels with an SNR<2 and/or mean neighbourhood SNR<2 were 
excluded. Noise was estimated by taking the standard deviation of an area of the image with 
no signal. The imcomplement function was then used to generate a mask of voxels to be 
analysed, generating an SNR based ventilated volume mask (Figure 4.4c). This SNR based 
ventilated volume mask was then multiplied by the total lung volume mask to exclude any 
background voxels outside the lung that may have had an SNR>2. Any voxels outside the 
SNR based ventilated volume mask, but within the total lung volume were set to 0 and 
included in the CV calculation whilst all voxels outside the total lung volume were set to not a 
number (NaN) and excluded from the CV calculation. 
4.3 Effect of image acquisition sequence, signal to noise 
ratio, kernel size and kernel dimensionality on CV 
4.3.1 Overview 
The next section presents the participants and imaging strategies used throughout this chapter. 
Section 4.3.3 discusses the effect of the imaging sequence used and its effect on CV 
histogram metrics in three healthy volunteers. Section 4.3.4 discusses the effect of image SNR 
on CV histogram (CVH) metrics. For CV metrics generated over the total lung histograms 
were generated using 200 equispaced bins ranging from 0-2, as the method introduced an 
increased number of values above 1 compared to estimating the CV on the ventilated lung. 
Section 4.3.5 demonstrates the effect of changing the size of the kernel used in the CV 
calculation, whilst section 4.3.6 demonstrates the effect of changing the dimensionality of the 
kernel on CV histogram metrics. Section 4.4 presents comparisons between health and disease 
using all kernel sizes and dimensionalities and presents the optimal choice for use in these 
cohorts and also demonstrates the correlations of the metrics derived using the optimal kernel 
size and dimensionality with spirometry and MBW outcomes. In addition, a method similar to 
that developed by Norberg et al. [339, 30] is investigated for its usefulness in differentiating 
health from disease. Finally, section 4.5 presents a comparison of metrics derived using HP 
129Xe and HP 3He images. 
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4.3.2 Participants and imaging 
Existing images from previous studies and a database of clinical imaging data were analysed. 
Healthy adults [66], healthy children [33], patients with asthma [71], COPD [340] and CF [33] 
were the selected cohorts. Five patients with asthma and five with COPD were chosen from 
the clinical database that had been segmented using the method described in chapter 3. 
Subject demographics are shown in Table 4.1. Table 4.2 shows the imaging parameters for all 
participants. HP gas ventilation-weighted images were acquired using HP 3He polarized on 
site to approximately 25% using a rubidium spin exchange polarizer (GE Healthcare, 
Amersham, UK). Images were acquired using a 3He transmit-receive flexible vest coil tuned 
to 48.62 MHz (Clinical MR Solutions, Brookfield, WI, USA) and the 1H system body coil as 
previously described [321, 66, 71]. Gas was inhaled from a Tedlar bag (Jensen Inert Products, 
Coral Springs, Florida, USA). 
 
Table 4.1 Subject overview 
 
a - reference [66]; b - reference [33]; c - reference [71]; d - reference [340] 
 
Table 4.2 Imaging parameters for the 3D and 2D scans used in this work. TR = Repetition time, TE = echo 
time, FA = flip angle. Note that slice number and field of view (FOV) was adjusted per patient to ensure 
full lung coverage 
 
 
Patients (acronym) Description Age range Number 3He sequence 1H sequence 
Healthy children (HC) 9 healthy paediatric controls, separate 
studyb, normal FEV1 z-score 
7-16 9 2D SPGR 2D SSFP 
Cystic fibrosis (CF) 19 mild CF paediatric patients, separate 
studyb, normal FEV1 z-score 
7-16 19 2D SPGR 2D SSFP 
Healthy adults (HA) 11 healthy volunteers, separate studya 24-70 11 3D bSSFP 3D SPGR 
Asthma normal FEV1 
(asthma_norm) 
16 patients with asthma, separate study, 
normal FEV1 z-scorec 
21-65 16 2D SPGR 2D SSFP 
Asthma abnormal FEV1 
(asthma_abnorm) 
18 patients with asthma, separate study, 
abnormal FEV1 z-scorec 
34-73 18 2D SPGR 2D SSFP 
Asthma clinical 
(asthma_clinical) 
5 Clinical referrals from Sheffield 
database 
33-72 5 3D bSSFP 3D SPGR 
Chronic obstructive 
pulmonary disease (COPD) 
5 patients from a separate studyd and 5 
clinical referrals from Sheffield database 
59-76 10 3D bSSFP 3D SPGR 
 
Acquisition Sequence TR 
(ms) 
TE 
(ms) 
FA 
(o) 
Bandwidth 
(kHz) 
Matrix size 
(frequency x 
phase) 
FOV 
(cm) 
Voxel size 
(mm) 
Slice 
thickness 
(mm) 
Slices 
1H (3D) SPGR 1.5 0.6 5 167 100x100 40-48 4x4-4.8x4.8 5 46-50 
3He (3D) SSFP 1.9 0.6 10 167 100x80 40-48 4x3.2-4.8x3.8 5 46-50 
1H (2D) SSFP 2.4 0.7 50 167 128x64 32-42 2.3x3.5-3.2x4.9 10 16-24 
3He (2D) SPGR 3.6 1.1 8 62.5 128x102 32-42 2.3x1.8-3.2x2.5 10 16-24 
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4.3.2.1 Healthy children, children with CF and patients with asthma (2D 
sequences) 
34 patients with asthma, 19 children with CF and 9 healthy children underwent multi-slice 2D 
spoiled gradient echo HP 3He ventilation imaging. Patients with asthma inhaled of 350ml 3He 
mixed with 650ml N2 from FRC. CF and HC subjects inhaled an amount of 3He based 
empirically on their FRC [341] mixed with an equal amount of N2 from FRC. Prior to the 3He 
scan a 1H anatomical image at the same inflation level as the 3He scan was acquired. In 
addition all subjects underwent spirometry and multiple breath washout (MBW) [120] in the 
supine position to calculate LCI, Scond and Sacin [342]. See Table 4.2 for imaging sequence 
parameters. 
4.3.2.2 Healthy adults, patients with COPD and patients with asthma (3D 
sequence) 
Three-dimensional 1H anatomical (SPGR) and HP 3He ventilation-weighted (bSSFP) images 
were acquired during the same breath hold for 11 healthy volunteers, 10 patients with COPD 
and 5 patients with asthma, [73, 66]. Imaging parameters can be seen in Table 4.2. HP gas 
ventilation-weighted images were acquired followed immediately by 1H anatomical images. 
Patients inhaled 200mL HP 3He mixed with 800mL N2 from FRC prior to the scan. 
4.3.3 Imaging sequence effects on CV 
4.3.3.1 Participants and materials and methods 
Three of the aforementioned 11 HAs were analysed to investigate the impact of a 2D and 3D 
sequence on CVH analysis. It was restricted to these subjects, since they were the only 
participants with 2D SPGR HP 3He scans carried out on the same day. The method described 
in section 4.2 was used to calculate CV with a kernel size of 3 voxels, and CV was analysed 
in plane only. This kernel size was chosen based on the size of the voxels of the acquired 
images to allow a fair comparison by including approximately the same in-plane area and thus 
an approximately equal number of acini in the measurement of CV. HAs were scanned using 
the 2D and 3D HP 3He sequences presented in section 4.3.1. A 3D SPGR 1H image was 
acquired following the 2D 3He image for the 2D acquisitions, rather than a 2D SSFP 1H 
image acquired in a separate-breath.  
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4.3.3.2 Results 
No statistical tests were carried out to compare SSFP and SPGR CV metrics due to the small 
sample size. When calculating the CV metrics using the VV mask mean and median CV were 
increased, CVH skewness and kurtosis increased and CVH IQR decreased for all participants 
when imaged using the 2D SPGR sequence compared to the 3D SSFP sequence. When 
calculating the CV metrics using the TLV mask mean and median CV were increased, CVH 
skewness and kurtosis decreased and CVH IQR increased for all participants when imaged 
using the 2D SPGR sequence compared to the 3D SSFP sequence. These changes are likely 
due to the generally lower SNR of the 2D SPGR data when compared to the 3D bSSFP data 
[72] and the fact the SPGR images are more heavily T2* weighted and thus show more 
contrast around regions of abrupt susceptibility difference e.g. next to the pulmonary blood 
vessels [343]. It should be noted that this change in SNR is affected mostly by the 2D and 3D 
nature of the sequences being acquired rather than the difference caused in signal generated 
using SPGR or SSFP imaging techniques. To assess the effect of imaging sequence on CV 
correctly a 3D SPGR and 3D bSSFP image should be acquired in healthy volunteers with the 
same dose of HP gas given to assess the change caused by the sequence. 
4.3.4 SNR effect on CV 
4.3.4.1 Participants and materials and methods 
To simulate the effect of image SNR on CVH analysis the 3D images of the 11 HAs scanned 
were analysed along with the asthma_clinical cohort, 5 of the 10 COPD cohort and 5 of the 19 
CF cohort. Gaussian white noise [344] was added to k-space to create images with 
approximately 75%, 50%, 25%, 10% and 5% of the original SNR. The k-space with noise 
added was then reconstructed into image space and analysed using the 2D CV code described 
in section 4.2 with a kernel size of 3x3 voxels. 
4.3.4.2 Results – Healthy adults 
Figure 4.5 shows an example image with an SNR of 42 (a) and 3 (d) with the corresponding 
CV maps generated on the ventilated lung volume mask (b,e) and the total lung volume mask 
(c,f). As can be seen the CV maps generated from the image with an SNR of 3 using the VV 
and TLV masks are quite different. This is because some voxels within the ventilated volume 
did not meet the SNR>2 criteria and thus are excluded from the SNR based ventilated volume 
mask (i.e. the black voxels within the lungs in Figure 4.5f). However, as they are within the 
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total lung volume mask they are set to 0, causing the surrounding regions to have increased 
CV due to their inclusion in the CV calculation. 
 
Figure 4.5 Example images from HA5 used to determine the effect of SNR on CV metrics. (a) original 
image with an SNR of 42 (b) the CV map generated from the original image and VV mask, (c) the CV 
map generated from the original image and TLV mask, (d) image with an SNR of 3, (e) the CV map 
generated from the image with an SNR of 3 and VV mask and (f) the CV map generated from the image 
with an SNR of 3 and TLV mask 
 
 
 
Figure 4.6 HA cohort average values CV metrics plotted as a function of SNR. (a) median CV, (b) CVH 
skewness, (c) CVH kurtosis and (d) CVH IQR generated from the VV and TLV masks. Note that each 
point represents the mean of all 11 HAs at each SNR level 
 
As SNR decreased median CV increased as did CVH IQR whilst CVH skewness and kurtosis 
decreased, this is true for both VV and TLV mask generated CV metrics. 
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Figure 4.7 HA cohort average histograms for all 6 SNR levels generated from the (a) VV mask and (b) 
TLV mask 
 
The histograms shown in Figure 4.7 shows little variation between 100% and 75% SNR with 
almost no movement in the peak location and very similar shapes. As SNR decreases, there is 
a clear shift to a higher peak location and a more Gaussian distribution, seen most clearly in 
the 5% SNR histogram when considering the CV histograms generated from the VV mask. 
When considering the CV histograms generated from the TLV masks there is the addition of a 
second peak at the lowest SNR value, with a similar pattern of a shifted peak as the SNR 
drops. The Friedman’s test summary for CV metrics generated using the VV and TLV masks 
can be seen in Table 4.3. 
Table 4.3 P-values returned by the multiple comparisons of the Friedman test comparing each SNR level 
to the control (100% SNR) when considering CV metrics generated from the VV mask and TLV mask 
 
 
Table 4.3 documents that there was no significant difference between any CV metric when 
image SNR is reduced to 75% of its original value when considering the metrics generated 
using the VV mask, with the lowest SNR seen in these healthy volunteers being 22 (at 100% 
SNR). Additionally, there was no significant difference between CV histogram metrics 
(skewness, kurtosis and IQR) as the image SNR was reduced to 50% of the original SNR. 
Once the image reaches 25% of the original SNR all metrics bar IQR had significant 
differences and as one would expect once the image SNR was 10% of the original value there 
were significant differences in all metrics. These differences of course depend on the original 
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Comparison Mean 
CV 
Median 
CV 
CVH 
skewness 
CVH 
kurtosis 
CVH 
IQR 
100% SNR vs. 75% SNR 0.8573 0.8573 >0. 9999 >0. 9999 >0. 9999 
100% SNR vs. 50% SNR 0.0438 0.0438 0.0835 0.0835 >0.9999 
100% SNR vs. 25% SNR 0.0025 0.0025 0.0039 0.0039 0.7715 
100% SNR vs. 10% SNR <0.0001 <0.0001 <0.0001 <0.0001 0.0017 
100% SNR vs. 5% SNR <0.0001 <0.0001 <0.0001 <0.0001 0.0021 
TLV metrics 
100% SNR vs. 75% SNR 0.9501 0.9501 >0.9999 >0.9999 >0.9999 
100% SNR vs. 50% SNR 0.0517 0.0517 >0.9999 0.7715 >0.9999 
100% SNR vs. 25% SNR 0.0007 0.0007 >0.9999 0.9501 0.8573 
100% SNR vs. 10% SNR <0.0001 <0.0001 >0.9999 >0.9999 0.0058 
100% SNR vs. 5% SNR <0.0001 <0.0001 0.0183 0.0058 <0.0001 
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value of the image SNR. When considering the TLV metrics mean and median CV did not 
become significantly different until the image reached 25% of its SNR level whilst CVH 
metrics do not become significantly different until the image reached 10% of its original value 
for IQR and 5% of its original value for skewness and kurtosis.  The TLV mask based method 
of calculating CV is of course more heavily influenced by the image SNR as is demonstrated 
with the large changes seen as image SNR drops below 10 (Figure 4.6), which also 
demonstrated the relative stability of the VV based method even at these low SNR values. 
The primary reason for this is of course the defined ventilated volume mask remains the same 
whilst the voxels included based on the SNR threshold will vary greatly. There is also a clear 
offset in values of CVH skewness and kurtosis which narrows as the SNR drops below 10, 
suggesting much more similar distributions, even with the introduction of a second peak using 
the TLV based CV method. As analysing the mean and median of this cohort resulted in 
identical p-values it was decided to continue the analysis by analysing the median values of 
the CV maps only. 
4.3.4.3 Results – Patients with asthma 
Figure 4.8 shows an example image with an SNR of 70 (a) and 4 (d) with the corresponding 
CV maps generated using the ventilated lung volume mask (b,e) and the total lung volume 
mask (c,f). As can be seen the same pattern of increased overall heterogeneity was seen in this 
patient with asthma as was seen in the healthy adult shown in Figure 4.5. 
 
Figure 4.8 Example images from a patient with asthma used to determine the effect of SNR on CV metrics. 
(a) original image with an SNR of 70 (b) the CV map generated from the original image and VV mask, (c) 
the CV map generated from the original image and TLV mask, (d) image with an SNR of 4, (e) the CV 
map generated from the image with an SNR of 4 and VV mask and (f) the CV map generated from the 
image with an SNR of 4 and TLV mask 
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Figure 4.9 Asthma_clinical cohort average values CV metrics plotted as a function of SNR. (a) median CV, 
(b) CVH skewness, (c) CVH kurtosis and (d) CVH IQR generated from the VV and TLV masks. Each 
point represents all 5 patients with asthma 
 
For patients with asthma the trends were similar for median CV, CVH skewness and kurtosis 
as those reported for the healthy adults. However, CVH IQR decreased as the SNR decreased 
when using the values from the VV mask and increased when using the TLV mask. In 
addition, the peak shifted to a higher CV value, and a more Gaussian distribution at lower 
SNR is observed when considering the histograms generated from the VV mask. Figure 4.10 
shows increased high CV tails compared to the HAs histograms. This is due to the fact that 
patients with obstructive airways disease in general will have a higher fraction of pixels with 
higher CV (CV>0.3). Histograms generated from the TLV mask do not change in the same 
way as those generated from the VV mask with an increased number of high CV values seen 
rather than a more Gaussian distribution. 
 
 
Figure 4.10 Asthma_clinical cohort average histograms for all 6 SNR levels generated from the (a) VV 
mask and (b) TLV mask 
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4.3.4.4 Results – Patients with COPD 
Figure 4.11 shows an example image with an SNR of 66 (a) and 4 (d) with the corresponding 
CV maps. 
 
Figure 4.11 Example images from a patient with COPD used to determine the effect of SNR on CV 
metrics. (a) original image with an SNR of 66 (b) the CV map generated from the original image and VV 
mask, (c) the CV map generated from the original image and TLV mask, (d) image with an SNR of 4, (e) 
the CV map generated from the image with an SNR of 4 and VV mask and (f) the CV map generated 
from the image with an SNR of 4 and TLV mask 
 
The trends for median CV, CVH skewness, kurtosis and IQR are similar to those seen for the 
patients with asthma as seen in Figure 4.12. 
 
 
Figure 4.12 COPD cohort average values CV metrics plotted as a function of SNR. (a) median CV, (b) 
CVH skewness, (c) CVH kurtosis and (d) CVH IQR generated from the VV and TLV masks. Each point 
represents all 5 patients with COPD 
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Furthermore, the shapes of the histograms for the patients with COPD (Figure 4.13) are 
similar to those for the patients with asthma, up until the image reaches 10% of the original 
SNR with the appearance of a second peak occurring at this point in these COPD patients 
when considering the histograms generated using the TLV mask. 
 
 
Figure 4.13 COPD cohort average histograms for all 6 SNR levels levels generated from the (a) VV mask 
and (b) TLV mask 
4.3.4.5 Results – Children with CF 
Figure 4.14 shows an example image with an SNR of 53 (a) and 3 (d) with the corresponding 
CV maps.  
 
Figure 4.14 Example images from a patient with CF used to determine the effect of SNR on CV metrics. (a) 
original image with an SNR of 53 (b) the CV map generated from the original image and VV mask, (c) the 
CV map generated from the original image and TLV mask, (d) image with an SNR of 3, (e) the CV map 
generated from the image with an SNR of 3 and VV mask and (f) the CV map generated from the image 
with an SNR of 3 and TLV mask 
 
Figure 4.15 shows the effect of changing SNR on median CV, skewness, kurtosis and IQR 
when generated from the VV mask and the TLV masks over the CF cohort analysed. 
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Figure 4.15 CF cohort average values CV metrics plotted as a function of SNR. (a) median CV, (b) CVH 
skewness, (c) CVH kurtosis and (d) CVH IQR generated from the VV and TLV masks. Each point 
represents all 5 patients with CF 
 
 
The patterns seen in are similar to those seen in the HAs. Figure 4.16 shows the results of 
changing the SNR on the cohort average histograms of the CF patients when generated using 
VV and TLV masks. As can be seen the peak shifts to the right as the SNR decreases with an 
increased number of CV values >0.3, rather than a shift to a more Gaussian distribution when 
visually assessing the CV histograms generated from the TLV mask and comparing them to 
those generated from the VV mask.  
 
 
Figure 4.16 CF cohort average histograms for all 6 SNR levels generated from the (a) VV mask and (b) 
TLV mask 
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CF histograms do not display the same frequency of high CV values as the other disease 
cohorts analysed when using the VV mask, possibly due to the mild nature and limited lung 
obstruction of these patients when compared to the other disease cohorts. 
4.3.5 Effect of kernel size on CV 
4.3.5.1 Participants and materials and methods 
All aforementioned datasets were analysed using the CV method mentioned in section 4.2 to 
study the effect of kernel size on CV and CVH metrics. Kernel sizes of 3, 5, 7 and 9 voxels 
were investigated for 2D CV calculation. Note that these kernel sizes were based on the 
resolution of the images used here as well as the size of the human acini [336-338]. 
4.3.5.2 Results 
Figure 4.17 shows the effect of changing kernel size on the CV map of a patient with COPD, 
generated using both the VV and TLV masks. With increasing kernel size the CV map 
becomes smoothed as more voxels are contained within the neighbourhood with any areas of 
high CV being exaggerated as the kernel size increases from 3x3 to 9x9 voxels. 
 
 
Figure 4.17 Examples of the original image and CV maps after increasing the kernel size from a patient 
with COPD. (a) original ventilation image, (b) 3 by 3 voxel kernel CV map generated from the VV mask, 
(c) 5 by 5 voxel kernel CV map generated from the VV mask, (d) 7 by 7 voxel kernel CV map generated 
from the VV mask, (e) 9 by 9 voxel kernel CV map generated from the VV mask, (f) 3 by 3 voxel kernel 
CV map generated from the TLV mask, (g) 5 by 5 voxel kernel CV map generated from the TLV mask, (h) 
7 by 7 voxel kernel CV map generated from the TLV mask and (i) 9 by 9 voxel kernel CV map generated 
from the TLV mask 
 
Additionally, the median CV over the whole map increases as the kernel size increases as 
represented by the shifting peak seen in the example histograms (Figure 4.18). 
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Figure 4.18 CV histograms generated using different kernel sizes from a patient with COPD generated 
using the (a) VV mask and (b) TLV mask 
  
Figure 4.19 shows the effect of increasing kernel size for all groups on median CV 
measurements generated from the VV mask and Figure 4.20 shows the change when 
considering metrics generated from the TLV mask. There is a clear trend of increasing 
median CV in all groups as the kernel size increases. 
 
 
Figure 4.19 Plots of median CV for different kernel sizes for all groups generated from the VV mask. (a) 
HC, (b) CF, (c) HV, (d) asthma_clincial, (e) COPD, (f) asthma_norm and (g) asthma_abnorm. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
0 0.2 0.4 0.6 0.8 1
CVH
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
Kernel	size	
0 0.2 0.4 0.6 0.8 1
CVH
0
0.5
1
1.5
2
2.5
3
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
Kernel	size	
(a) (b)
0 0.5 1 1.5 2
CVH
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
(a) (b)
0 0.2 0.4 0.6 0.8 1
CVH
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 els
9 by 9 els
Kernel	size	
0 0.2 0.4 0.6 0.8 1
CVH
0
0.5
1
1.5
2
2.5
3
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
Kernel	size	
(a) (b)
0 0.5 1 1.5 2
CVH
0
0.5
1
1.5
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
(a) (b)
0 0.5 1 1.5 2
CVH
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
0 0.2 0.4 0.6 0.8 1
CVH
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by  xels
Kernel	size	
0 0.2 0.4 0.6 0.8 1
CVH
0
0.5
1
1.5
2
2.5
3
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
Kernel	size	
(a) (b)
0 0.5 1 1.5 2
CVH
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
3 by 3 voxels
5 by 5 voxels
7 by 7 voxels
9 by 9 voxels
(a) (b)
(a) (b)
HC
_3
by
3
HC
_5
by
5
HC
_7
by
7
HC
_9
by
9
0
5
10
15
20
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
no
rm
_3
by
3
as
thm
a_
no
rm
_5
by
5
as
thm
a_
no
rm
_7
by
7
as
thm
a_
no
rm
_9
by
9
0
10
20
30
40
Kernel size
M
ed
ia
n 
C
V 
(%
)
CO
PD
_3
by
3
CO
PD
_5
by
5
CO
PD
_7
by
7
CO
PD
_9
by
9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
CF
_3
by
3
CF
_5
by
5
CF
_7
by
7
CF
_9
by
9
0
10
20
30
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
ab
no
rm
_3
by
3
as
thm
a_
ab
no
rm
_5
by
5
as
thm
a_
ab
no
rm
_7
by
7
as
thm
a_
ab
no
rm
_9
by
9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
HA
_3
by
3
HA
_5
by
5
HA
_7
by
7
HA
_9
by
9
0
5
10
15
20
25
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
cli
nic
al_
3b
y3
as
thm
a_
cli
nic
al_
5b
y5
as
thm
a_
cli
nic
al_
7b
y7
as
thm
a_
cli
nic
al_
9b
y9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
(a)	 (b)	 (c)	
(d)	 (e)	 (f)	
(g)	
HC
_3
by
3
HC
_5
by
5
HC
_7
by
7
HC
_9
by
9
0
5
10
15
20
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
no
rm
_3
by
3
as
thm
a_
no
rm
_5
by
5
as
thm
a_
no
rm
_7
by
7
as
thm
a_
no
rm
_9
by
9
0
10
20
30
40
Kernel size
M
ed
ia
n 
C
V 
(%
)
CO
PD
_3
by
3
CO
PD
_5
by
5
CO
PD
_7
by
7
CO
PD
_9
by
9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
CF
_3
by
3
CF
_5
by
5
CF
_7
by
7
CF
_9
by
9
0
10
20
30
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
ab
no
rm
_3
by
3
as
thm
a_
ab
no
rm
_5
by
5
as
thm
a_
ab
no
rm
_7
by
7
as
thm
a_
ab
no
rm
_9
by
9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
HA
_3
by
3
HA
_5
by
5
HA
_7
by
7
HA
_9
by
9
0
5
10
15
20
25
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
cli
nic
al_
3b
y3
as
thm
a_
cli
nic
al_
5b
y5
as
thm
a_
cli
nic
al_
7b
y7
as
thm
a_
cli
nic
al_
9b
y9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
(a)	 (b)	 (c)	
(d)	 (e)	 (f)	
(g)	
HC
_3
by
3
HC
_5
by
5
HC
_7
by
7
HC
_9
by
9
0
5
10
15
20
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
no
rm
_3
by
3
as
thm
a_
no
rm
_5
by
5
as
thm
a_
no
rm
_7
by
7
as
thm
a_
no
rm
_9
by
9
0
10
20
30
40
Kernel size
M
ed
ia
n 
C
V 
(%
)
CO
PD
_3
by
3
CO
PD
_5
by
5
CO
PD
_7
by
7
CO
PD
_9
by
9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
CF
_3
by
3
CF
_5
by
5
CF
_7
by
7
CF
_9
by
9
0
10
20
30
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
ab
no
rm
_3
by
3
as
thm
a_
ab
no
rm
_5
by
5
as
thm
a_
ab
no
rm
_7
by
7
as
thm
a_
ab
no
rm
_9
by
9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
HA
_3
by
3
HA
_5
by
5
HA
_7
by
7
HA
_9
by
9
0
5
10
15
20
25
Kernel size
M
ed
ia
n 
C
V 
(%
)
as
thm
a_
cli
nic
al_
3b
y3
as
thm
a_
cli
nic
al_
5b
y5
as
thm
a_
cli
nic
al_
7b
y7
as
thm
a_
cli
nic
al_
9b
y9
0
10
20
30
40
50
Kernel size
M
ed
ia
n 
C
V 
(%
)
(a)	 (b)	 (c)	
(d)	 (e)	 (f)	
(g)	
 76 
 
Figure 4.20 Plots of median CV for different kernel sizes for all groups generated from the TLV mask. (a) 
HC, (b) CF, (c) HV, (d) asthma_clincial, (e) COPD, (f) asthma_norm and (g) asthma_abnorm. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
Increase in kernel size causes a decrease in CVH skewness for all groups as shown in Figures 
4.21 and 4.22 and this pattern is seen when the CV metrics are generated from both the VV 
and TLV masks. 
 
Figure 4.21 Plots of CVH skewness at different kernel sizes for each of the groups of subjects imaged 
generated from the VV mask. (a) HA, (b) HC, (c) asthma_clinical, (d) COPD, (e) CF, (f) asthma_norm 
and (g) asthma2Dabnorm. Each point represents a measurement from a single subject, error bars 
represent group means and standard deviations 
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Figure 4.22 Plots of CVH skewness at different kernel sizes for each of the groups of subjects imaged 
generated from the TLV mask. (a) HA, (b) HC, (c) asthma_clinical, (d) COPD, (e) CF, (f) asthma_norm 
and (g) asthma2Dabnorm. Each point represents a measurement from a single subject, error bars 
represent group means and standard deviations 
 
CVH kurtosis also decreases as the kernel size increases (Figures 4.23 to 4.24) with the most 
marked change being seen between the kernel sizes of 3 and 5 voxels for all groups and this 
pattern is seen when the CV metrics are generated from both the VV and TLV masks. 
 
Figure 4.23 Plots of CVH kurtosis at different kernel sizes for all groups generated from the VV mask. (a) 
HC, (b) CF, (c) HV, (d) asthma_clincial, (e) COPD, (f) asthma_norm and (g) asthma_abnorm. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
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Figure 4.24 Plots of CVH kurtosis at different kernel sizes for all groups generated from the TLV mask. (a) 
HC, (b) CF, (c) HV, (d) asthma_clincial, (e) COPD, (f) asthma_norm and (g) asthma_abnorm. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
CVH IQR increases as kernel size increases for HA, HC and COPD groups (Figures 4.25 to 
4.26). However, for the asthma_clinical group there is an increase between 3 and 7 voxels and 
then a decrease at 9 voxels, this pattern is also seen, but not to the same extent, in both asthma 
groups scanned with the 2D sequence. CF patients have an increase when the kernel size 
increases from 3 to 5 voxels, with the values at a kernel size of 5 and 7 voxels being similar 
before a slight decrease at a kernel size of 9 voxels occurs when generated from the VV mask.  
 
 
Figure 4.25 Plots of CVH IQR at different kernel sizes for each of the groups of subjects imaged generated 
from the VV mask. (a) HC, (b) CF, (c) HV, (d) asthma_clincial, (e) COPD, (f) asthma_norm and (g) 
asthma_abnorm. Each point represents a measurement from a single subject, error bars represent group 
means and standard deviations 
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Figure 4.26 Plots of CVH IQR at different kernel sizes for each of the groups of subjects imaged generated 
from the TLV mask. (a) HC, (b) CF, (c) HV, (d) asthma_clincial, (e) COPD, (f) asthma_norm and (g) 
asthma_abnorm. Each point represents a measurement from a single subject, error bars represent group 
means and standard deviations 
 
When considering the metrics generated from the TLV mask CVH IQR increases as kernel 
size increases for the HC and HA groups, although the increase is minimal in the HA group 
when compared to the HC group. Patients with CF and asthma CVH IQR values increase as 
the kernel increases from 3 to 7 voxels with a small reduction in CVH IQR between the 
kernel sizes of 7 and 9 voxels. Interestingly COPD patients follow this pattern when the 
metrics are generated from the TLV mask. 
4.3.6 2D vs 3D dimensionality - effect on CV 
4.3.6.1 Participants and materials and methods 
All participants scanned with the 3D bSSFP 3He sequence were analysed to compare the 
effect of the dimensionality of the kernel used on CV and CVH metrics. A kernel size of 3x3 
voxels was used for 2D CV calculation, and a kernel size of 3x3x3 voxels (~9x9x10mm) was 
used for 3D CV calculation – this resulted in an approximately isotropic cube once the 3D 
image was subsampled.  
4.3.6.2 Results 
Figure 4.27 shows the results of changing the dimensionality of the kernel used to generate 
CV maps from images of a healthy volunteer and patients with COPD and asthma. Changing 
from a 2D to a 3D kernel introduced pronounced smoothing. Additionally, areas of high CV 
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became more pronounced in the 3D CV map, particularly for the patients with asthma and 
COPD (note that the same pattern is seen when considering the CV map generated using the 
TLV mask).  
 
 
Figure 4.27 Example slices of a 3D ventilation image dataset and the corresponding CV maps generated 
from 2 and 3 dimensional kernels and the VV mask generated from a healthy volunteer (a-c) a patient 
with COPD (d-f) and a patient with asthma (g-i). (a) HA ventilation image, (b) HA 2D CV map, (c) HA 3D 
CV map, (d) COPD ventilation image, (e) COPD 2D CV map, (f) COPD 3D CV map, (g) patient with 
asthma ventilation image, (h) patient with asthma 2D CV map and (i) patient with asthma 3D CV map 
 
This change can also be seen in the histograms for these examples (Figure 4.28), with a 
broader shape and peak shifted to the right indicating higher CV overall in the 3D map when 
compared to the 2D map. 
 
 
Figure 4.28 Example histograms for the HA, asthma and COPD patients shown in Figure 4.27 generated 
using the (a) VV mask and (b) the TLV mask 
 
Figure 4.29 shows plots for the three patient groups analysed to compare the effect of 
dimensionality on the CV metrics. When comparing the 2D and 3D metrics generated from 
the VV mask a significant increase was seen in median CV for HAs (p=0.0010) when a 3D 
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kernel was used compared to a 2D kernel, as well as a significant decrease in both CVH 
skewness and kurtosis (p=0.0010 for both). CVH IQR changed non-significantly for HAs 
(p=0.2402). No significant changes were seen in median CV, CVH skewness or CVH kurtosis 
for the asthma_clinical group (p=0.0625 for all), but this may be due to the small sample size, 
and similar to the HA group no significant difference was seen in CVH IQR (p=0.1250). All 
metrics were significantly different using 2D and 3D kernels for the COPD group; median CV 
(p=0.002), CVH skewness (p=0.002), CVH kurtosis (p=0.0039) and CVH IQR (p=0.0039). 
When considering the 2D and 3D metrics generated from the TLV mask median CV, CVH 
skewness and kurtosis all increased significantly for the HAs (p=0.0010 for all) whilst CVH 
IQR was not significantly different (p=0.2305). No metric changed significantly for the 
asthma_clinical cohort (p=0.0625 for median CV, CVH skewness and kurtosis, p>0.9999 for 
CVH IQR). When considering the 2D and 3D metrics generated from the TLV mask for the 
COPD cohort median CV and CVH skewness were significantly different (p=0.0020 and 
p=0.0059 respectively) whilst CVH kurtosis was not significantly different (p=0.5566). In 
contrast to the two other cohorts analysed CVH IQR was significantly different (p=0.0195). 
 
 
Figure 4.29 Plots of CV metrics for 2D and 3D CV calculation for all groups analysed generated from VV 
(a-d) and TLV(e-h) masks. (a) median CV, (b) CVH skewness, (c) CVH kurtosis, (d) CVH IQR, (e) 
median CV, (f) CVH skewness, (g) CVH kurtosis and (h) CVH IQR. Each point represents measurements 
from a single subject, error bars represent group means and standard deviations 
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4.4 CVH metrics as a tool to differentiate health from 
disease 
The aim of this work was to use CVH metrics to differentiate different disease groups from 
healthy volunteers. For this study the 2D CVH metrics are reported with the healthy children 
when compared to the mild cystic fibrosis patients only, and the healthy adults are compared 
to the remaining groups. It is not yet clear what effect age might have on the heterogeneity of 
ventilation as measured using the CVH metrics. 
4.4.1 Participants and imaging 
All participants (HA, HC, CF, asthma_norm, asthma_abnorm, asthma_clinical and COPD) 
were analysed for this section of the work. Imaging parameters are listed in section 4.3.  
4.4.2 Analysis 
All images were analysed using the 2D CV methodology (section 4.2) with all 
aforementioned kernel sizes investigated to establish which provided the best distinction 
between health and disease. Additionally, the participants scanned with the 3D bSSFP 3He 
sequence were compared via the optimal 2D kernel size and the 3D kernel to establish which 
dimension kernel best separated health from disease. The Kruskal-Wallis test was used to 
compare the HA to patient groups, whilst the Mann-Whitney test was used to compare HC to 
CF. In addition, the HC, CF, asthma_norm and asthma_abnorm datasets were analysed for 
correlations with LCI and Scond metrics derived from MBW, as well as correlation with FEV1 
and the FEV1/FVC ratio. 
4.4.3 Results 
4.4.3.1 Differentiating health from disease by kernel size 
Figure 4.27 shows a plot of the metrics (generated from both the VV and TLV masks) found 
for the disparate groups when analysed with the 2D CV methodology and a kernel size of 3x3 
voxels. Median CV was found to increase in all patient groups when compared to the HA/HC 
groups. Additionally, all patient groups had lower CVH skewness and kurtosis and increased 
CVH IQR when compared to the corresponding healthy groups. VDP is also increased in all 
patient groups when compared to the HA/HC groups as has been shown previously [77, 33]. 
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Figure 4.30 Plots of CV metrics for all groups analysed generated using a kernel size of 3 voxels generated 
from VV (a-d) and TLV(f-i) masks. (a) median CV, (b) CVH skewness, (c) CVH kurtosis, (d) CVH IQR, (e) 
VDP, (f) median CV, (g) CVH skewness, (h) CVH kurtosis and (i) CVH IQR. Ventilation defect percent 
(VDP) is shown for comparison. Each point represents a measurement from a single subject, error bars 
represent group means and standard deviations 
 
Table 4.4 shows the results of the Kruskal-Wallis test to compare differences seen between 
CV metrics for the healthy adults and the asthmatic and COPD groups, and the Mann-
Whitney test to compare the healthy children and CF group using CV metrics generated by 
both VV and TLV masks. The Kruskal-Wallis test was used as the comparisons made were 
between 4 groups and the Mann-Whitney test used as the comparison was between two 
groups only.  
 
Table 4.4 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD groups, as 
well as Mann-Whitney results comparing the healthy children and CF group using CV metrics. Results 
are calculated using a kernel size of 3 voxels and the standard measure of lung function in pulmonary 
MRI, VDP 
 
 
When considering metrics generated from the VV mask all CVH metrics can differentiated 
the healthy children from the CF cohort, with CVH IQR providing the same significance level 
as VDP. CVH skewness and CVH kurtosis were the only metrics, including VDP, that 
differentiated the healthy adults from the patients with asthma and normal FEV1 z-score. All 
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CV metrics also significantly differentiated the healthy adults from the remaining groups, 
with median CV, CVH skewness and kurtosis at the same significance as VDP when 
comparing the healthy adults and the patients with asthma and abnormal FEV1 z-score. 
Additionally, CVH metrics differentiated the healthy adults from the clinical asthma group 
more significantly than VDP. CVH IQR and median CV also differentiated the healthy adults 
from the COPD group to the same significance level as VDP, whilst CVH skewness and 
kurtosis separated them to a lesser extent than VDP. When considering metrics generated 
from the TLV mask only median CV and CVH IQR separated the healthy children from the 
children with CF, with CVH IQR providing the same significance level as VDP. No CVH 
metric could differentiate the healthy adults from the patients with asthma and normal FEV1 
z-score. Median CV, CVH kurtosis and CVH IQR were the only metrics able to differentiate 
the healthy adults from the patients with asthma and abnormal FEV1 z-score and the healthy 
adults from the asthma_clinical cohort. CVH IQR separated the healthy adults from the 
patients with asthma and abnormal FEV1 z-score to the same level of significance as VDP. 
All CVH metrics differentiated the healthy adults from the patients with COPD with median 
CV, CVH kurtosis and CVH IQR providing the same significance level as VDP.  
 
Figure 4.31 shows a plot of all metrics for all groups when analysed with the 2D CV 
methodology and a kernel size of 5 voxels. Similar patterns of change in each of the CV 
metrics were seen using this kernel size as were seen using a kernel size of 3 voxels. 
 
Figure 4.31 Plots of CV metrics for all groups analysed generated using a kernel size of 5 voxels generated 
from VV (a-d) and TLV(e-h) masks. (a) median CV, (b) CVH skewness, (c) CVH kurtosis, (d) CVH IQR, 
(e) median CV, (f) CVH skewness, (g) CVH kurtosis and (h) CVH IQR. Ventilation defect percent (VDP) 
is shown for comparison. Each point represents a measurement from a single subject, error bars 
represent group means and standard deviations 
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Table 4.5 shows the results of the Kruskal-Wallis test to compare the healthy adults to the 
asthmatic and COPD groups, and the Mann-Whitney test to compare the healthy children and 
CF group using both CV metrics.  
 
Table 4.5 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD groups 
and the Mann-Whitney results comparing the healthy children and CF group using CV metrics calculated 
using a kernel size of 5 voxels 
 
 
When considering metrics generated from the VV mask all CVH metrics differentiated the 
healthy children from the patients with CF. Only CVH skewness and kurtosis were able to 
differentiate the healthy adults from the patients with asthma and normal FEV1 z-score at a 
kernel size of 5 voxels. All CV metrics also significantly differentiated the healthy adults 
from the remaining groups, with all CVH metrics bar IQR providing the same level of 
significance as VDP at a kernel size of 5 voxels to differentiate the healthy adults from the 
patients with asthma and abnormal FEV1 z-score. Additionally, CVH metrics differentiated 
the healthy adults from the asthma_clinical cohort more significantly than VDP at a kernel 
size of 5 voxels. CVH IQR and median CV also differentiate the healthy adults from the 
COPD group to the same significance level as VDP, whilst CVH skewness and kurtosis 
separated them to a lesser extent than VDP.  When considering metrics generated from the 
TLV mask, median CV and CVH IQR were the only metrics that separated the healthy 
children from the children with CF, the healthy adults from the patients with asthma and 
abnormal FEV1 z-score, and the healthy adults from the asthma_clinical cohort. All CVH 
metrics differentiated the healthy adults from the patients with COPD. As with a kernel size 
of 3 voxels no CVH metric differentiated the healthy adults from the patients with asthma and 
normal FEV1 z-score. 
 
Comparison Median 
CV 
CVH 
Skewness 
CVH 
Kurtosis 
CVH 
IQR 
HC vs. CF 0.0020 <0.0001 0.0002 <0.0001 
HA vs. asthma_norm 0.2007 0.0061 0.0118 0.2116 
HA vs. asthma_abnorm <0.0001 <0.0001 <0.0001 0.0004 
HA vs. asthma_clinical 0.0089 0.0063 0.0006 0.0002 
HA vs. COPD <0.0001 0.0007 0.0005 <0.0001 
TLV comparison 
HC vs. CF 0.0016 0.5619 0.3829 <0.0001 
HA vs. asthma_norm 0.1651 >0.9999 >0.9999 0.2705 
HA vs. asthma_abnorm <0.0001 0.2591 0.0631 <0.0001 
HA vs. asthma_clinical 0.0033 0.3226 0.1645 0.0007 
HA vs. COPD <0.0001 0.0005 <0.0001 <0.0001 
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Figure 4.32 shows a plot of all metrics for all groups when analysed with the 2D CV 
methodology and a kernel size of 7 voxels. As with using a kernel size of 3 or 5 voxels there 
is the same pattern of change seen when comparing the CV metrics between the groups. 
 
 
Figure 4.32 Plots of CV metrics for all groups analysed generated using a kernel size of 7 voxels generated 
from the VV (a-d) and TLV(e-h) masks. (a) median CV, (b) CVH skewness, (c) CVH kurtosis, (d) CVH 
IQR, (e) median CV, (f) CVH skewness, (g) CVH kurtosis and (h) CVH IQR. Ventilation defect percent 
(VDP) is shown for comparison. Each point represents a measurement from a single subject, error bars 
represent group means and standard deviations 
 
Table 4.6 shows the results of the Kruskal-Wallis test comparing the healthy adults to the 
asthmatic and COPD groups, and the Mann-Whitney test comparing the healthy children and 
CF group.  
 
Table 4.6 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD groups 
and the Mann-Whitney results comparing the healthy children and CF group using CV metrics calculated 
using a kernel size of 7 voxels 
 
 
When considering metrics generated from the VV mask all CVH metrics differentiated the 
healthy children from the CF. Only CVH skewness was able to differentiate the healthy adults 
from the patients with asthma and normal FEV1 z-score at a kernel size of 7 voxels. All CV 
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Comparison Median 
CV 
CVH 
Skewness 
CVH 
Kurtosis 
CVH 
IQR 
HC vs. CF 0.0020 0.0001 0.0001 <0.0001 
HA vs. asthma_norm 0.3670 0.0326 0.0994 0.3575 
HA vs. asthma_abnorm <0.0001 0.0004 0.0004 0.0004 
HA vs. asthma_clinical 0.0111 0.0246 0.0036 0.0005 
HA vs. COPD <0.0001 0.0003 0.0005 <0.0001 
TLV comparison 
HC vs. CF 0.0010 >0.9999 0.8470 <0.0001 
HA vs. asthma_norm 0.2130 >0.9999 >0.9999 0.3326 
HA vs. asthma_abnorm <0.0001 0.6837 0.1832 <0.0001 
HA vs. asthma_clinical 0.0045 >0.9999 0.3754 0.0008 
HA vs. COPD <0.0001 0.0016 0.0003 <0.0001 
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metrics also significantly differentiated the healthy adults from the remaining groups, with 
median CV and CVH IQR differentiating the healthy adults from the patients with asthma and 
abnormal FEV1 z-score to the same level of significance as VDP. Additionally, CVH metrics 
differentiated the healthy adults from the clinical asthma group more significantly than VDP 
at a kernel size of 7 voxels, although the p value of CVH skewness is very similar to that of 
VDP for this group. CVH IQR and median CV also differentiate the healthy adults from the 
COPD group to the same significance level as VDP, whilst CVH skewness and kurtosis 
separate them to a lesser extent than VDP. When considering metrics generated from the TLV 
mask no CVH metric differentiated the healthy adults from the patients with asthma and 
normal FEV1 z-score, median CV and CVH IQR separated the healthy children from the 
children with CF, the healthy adults from the patients with asthma and abnormal FEV1 z-
score, and the healthy adults from the asthma_clinical cohort, whilst all CVH metrics 
differentiated the healthy adults from the patients with COPD. 
 
Figure 4.33 shows a plot of all metrics for all groups when analysed with the 2D CV 
methodology and a kernel size of 9 voxels.  
 
 
 Figure 4.33 Plots of CV metrics for all groups analysed generated using a kernel size of 9 voxels 
generated from the VV (a-d) and TLV(e-h) masks. (a) median CV, (b) CVH skewness, (c) CVH kurtosis 
and (d) CVH IQR. Each point represents a measurement from a single subject, error bars represent 
group means and standard deviations 
 
Table 4.7 shows the results of the Kruskal-Wallis in comparing healthy adults to asthmatic 
and COPD groups. Results of the Mann-Whitney test in comparing healthy children to the CF 
group using CV metrics are also shown.  
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Table 4.7 Kruskal-Wallis test results comparing the healthy adults to the asthmatic and COPD groups 
and the Mann-Whitney results comparing the healthy children and CF group using CV metrics calculated 
using a kernel size of 9 voxels 
 
 
When considering metrics generated from the VV mask all CVH metrics differentiated the 
healthy children from the CF. No CVH metrics were able to differentiate the healthy adults 
from the patients with asthma and normal FEV1 z-score at a kernel size of 9 voxels. Only 
median CV provided the same level of significance as VDP at a kernel size of 9 voxels to 
differentiate the healthy adults from the patients with asthma and abnormal FEV1 z-score, 
although all other metrics still differentiated these groups. Median CV, CVH kurtosis and 
IQR differentiated the healthy adults from the asthma_clincial cohort at a kernel size of 9 
voxels. CVH IQR and median CV also differentiated the healthy adults from the COPD group 
to the same significance level as VDP, whilst CVH skewness and kurtosis separated them to a 
lesser extent than VDP. When considering metrics generated from the TLV mask only median 
CV and CVH IQR separated the healthy children from the children with CF. No CVH metrics 
were able to differentiate the healthy adults from the patients with asthma and normal FEV1 z-
score. All CVH metrics can differentiate the healthy adults from the patients with asthma and 
abnormal FEV1 z-score. Median CV and CVH IQR differentiated the healthy adults from the 
asthma_clincial cohort. All CVH metrics differentiated the healthy adults from the COPD 
group to the same significance level as VDP. 
 
Generally, the level of significance between the healthy children and patients with CF 
remained at similar levels or became less significant when increasing the kernel size from 3 to 
9 voxels, although at a kernel size of 7 voxels CVH kurtosis and skewness differentiated the 
groups more significantly than at 3 voxels. CVH IQR remained at the same significance level 
(p<0.0001) and significant differences remained between all other metrics generated using the 
VV mask. 
 
Comparison Median 
CV 
CVH 
Skewness 
CVH 
Kurtosis 
CVH 
IQR 
HC vs. CF 0.0007 0.0003 0.0016 <0.0001 
HA vs. asthma_norm 0.4337 0.1453 0.4057 0.4890 
HA vs. asthma_abnorm <0.0001 0.0017 0.0013 0.0004 
HA vs. asthma_clinical 0.0099 0.1653 0.0227 0.0012 
HA vs. COPD <0.0001 0.0006 0.0013 <0.0001 
TLV comparison 
HC vs. CF 0.0007 0.2634 0.1564 <0.0001 
HA vs. asthma_norm 0.2061 >0.9999 >0.9999 0.4247 
HA vs. asthma_abnorm <0.0001 0.0401 0.0072 <0.0001 
HA vs. asthma_clinical 0.0046 0.3461 0.0637 0.0016 
HA vs. COPD <0.0001 <0.0001 <0.0001 <0.0001 
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The level of significance when comparing the healthy adults to the patients with asthma and 
normal FEV1 z-scores decreased as the kernel size increases with median CV not being able 
to differentiate these groups at any kernel size. When comparing the healthy adults to the 
patients with asthma and abnormal FEV1 z-scores median CV remained at the same 
significance level regardless of kernel size, while CVH skewness and kurtosis became less 
significantly different at a kernel size of 7 voxels. CVH IQR became less significantly 
different at a kernel size of 5 voxels. When comparing the healthy adults to the 
asthma_clinical cohort median CV became more significantly different as kernel size 
increased while CVH IQR became less significant. CVH skewness and kurtosis became more 
significantly different at a kernel size of 5 voxels when compared to a kernel size of 3 voxels 
before becoming less significant at kernel sizes of 7 and 9 voxels.  When comparing the 
healthy adults to the patients with COPD the difference in median CV and CVH IQR 
remained at the same significance (p<0.0001). CVH skewness became more significantly 
different at a kernel size of 5 and 7 voxels before decreasing at 9 voxels, although at all kernel 
sizes the difference was more significant than that seen at a kernel size of 3 voxels. CVH 
kurtosis became more significantly different at a kernel size of 5 voxels compared to 3 voxels 
and remained at this significance level at a kernel size of 7 voxels before becoming less 
significantly different at a kernel size of 9 voxels. 
 
When considering the metrics generated using the TLV mask, the difference in median CV 
became more significant as kernel size increases, whilst the level of significance of CVH IQR 
remained at p<0.0001. The level of significance when comparing the healthy adults to the 
patients with asthma and normal FEV1 z-scores decreased as the kernel size increased with no 
CV metric being able to differentiate these groups at any kernel size. When comparing the 
healthy adults to the patients with asthma and abnormal FEV1 z-scores median CV and CVH 
IQR remained at the same significance level regardless of kernel size, while CVH skewness 
and kurtosis did not separate these groups at a kernel size of 5 and 7 voxels but was able to at 
kernel sizes of 3 and 9 voxels. When comparing the healthy adults to the asthma_clinical 
cohort median CV became more significantly different between a kernel size of 3 and 5 
voxels, and then became less significantly different, and CVH IQR follows this pattern in 
differentiating these groups. CVH skewness did not separate these groups at any kernel size, 
whilst CVH kurtosis only separated these groups at a kernel size of 3 voxels. When 
comparing the healthy adults to the patients with COPD the difference in median CV and 
CVH IQR remained at the same significance (p<0.0001) regardless of kernel size. CVH 
skewness became less significantly different between a kernel size of 3 and 7 voxels, before 
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becoming more significantly different at a kernel size of 9 voxels, with CVH kurtosis 
following the same pattern. In summary based on these results it seems the most logical 
kernel size to use in CV calculations is 3 voxels as it was best able to differentiate the healthy 
adults from the patients with asthma and normal FEV1 z-scores whilst all other kernel sizes 
are either less significantly different or fail to differentiate these groups. Furthermore, it 
appears using metrics generated using the VV mask is optimal as using those generated from 
the TLV mask could not differentiate these groups, and in most cases the level of significance 
is decreased when analysing the CV metrics generated on the TLV mask, although the metrics 
generated using this mask are more significantly different in some cases. The next stage was 
to determine whether a 2D or 3D kernel was optimum and if this would alter the choice of 
using the VV or TLV masks. 
4.4.3.2 Differentiating ventilation heterogeneity in health and disease by 
kernel dimensionality 
4.4.3.2.1 Participants and materials and methods 
The participants for this study were the same as those listed in section 4.3.5 with the same 
methodology for CV calculation (section 4.2) also being used and a kernel size of 3x3 voxels 
for the 2D calculation and 3x3x3 for the 3D calculation. 
4.4.3.2.2 Results 
Table 4.8 shows the results of comparing the HA group to the asthma_clinical and COPD 
groups with metrics calculated using the 2D and 3D CV methodologies. 
Table 4.8 Kruskal-Wallis test results comparing groups using 2D and 3D CV metrics  
 
 
Comparison Median 
CV 
CVH 
Skewness 
CVH 
Kurtosis 
CVH 
IQR 
2D metrics 
HA vs. asthma_clinical 0.0246 0.0028 0.0015 0.0073 
HA vs. COPD <0.0001 0.0025 0.0028 0.0001 
3D metrics 
HA vs. asthma_clinical 0.0175 0.0098 0.0021 0.0098 
HA vs. COPD <0.0001 0.0018 0.0038 <0.0001 
TLV comparison 
2D metrics 
HA vs. asthma_clinical 0.0268 0.0718 0.0481 0.0453 
HA vs. COPD <0.0001 <0.0001 <0.0001 <0.0001 
3D metrics 
HA vs. asthma_clinical 0.0153 0.0509 0.0074 0.0083 
HA vs. COPD <0.0001 0.0008 0.0013 0.0002 
 
 91 
When considering the metrics generated from the VV mask and comparing the HA group to 
the asthma_clinical group using the 3D CV methodology the difference in median CV 
became more significant when compared to the 2D method, whilst CVH skewness, kurtosis 
and IQR differences became less significant. When comparing the HA group to the COPD 
group using the 3D CV methodology there was no change in the significance of difference 
between the median CV of the two groups. CVH skewness and IQR differences became more 
significant, whilst CVH kurtosis differences became less significant. When considering the 
metrics generated from the TLV mask and comparing the HA group to the asthma_clinical 
group using the 3D CV methodology the difference in median CV became more significantly 
different when compared to the 2D method, as did CVH skewness, kurtosis and IQR, 
although CVH skewness was not able to differentiate these groups using either method. When 
comparing the HA group to the COPD group using the 3D CV methodology there was no 
change in the significance of difference between the median CV of the two groups. CVH 
skewness, kurtosis and IQR differences became less significant. Taking into account all 
metrics these results further corroborate the results of the previous section in suggesting that 
based on the data used here the 2D CV methodology with a kernel size of 3 voxels is the most 
suitable to differentiate health from disease, with the metrics being generated on the ventilated 
lung mask rather than the total lung volume mask. However, it should be noted that this 
becomes a more complex with the 3D CV metrics and metrics generated using the TLV mask 
increasing the significance in some situations when compared to the 2D metrics. 
4.4.3.3 Correlations with Spirometry and MBW metrics 
4.4.3.3.1 Participants and materials and methods 
The participants for this study were the healthy children, patients with CF and the patients 
with asthma listed in section 4.3.2.1 (subjects scanned with the 2D sequence). Spearman 
correlations were carried out to determine if CVH metrics reflected multi-breath washout 
metrics and standard clinical measurements of lung function. The 2D CV methodology 
calculated on the ventilated lung and total lung masks. 
4.4.3.3.2 Results 
Figure 4.34 shows the correlations of CV metrics with LCI. Median CV had the highest 
correlation with the LCI metric whilst CVH kurtosis had the next best correlation, for metrics 
generated using the VV mask and median CV and CVH IQR had the best correlations for 
metrics generated using the TLV mask. All correlations were significant with p<0.001. 
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Figure 4.34 Spearman correlations of coefficient of variation histogram metrics with LCI generated from 
VV (a-d) and TLV(e-h) masks. (a) correlation of median CV with LCI, (b) correlation of CVH skewness 
with LCI, (c) correlation of CVH kurtosis with LCI, (d) correlation of CVH IQR with LCI, (e) correlation 
of median CV with LCI, (f) correlation of CVH skewness with LCI, (g) correlation of CVH kurtosis with 
LCI and (h) correlation of CVH IQR with LCI 
 
Figure 4.35 shows the correlations of CV metrics with Scond. CVH IQR had the highest 
correlation with Scond whilst median CV had the second highest correlation for both metrics 
generated from the VV and TLV masks. As with the correlations with LCI all were significant 
with p<0.001. 
 
Figure 4.35 Spearman correlations of coefficient of variation histogram metrics with Scond generated from 
VV (a-d) and TLV(e-h) masks. (a) correlation of median CV with Scond, (b) correlation of CVH skewness 
with Scond, (c) correlation of CVH kurtosis with Scond, (d) correlation of CVH IQR with Scond, (e) correlation 
of median CV with Scond, (f) correlation of CVH skewness with Scond, (g) correlation of CVH kurtosis with 
Scond and (h) correlation of CVH IQR with Scond 
 
Figure 4.36 shows the correlation of CVH metrics with Sacin. All correlations are significant 
with median CV and CVH kurtosis having p<0.001 whilst CVH skewness had a p value of 
0.0014, all correlations had p<0.001 for the metrics generated from the TLV mask.  
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Figure 4.36 Spearman correlations of coefficient of variation histogram metrics with Sacin generated from 
VV (a-d) and TLV(e-h) masks. (a) correlation of median CV with Sacin, (b) correlation of CVH skewness 
with Sacin, (c) correlation of CVH kurtosis with Sacin, (d) correlation of CVH IQR with Sacin, (e) correlation 
of median CV with Sacin, (f) correlation of CVH skewness with Sacin, (g) correlation of CVH kurtosis with 
Sacin and (h) correlation of CVH IQR with Sacin 
 
Figure 4.37 shows the correlations of CV metrics with the standard measure used in clinic to 
evaluate lung function – FEV1 and Figure 4.38 shows the correlations with the FEV1/FVC 
ratio.  
 
Figure 4.37 Spearman correlations of coefficient of variation histogram metrics with FEV1 generated from 
VV (a-d) and TLV(e-h) masks. (a) correlation of median CV with FEV1, (b) correlation of CVH skewness 
with FEV1, (c) correlation of CVH kurtosis with FEV1, (d) correlation of CVH IQR with FEV1, (e) 
correlation of median CV with FEV1, (f) correlation of CVH skewness with FEV1, (g) correlation of CVH 
kurtosis with FEV1 and (h) correlation of CVH IQR with FEV1 
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Figure 4.38 Spearman correlations of coefficient of variation histogram metrics with the FEV1/FVC ratio 
generated from VV (a-d) and TLV(e-h) masks. (a) correlation of median CV with FEV1/FVC, (b) 
correlation of CVH skewness with FEV1/FVC, (c) correlation of CVH kurtosis with FEV1/FVC, (d) 
correlation of CVH IQR with FEV1/FVC, (e) correlation of median CV with FEV1/FVC, (f) correlation of 
CVH skewness with FEV1/FVC, (g) correlation of CVH kurtosis with FEV1/FVC and (h) correlation of 
CVH IQR with FEV1/FVC 
 
All CV metrics had lower correlations with FEV1 than with LCI and Scond, however all 
correlations were significant. The correlations with FEV1/FVC were lower than with LCI and 
Scond, although again all correlations were significant. It should be noted that Sacin has 
moderate correlation with CVH metrics similar to FEV1 and FEV1/FVC. 
4.4.3.4 Differentiating health from disease by area under the curve of the CV 
histogram 
4.4.3.4.1 Participants and materials and methods 
The participants for this study are the same as those listed in section 4.4.1. The area under the 
curve (AUC) of the CV histogram was calculated using MATLAB. To determine threshold 
values mean histograms of the healthy children and healthy adults populations were 
calculated similar to the method developed by Norberg et al. [30] and then the mean, median 
and 95th percentile values of these mean histograms were calculated. The AUC greater than 
each of these threshold values was then defined by taking the number of counts in each bin 
larger than the threshold value defined and less than one and multiplying by the step size of 
the bins in order to calculate an area. 
 
The AUC measures of healthy children and patients with CF were compared via an unpaired 
t-test with Welch’s correction, whilst the AUC measures of patients with asthma and COPD 
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were compared to those of the healthy adults via the Kruskal-Wallis test when using the 95th 
percentile as a threshold and via a one-way ANOVA when using the mean and median 
population CV as a threshold. AUC values from patients with CF and asthma were compared 
to lung function values of FEV1 % predicted, FEV1/FVC ratio, LCI, Scond and Sacin using 
Spearman’s correlation. 
4.4.3.4.2 Results  
Figure 4.39 shows the histograms of the healthy children and Figure 4.40 shows histograms 
of the healthy adults, along with the mean population histogram (black line with star markers), 
location of the mean, median and 95th percentiles of the mean population histogram. There 
was some variation seen in the histograms of these healthy cohorts, with one of the healthy 
adults (HA8) having a broader CV histogram than the others, due to some small defects in the 
posterior of the lung. Table 4.9 gives the mean, median and 95th percentile values for the 
healthy children and adults used as thresholds to calculate the area under the curve measures 
of the CV histogram generated from the VV mask (a) and (b) TLV mask. 
 
Figure 4.39 Histograms of all healthy children analysed along with the mean histogram generated from 
the population distributions.generated from the VV mask and (b) generated from the TLV mask 
 
 
Figure 4.40 Histograms of all healthy adults analysed along with the mean histogram generated from the 
population distributions. (a) generated from the VV mask and (b) generated from the TLV mask 
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Table 4.9 Mean, median and 95th percentile values derived from mean histograms 
Value Healthy children Healthy adults 
Mean 0.1298 0.1183 
Median 0.1060 0.0983 
95th percentile 0.2974 0.2675 
TLV values 
Mean 0.1346 0.1231 
Median 0.1064 0.0991 
95th percentile 0.3148 0.2864 
 
The mean, median and 95th percentile values were slightly higher in healthy children than 
those values seen in the healthy adults. The children were scanned with an SPGR sequence, 
resulting in lower SNR than images acquired in the adults using an SSFP sequence. Figure 
4.41 shows plots of the area under the curve of the CV histogram using the thresholds listed 
in  
Table 4.9. As can be seen the patients with asthma from the clinical database in Sheffield and 
the patients with COPD had both the highest value of AUC and the highest variability in 
AUC when compared to all other cohorts. As can be seen the patterns for AUC generated 
from either the VV or TLV masks have the same pattern with patient cohorts generally 
demonstrating higher AUC values.  
 
 
Figure 4.41 Plots of area under the histogram curve using the thresholds listed in  
Table 4.9 generated from the VV mask (a-c) and TLV mask (d-f). (a) mean, (b) median, (c) 95th percentile, 
(d) mean, (e) median and (f) 95th percentile. Each point represents a measurement from a single subject, 
error bars represent group means and standard deviations 
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Table 4.10 shows the results of the statistical comparisons of the area under the curve of the 
CV histogram using the threshold values presented in  
Table 4.9. 
 
Table 4.10 Kruskal-Wallis/One-way ANOVA test results comparing the healthy adults to the asthmatic 
and COPD groups and the unpaired t-test results comparing the healthy children and CF group using 
area under the curve of the CV histogram 
Comparison Mean Median 95th percentile 
HC vs. CF 0.6079 0.9838 0.0022 
HA vs. asthma_norm 0.8338 0.1816 >0.9999 
HA vs. asthma_abnorm 0.9993 0.2850 0.0189 
HA vs. asthma_clinical 0.0007 0.0122 0.0006 
HA vs. COPD 0.0001 0.0001 <0.0001 
TLV values 
HC vs. CF 0.3639 0.9205 0.0013 
HA vs. asthma_norm 0.9980 0.2433 >0.9999 
HA vs. asthma_abnorm 0.5021 0.8088 0.0026 
HA vs. asthma_clinical 0.0001 0.0003 0.0011 
HA vs. COPD 0.0001 0.0001 <0.0001 
 
Using the mean and median value of the population histogram as a limit of integration to 
calculate area under the curve of the CV histogram did not separate patients with CF from the 
healthy children significantly. However, using the 95th percentile values as a threshold did 
enable separation. Healthy adults were significantly different from the clinical patients with 
asthma and COPD patients using all thresholds, however the healthy adults were not 
significantly different from the patients with asthma and normal FEV1 using any threshold. 
Healthy adults were significantly different from patients with asthma and abnormal FEV1 
only when using the 95th percentile value as a threshold to calculate area under the curve of 
the CV histogram. When considering the metrics generated from the TLV mask it is 
interesting to see that using the 95th percentile as a threshold is able to differentiate the 
healthy adults from the patients with asthma and abnormal FEV1 z-score more significantly 
than the metrics generated from the VV mask. In addition, using the median or mean as a 
threshold is able to more significantly differentiate the asthma_clincial cohort from the 
healthy adults. 
 
Figure 4.42 shows the correlation of the area under the curve of the CV histogram, using the 
95th percentile as a threshold, with LCI, Scond, Sacin, FEV1 % predicted and the FEV1/FVC 
ratio for metrics generated using the VV mask. 
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Figure 4.42 Spearman correlations of the area under the curve of the CV histogram generated from the 
VV mask with (a) LCI, (b) Scond, (c) Sacin, (d) FEV1 % predicted and (e) FEV1/FVC ratio 
 
The strongest correlations of the area under the curve of the CV histogram were with LCI and 
Scond. A moderate correlation is seen with FEV1 % predicted whilst a weak correlation was 
seen with the FEV1/FVC ratio and Sacin. Figure 4.43 shows the same correlations for the 
metrics generated using the TLV mask. AUC metrics generated using the TLV mask had 
stronger correlations with LCI, Sacin, FEV1 % predicted and the FEV1/FVC ratio when 
compared to the metrics generated using the TLV mask. A weaker correlation was seen with 
Scond. 
 
Figure 4.43 Spearman correlations of the area under the curve of the CV histogram generated from the 
TLV mask with (a) LCI, (b) Scond, (c) Sacin, (d) FEV1 % predicted and (e) FEV1/FVC ratio 
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4.5 3He vs. 129Xe CVH metrics 
With the growing cost of 3He [221], and improving methods of increasing the signal obtained 
using HP 129Xe [246, 221], more research is focused on quantifying lung function using 129Xe 
[63, 237, 70, 340, 285, 242]. Therefore, it is necessary to ensure that the proposed CV metrics 
are suitable for use with the lower SNR images generated when using 129Xe in place of 3He. 
The aim here was to compare the metrics generated from 129Xe and 3He images acquired on 
the same day in the same session. 
4.5.1 Participants 
To compare the metrics from 3He and 129Xe images 11 patients with NSCLC were analysed. 
PFTs were not carried out as part of this study. 
4.5.2 Imaging 
4.5.2.1 3He imaging 
3He imaging was carried out using the method presented in section 4.3.2.2. 
4.5.2.2 129Xe imaging 
HP 129Xe ventilation-weighted images were acquired using HP 129Xe polarized on site [76]. 
Images were acquired using a 129Xe transmit-receive flexible vest coil tuned to 17.65 MHz 
(Clinical MR Solutions, Brookfield, WI, USA) and the 1H system body coil. 1H anatomical 
images were acquired in a separate breath prior to the HP gas ventilation images. Patients 
inhaled 550mL HP 129Xe mixed with 450mL N2 from a Tedlar bag from FRC prior to the 
ventilation scan. Images were registered using ANTs registration software [84]. 
4.5.3 Analysis 
Images were analysed using the 2D CVH method discussed in section 4.2 with a kernel size 
of 3. Wilcoxon matched-pairs signed rank tests were used to compare the metrics from 
NSCLC patients 3He and 129Xe ventilation images.  
4.5.4 Results 
Figure 4.44 shows plots of all CVH metrics for the 11 NSCLC patients analysed generated 
from both the VV (a-d) and TLV (e-h) masks. CVH skewness and kurtosis decreased when 
 100 
analysing 129Xe images compared to 3He images (pskewness = 0.0098, pkurtosis =0.0137) whilst 
median CV and CVH IQR increased (pmedian = 0.0010, piqr = 0.0059). When considering the 
metrics generated from the TLV mask the same patterns were seen. CVH skewness and 
kurtosis decreased when analysing 129Xe images compared to 3He images (pskewness = <0.0001, 
pkurtosis =0.0010) whilst median CV and CVH IQR increased (pmedian = 0.0010, piqr = 0.0020). 
 
 
Figure 4.44 Plots of CV metrics for all NSCLC patients analysed generated from the VV mask (a-d) and 
TLV mask (e-h). (a) Median CV, (b) CVH skewness, (c) CVH kurtosis and (d) CVH IQR. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
These changes are clear when comparing the cohort average histograms from 3He and 129Xe 
acquisitions (Figure 4.45). This follows the pattern of decreasing the image SNR shown in 
section 4.3.4, which is logical considering the significant (p=0.0068) difference in SNR 
between the 3He and 129Xe acquisitions for these patients (Figure 4.46). Additionally, a longer 
high CV tail is seen when considering the average histograms generated from the TLV mask 
when compared to the VV mask. 
 
Figure 4.45 Average histograms for NSCLC patients comparing 3He and 129Xe CVH values generated 
from the (a) VV mask and (b) TLV mask 
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Figure 4.46 Plots of 3He and 129Xe SNR for NSCLC patients. Each point represents measurements from a 
single subject, error bars represent group means and standard deviations 
4.6 Discussion and conclusion 
The main limitation of the studies carried out here is the small number of participants scanned 
with both SPGR and SSFP ventilation-weighted imaging and the small sample size of the 
patient groups on which the CVH metrics were tested. Additionally no bias field correction 
for RF coil sensitivity was carried out, unlike other studies utilizing the ventilation image 
signal [285]. The reason the popular N4 bias field correction [293] was not carried out is 
mainly due to the frequent disappearance of what appear to be defects when the bias field 
correction is carried out, such as the reduced ventilation in the upper lobe, exemplified in 
Figure 4.47. Additionally, there is a large difference in the fractional ventilation (FV) 
histogram calculated following N4 correction when compared to the original uncorrected 
image histogram (Figure 4.47c). 
 
Figure 4.47 Example slices from an uncorrected 3He and bias field corrected image from a healthy 
volunteer. (a) original image, (b) corrected image and (c) comparison of the fractional ventilation 
histograms pre and post bias field correction 
 
Due to these changes, it would appear that the N4 bias field correction method would reduce 
the local variation in these areas, which may hide physiologically relevant information, thus 
in future work acquisition of a B1 map and correction of the image using this method should 
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be applied and compared to the results obtained using the N4 method commonly used [283, 
291, 285]. However, there are of course trade-offs in acquiring a B1 map – the most obvious 
being the additional dose of gas and extra scan. Additionally, were the B1 map to be acquired 
in a separate breath-hold there is the inherent difficulty of registering this image to the 
ventilation image being used for analysis. There exists the option to acquire the B1 map in the 
same breath-hold as the ventilation scan as was done by Miller et al. [323], however using the 
technique there would result in a longer breath-hold time and require the use of a smaller flip 
angle to maintain magnetisation for the B1 mapping, resulting in lower quality diagnostic 
images. 
 
From the cohorts analysed in the previous sections the total lung volume method excluded 
significantly fewer voxels (p<0.0001) than the ventilated lung based method with a mean±SD 
of 23771± 38100 voxels excluded per patient for the total lung volume method and 
49685±72229 voxels excluded per patient for the ventilated lung volume method. Note that 
this is the number of voxels excluded within the total lung volume. To calculate these values 
the ventilated volume mask or SNR based ventilated volume mask was multiplied by the total 
lung volume mask, then the ventilated volume or SNR based ventilated volume masks were 
subtracted from the total lung volume mask and the number of values greater than zero 
counted to find the number of voxels excluded. 
4.6.1 Effect of sequence and SNR on CV metrics 
Imaging parameters along with gas dose have an effect on CV metrics. This is clearly 
visualized by comparing the 3 healthy adults analysed with both SPGR and SSFP imaging. It 
is clear that the reduced image SNR and _g∗ weighted contrast (susceptibility weighted image 
texture) of the SPGR sequence leads to increased median CV and CVH IQR values and 
decreased CVH skewness and kurtosis. Artificially reducing the SNR of ventilation images 
also caused these changes in the HAs scanned with SSFP imaging only. An interesting 
finding was the reduction in CVH IQR at lower SNR in the patient cohorts analysed, 
suggesting that as the SNR decreases in these patient cohorts the CV values become more 
tightly grouped, moving towards a more Gaussian distribution with the histogram peak shifted 
to a higher CV value. 
 
Throughout this study it was also noted that there were no significant differences between CV 
metrics in healthy volunteers measured from simulated SNR of 75% of the original image, 
although this could be due to the small numbers. This is an important finding in the context of 
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longitudinal and repeat studies if CVH metrics are to be used in conjunction with the standard 
metric of VDP to represent lung function as this can be considered the cut-off point of image 
SNR difference between time points to compare the metrics. This means that, from the data 
analysed here, a difference in SNR of approximately 20 between acquisitions is acceptable 
based on the metrics from the VV mask whereas the metrics from the TLV mask show no 
significant differences at 50% image SNR – although mean and median CV are approaching a 
p value of 0.05 suggesting from this data that using the TLV mask generated metrics would 
allow a difference of closer to 30. 
4.6.2 Effect of kernel size on CV metrics 
As one would expect modifying the kernel size to calculate CV will modify CVH metrics as 
signal variation is then analysed on different length scales. As expected, the median CV 
increased as the kernel size increased due to more of the lung being involved in the CV 
calculation, with a greater likelihood of increased standard deviation in the neighbourhood 
being analysed in patients. CVH skewness and kurtosis decreased with greater kernel size due 
to the smoothing of the CV maps. A decrease of CVH IQR in the asthmatic cohorts using a 
neighbourhood of 9x9 voxels when compared to 7x7 voxels was found, whilst there was a 
slight increase or no difference in all other groups analysed. This suggests a tighter grouping 
of values at this neighbourhood size compared to the other sizes used in this work. 
 
The neighbourhood of 9x9 voxels is more similar to the size used in previous work [326] 
analysing images of asthmatic patients, where 10% of the maximum width of the lung was 
chosen as the neighbourhood size for CV calculation although histogram metrics were not 
reported in that work. As reported above the optimal kernel for the images analysed here 
seems to be 3x3 voxels based on the significance of differentiating patient groups with mild 
disease from healthy volunteers. 
4.6.3 Effect of kernel dimensionality on CV metrics 
Modifying the kernel from 2D to 3D increased median CV and produced a CV map that is 
smoothed due to the inclusion of through-plane voxels and having to increase in-plane 
downsampling from 2 to 3 to allow for CV calculation in an approximately isotropic cube. 
CVH skewness and kurtosis did not change to the same extent as median CV whilst CVH 
IQR has a minor change for all cohorts analysed. This is an interesting finding as although the 
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median CV increased, suggesting a shift of the peak, the values are similarly grouped between 
the 2D and 3D CVH histograms.  
4.6.4 CV metrics as a tool to differentiate groups 
One key point to consider is that the differences in CV metrics seen between the healthy 
adults, scanned with a 3D bSSFP sequence, and the asthma_norm/asthma_abnorm cohorts, 
scanned with a 2D SPGR sequence, are of a similar magnitude to those seen when comparing 
the healthy adults scanned with both the 3D bSSFP and 2D SPGR sequences. However, one 
key difference with the asthma cohort is a generally higher SNR for the participants as 
exemplified in Figure 4.48 , suggesting that although there is an SNR difference as one would 
expect it is not to the same extent as that seen in the healthy volunteers 2D SPGR v 3D SSFP 
image SNR, hence the differences seen may be caused by the effects of the disease rather than 
imaging methods. An important consideration here is the lower dose of HP 3He given for the 
HA scans due to increased polarisation of 3He at the time of the experiment for the 2D SPGR 
scans. 
 
Figure 4.48 Plots of SNR values for the three healthy adults scanned on the same day with SPGR and 
SSFP and the healthy adults scanned with a 2D SPGR sequence and the asthma_norm and 
asthma_abnorm cohorts. Each point represents a measurement from a single subject, error bars 
represent group means and standard deviations.  
 
The main limitation in this study is the lack of FEV1 values for the HA, COPD and 
asthma_clinical cohorts to assess if CV metrics are able to distinguish patient groups from 
healthy volunteers to the same extent as the clinical gold standard for evaluating respiratory 
disease. However, when comparing imaging methods to differentiate patient groups it appears 
CV metrics are a useful tool to accompany the standard method of VDP analysis and can 
differentiate health from disease more strongly than VDP in some cases. Additionally, by 
comparing CV metrics alone the asthma_norm cohort had similar values of median CV and 
CVH IQR to the mild CF cohort analysed for this study. 
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The moderate and significant correlations of the CV metrics with MBW metrics for the HC, 
CF and asthma2D cohorts suggest that these metrics may be a useful tool to differentiate 
patient groups and also reflect disease severity as clinically measured by spirometry. These 
correlations suggest that imaging ventilation heterogeneity measured by CV and MBW 
ventilation heterogeneity metrics may be reflecting a similar underlying pathophysiology. The 
moderate correlations of median CV and CVH skewness with FEV1 and the FEV1/FVC ratio 
also support this statement. LCI appears to be the best MBW metric to represent ventilation 
heterogeneity derived using the coefficient of variation of signal intensity. One possible 
reason for this is the fact that LCI represents early changes to the small airways, as does the 
imaging methodology used in this work [33]. Scond also appears to be a good representative of 
ventilation heterogeneity, possibly due to the fact that the heterogeneity of the conducting 
zone in the lung can be more clearly distinguished using imaging than that in the acinar zones. 
The ventilated lung volume based method provided improved separation of patients with mild 
disease from healthy controls possibly due to the exclusion of voxels which result in high CV 
values, leading to reduced median, skewness and kurtosis values when compared to the total 
lung volume method e.g. Figure 4.49. The example in Figure 4.49 from a patient with CF 
shows increased CV at the ‘transitional’ areas of the defect, and it is these areas which lead to 
histogram metrics more similar to the healthy controls in the mild disease cohorts used here. 
 
Figure 4.49 Example CV maps generated using the (a) VV mask and (b) the TLV mask from a ptient with 
CF 
 
As seen in the work of Norberg et al. [339, 30, 345] area under the curve of the CV histogram 
is a useful metric to differentiate patient groups, although it was not successful in separating 
health from disease in all cohorts. By using the 95th percentile rather than the mean as a 
threshold, improved differentiation was seen between groups. However, the healthy cohorts 
from whom the values were determined are small in this work. 
(a) (b)
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4.6.5 3He vs. 129Xe CVH metrics 
129Xe and 3He CVH metrics were significantly different in the 11 NSCLC patients analysed in 
this study, likely due to the lower SNR in the 129Xe images. Therefore, the different intrinsic 
gas properties and imaging quality are important factors to consider when developing analysis 
techniques for quantifying these images. One possible solution could be to remove noise from 
the image using a method similar to that developed in [326], where the mean noise level was 
subtracted from all pixels, and evaluate whether this will result in more similar metrics when 
comparing these two gases. Of course, the small sample size and specificity of the patients 
included in this study mean that these results are not generalizable and should be considered 
only in the context of the comparisons carries out here.  
4.7 Conclusion 
The histogram-based method of CV analysis has the ability to differentiate patient groups 
from healthy volunteers to the same, or in some cases more significant, extent as the 
commonplace measure of VDP. Additionally, CV metrics had strong correlations with MBW 
outputs and moderate correlations with spirometry measures suggesting that these metrics 
may be useful in clinical assessment of patients. Unlike VDP, CVH analysis makes use of the 
rich spatial information available in HP gas ventilation-weighted images. From the small 
numbers of data sets analysed in this work it seems that using 2D CV metrics seems to better 
differentiate health from disease when considering only CVH kurtosis with mixed results seen 
when comparing CVH skewness and IQR. One important consideration here is the small 
number of asthmatic and COPD patients and lack of other disease groups being analysed. 
Additionally, by comparing the metrics generated over the ventilated volume and total lung 
volume masks it was shown that using the ventilated volume mask allows improved 
differentiation, particularly of the healthy adults and asthma_norm group – although in certain 
instances the metrics generated from the total lung volume mask outperformed those 
generated from the ventilated volume mask. 
 
Additional work is necessary to determine if CV metrics derived from 129Xe ventilation 
images are able to differentiate to the same extent as 3He between health and disease and also 
to refine the methodology and reduce the effect image SNR has on the derived quantities. CV 
metrics are more sensitive to image SNR than %VV and thus more care must be taken when 
calculating and making use of CV metrics. 
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CHAPTER 5. ASSESSMENT OF THE 
INFLUENCE OF LUNG INFLATION STATE 
ON THE QUANTITATIVE PARAMETERS 
DERIVED FROM HP GAS LUNG 
VENTILATION MRI3 
5.1 Introduction 
The lung has a dynamic range of volumes as presented in Figure 2.3 and will change shape 
during inspiration and expiration within the thorax. Lung volumes are indicated on Figure 2.3 
along with one of the standard metrics used in analysing pulmonary function, FEV1. 
 
As shown in Figure 2.3 there are a number of quantities that can be measured by either 
spirometry or body plethysmography. The results of these tests are compared to reference 
values predicted for the subject undergoing the tests based on numerous factors including age 
and height [118, 346]. For both spirometry and body plethysmography there are international 
standards to be followed that ensure repeatable measures of the quantities derived from these 
methods. Indeed for spirometry there are strict guidelines where measured values must be 
within an accepted threshold over the repetitions within the exam, whilst measurement of lung 
volumes using body plethysmography also have their own detailed standards [112] to be 
followed during examinations. Reported within a day, week to week and year to year changes 
for FEV1 and FVC in normal subjects measured using spirometry are considered significant if 
they are over 5%, 11% and 15% respectively [5].  
 
The lung volumes at which HP MRI or even computed tomography (CT) are performed are 
usually obtained by training and instructing the patient on the manoeuvre beforehand, 
however it has been shown that the use of spirometrically-gated CT and non-gated CT 
provide different estimates for lung density due to the difference in volume [347-352] and 
provide improved repeatability of lung inflation level. Additionally, as gas trapping is 
                                                
3I would like to acknowledge the efforts of Laurie Smith, Fung Chan, Oliver Rodgers, Dr Guilhem Collier and Dr Graham Norquay for their 
help in acquiring the healthy volunteer data for this study. I also acknowledge the efforts of Dr Bilal Tahir in aiding with registration for the 
analysis of this data. 
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assessed using the difference of attenuation between an inspiratory and expiratory scan 
controlling the volumes these are acquired at is a key factor to ensure that this dynamic 
process is assessed correctly [353, 354]. 
5.1.1 Review of HP gas methods to assess ventilation heterogeneity 
at different states of lung inflation 
Most HP gas studies carried out to evaluate lung function are acquired at a single fixed 
volume, generally functional residual capacity plus 1L (FRC+1L), to ensure repeatability in 
longitudinal studies [58-60, 62, 63, 355, 221, 78, 71]. These images are ‘snapshots’ of the 
ventilation distribution at a fixed point of the respiratory cycle and may not truly be 
representative of the dynamic nature of the lung. However, dynamic imaging methodologies 
enable visualisation of the lung ventilation over a range of volumes [356, 226, 227], whilst 
wash-in/wash-out techniques allow for assessment of gas turnover [67, 327]. 
 
Salerno et al. [357] developed a dynamic spiral HP MRI sequence capable of visualizing gas 
flow during breathing in healthy volunteers and patients with a variety of lung pathologies. 
Their method built on a number of previous studies to produce a pulse sequence that had 
similar spatial resolution to the static ventilation imaging available at the time. The method 
developed by Salerno et al. was capable of identifying the difference in filling of the 
parenchyma between patients and healthy volunteers and also could characterise ventilation 
defects. Wild et al. [356] developed an alternative methodology of monitoring the lung using 
a dynamic HP gas sequence where rather than an interleaved spiral acquisition a radial 
sequence was used. Koumellis et al. [358] built on this work by quantitatively evaluating the 
signal kinetics of HP 3He in the lungs of patients with CF to derive metrics of gas flow. This 
was accomplished by imaging paediatric CF patients during inhalation and expiration of HP 
gas with a dynamic radial sequence, and showed that flow rate was altered in this cohort. 
Holmes et al. [226, 359, 227] developed protocols to assess ventilation impairment, including 
gas trapping, using dynamic HP gas MRI. A 3D multi-echo projection acquisition was used to 
dynamically scan a participant throughout respiration, breath hold, a forced expiratory 
manoeuvre to residual volume (RV) and tidal breathing [227]. Gas trapping was indicated by 
a consistent signal in a voxel rather than loss of signal, as one would expect whilst exhaling 
the HP gas. These areas of gas trapping were then compared to results from MDCT, showing 
strong agreement in the areas defined as gas trapping from HP MRI and MDCT. Kyriazis et al. 
[228] imaged rats dynamically during inspiration of HP gas to develop a metric of regional 
inflation rate, which they showed was altered in elastase-treated rats compared to normal rats. 
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Horn et al. [67, 70] developed a multiple breath washout imaging protocol to assess gas 
turnover in the lung using HP gases to derive a quantitative estimation of fractional 
ventilation. The method developed by Horn et al. [67, 70] differs from Holmes et al. [226, 
359, 227] as the images are acquired while the subject holds their breath in between normal 
tidal breathing, and a lower resolution, Cartesian pulse sequence is used. Additionally, Horn 
et al. correct for the change in _z and RF decay and this provides quantitative measures of 
fractional ventilation. Hamedani et al. [327] recently developed a technique where the wash-
in curve of HP gas is fitted to derive fractional ventilation using a 2D gradient-echo pulse 
sequence that employed parallel imaging. 
 
Of course, with the availability of these dynamic imaging methods and wash-in/wash-out 
techniques it appears as though static ventilation imaging might become obsolete, however 
there are reasons that this technique is still being used in the pulmonary MRI community. One 
reason is that although washout imaging provides quantification of gas turnover it is limited 
in spatial resolution, with the in-plane resolution being ~12mm2 [67], whereas static 
ventilation images have a resolution of ~3.2mm2 [66], allowing for improved detection of 
small defects with this static methodology. With the dynamic sequences, there are also 
temporal resolution limits based on the speed of inhalation and expiration, requiring rapid 
image sampling which in itself is constrained by the choice of sequence and the 
considerations of HP gas imaging discussed in Chapter 2, section 2.4.4. 
 
In a pilot study from our group in patients with asthma it was previously shown that there is a 
marked difference in %VV between HP gas ventilation images acquired at FRC+1L and total 
lung capacity (TLC) [360]. Additionally, the gas distribution within the lung improved at 
TLC when compared to FRC+1L suggesting that for better impact of treatment patients with 
asthma should inhale deeply to open the more vulnerable airways which would close at lower 
lung volumes due to inflammation and remodelling [99, 361, 362]. Increased ventilation 
heterogeneity has been observed in elite divers imaged close to their RV, after inhalation from 
sub RV volumes, when compared to normal control subjects imaged following inhalation 
from RV, resulting in volumes close to FRC [363]. In this work two elite divers were imaged 
after inhaling a small volume from sub RV (0.9 and 0.4L respectively of a mix of HP 129Xe 
and O2) and a larger volume (1.3 and 0.9L respectively of a mix of HP 129Xe and O2) with 
higher heterogeneity being seen after inhalation of the smaller volumes of gas. The healthy 
controls on the other hand had a lower heterogeneity score after inhaling from RV. The cause 
of this heterogeneity in the elite divers is assumed to be punctate opening of the airways; that 
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is a reopening of frankly closed airways rather than functionally closed airways, although this 
was not seen in the volunteers possibly due to not being able to match the manoeuvre 
performed by the divers.  
 
It is therefore important to assess the effect of lung inflation state on the qualitative 
appearance of HP gas ventilation images when imaging at breath hold and also to assess the 
effect of lung inflation state on the values and inter scan reproducibility of quantitative 
parameters derived from HP gas images. As covered in Chapter 3, the most widely used 
quantitative index of lung ventilation derived from HP gas and 1H images is %VV and its 
counterpart VDP. These measures have been used to differentiate mild CF patients from age-
matched healthy controls [33], to detect early obstructive changes in smokers [77] and have 
also been shown to be sensitive to disease severity and treatment [58-60, 63]. Additionally, 
they have been used to monitor patients with asthma in longitudinal studies [315, 316] to 
allow for disease monitoring and response to therapy and have correlation with spirometric 
findings [364, 60]. With the adoption of HP gas imaging for quantitative clinical assessment 
of lung obstruction [365] it is important to understand the effect of the inflation level of the 
lung on this measure. Additional measures of ventilation heterogeneity such as the coefficient 
of variation of ventilation signal intensity (CV, Chapter 4) [326] might also be expected to 
change with lung inflation particularly in partially obstructed lungs. 
5.1.2 Aims of the study 
The aim of the work performed in this chapter was to assess the effect of lung inflation on 3D 
HP gas lung ventilation images in a group of healthy subjects, a small cohort of patients with 
CF and a small cohort of patients with asthma by scanning at different lung inflation levels 
using same breath hyperpolarised 3He and 1H imaging. Additionally, a subgroup of the 
healthy subjects was scanned using separate breath hyperpolarised 129Xe and 1H imaging to 
determine if the same changes were seen using 129Xe.  
 
As a secondary aim the volumes obtained from the MRI data were compared with those 
obtained from body plethysmography. One important difference between these tests is that 
MRI was performed supine whilst body plethysmography was performed sitting. The values 
obtained from body plethysmography were RV, FRC and TLC. As it is not standard practice 
to measure FRC+1L and RV+1L using this technique, FRC+1L and RV+1L values were 
excluded from this comparison. Note that body plethysmography was carried out once for all 
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healthy volunteers on the same day as the HP 3He imaging session, except for HV6 where 
body plethysmography was carried out on the same day as the HP 129Xe imaging session. 
5.2 Materials and methods 
5.2.1 Participants 
Six healthy volunteers (one current smoker, one former smoker, two occasional smokers and 
two never smokers, all male) were recruited for this study with no exclusion criteria applied. 
The volunteers ranged in age from 27 to 35. The study was performed with National Research 
Ethics Committee and MHRA approval with informed consent from all volunteers. 6 patients 
with CF (3 male, 3 female) were selected from a separate study where images were acquired 
at FRC+1L and TLC with informed consent given by parents or participants depending on 
age. Additionally, 6 patients with asthma (3 male, 3 female) were selected from a separate 
study [71] where images were also acquired at FRC+1L and TLC. CF patients FEV1 % 
predicted ranged from 39% to 112%, and age from 11 to 37, whilst asthmatic patients’ FEV1 % 
predicted ranged from 32% to 95% and age ranged from 41 to 64. Table 5.1 shows the 
demographics of the healthy volunteers and patients analysed here. 
 
Table 5.1 Patient demographics for the multiple inflation level study 
 
Patient Age 
(years) 
Sex Height 
(cm) 
Weight 
(kg) 
FEV1 
(% predicted) 
HV1 32 M 183.0 87.0 102.0 
HV2 35 M 184.0 76.0 77.2 
HV3 31 M 182.0 83.0 105.0 
HV4 34 M 185.6 94.0 83.6 
HV5 27 M 189.5 74.0 102.9 
HV6 28 M 187.6 90.0 99.9 
CF1 37 M 167.9 59.0 57.5 
CF2 25 F 153.2 45.0 39.7 
CF3 26 F 160.9 52.0 96.6 
CF4 24 M 174.4 59.0 112.7 
CF5 25 M 166.4 55.4 100.6 
CF6 11 F 143.7 30.0 92.3 
Asthma1 41 M 173.0 77.0 84.9 
Asthma2 51 F 158.0 62.4 31.0 
Asthma3 45 M 174.0 88.3 99.1 
Asthma4 64 F 156.0 57.8 96.2 
Asthma5 62 M 177.0 90.6 66.1 
Asthma6 52 F 152.0 51.4 89.2 
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5.2.2 Study protocol 
Healthy volunteers were imaged with a 3He transmit-receive flexible chest coil (Clinical MR 
Solutions, Brookfield, WI, USA). Imaging was carried out on a GE HDx 1.5T MRI scanner 
(GE Healthcare, Milwaukee, IL, USA). HP 3He and 1H images were acquired in the same 
breath at five different inflation levels: RV, RV+1L, FRC, FRC+1L and TLC (Figure 2.3, 
Figure 5.1 ). All breathing manoeuvres started with inhalation of the 1L bag from FRC, 
except for the RV+1L image where the inhalation started after first exhaling to RV. To 
acquire images at TLC, volunteers first inhaled the 1L bag from FRC to reach FRC+1L and 
then topped up the volume with room air. For imaging at FRC, volunteers inhaled the 1L bag 
from FRC and then exhaled back to FRC. For RV imaging, volunteers inhaled the bag from 
FRC and then exhaled to RV. 
 
Figure 5.1 Breathing manoeuvres and acquisition volumes. RV = residual volume, FRC = Functional 
residual capacity, TLC = total lung capacity. Blue lines indicate an exhalation; red lines indicate an 
inhalation from a 1L bag and purple lines represent an inhalation of room air following inhalation from a 
bag 
 
Same-breath 3D bSSFP 3He and 1H SPGR images were acquired using the gas doses given in 
Table 5.2. Imaging sequence parameters can be found in Chapter 3, section 3.3.1.3. 
 
Table 5.2 Gas doses for 3He acquisitions 
 HV Asthma CF 
Acquisition 3He N2 3He N2 3He N2 
RV 200 800 - - - - 
RV+1L 150 850 - - - - 
FRC 200 800 - - - - 
FRC+1L 150 850 350 650 110-150 290-850 
TLC 200 800 400 600 160-200 240-800 
 
The gas doses for healthy volunteers were chosen empirically with the aim being to achieve 
approximately the same gas nuclear spin density, and hence, SNR in all images due to gas 
FRC FRC+1L 
TLC 
FRC 
RV RV RV+1L 
Inhale 
room air 
Exhale 
Exhale 
Inhale 1L 
bag 
Inhale 1L 
bag 
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dilution at TLC and gas exhalation with the exhalation scans. Images were acquired in two 
sessions with a 10-minute break between the first and second set of acquisitions, with patients 
remaining in the scanner throughout. A qualified respiratory physiologist gave breathing 
instructions. Following all acquisitions patients underwent spirometry and body 
plethysmography performed to international standards [112]. 
 
3He doses for patients with CF were scaled by height and predicted values of FRC and TLC 
based on normal values [341, 33] and they underwent the same image acquisition protocol as 
the healthy volunteers [66] but scans were not repeated and were only acquired at FRC+1L 
and TLC. Patients with asthma underwent multi-slice 2D spoiled gradient echo HP 3He 
ventilation imaging following inhalation of 350ml 3He mixed with 650ml N2 from a Tedlar 
bag (Jensen Inert Products, Coral Springs, Florida, USA) from FRC. The imaging matrix was 
fixed at 128x102 resulting in resolutions of ~3x3x10mm. Same-breath 2D balanced steady 
state free precession 1H anatomical images were acquired using the system body coil with a 
lower resolution. For TLC imaging patients inhaled a gas mixture consisting of 400ml 3He 
mixed with 600ml N2 and inhaled room air to reach TLC. Asthma patients were imaged with a 
2D sequence as this study was carried out prior to the 3D HP 3He imaging being optimised for 
use. 
 
Three of the five healthy volunteers (HV2, HV3 and HV6) were scanned using HP 129Xe at 
the aforementioned five lung volumes twice. 129Xe was polarized on site [23]. Images were 
acquired using a 129Xe transmit-receive flexible vest coil (Clinical MR Solutions, Brookfield, 
WI, USA) and the 1H system body coil. 1H anatomical images were acquired in a separate 
breath prior to the HP gas ventilation images. Between each session, patients were removed 
from the scanner as the waiting time was increased due to production limitations of the 129Xe. 
Gas doses are given in Table 5.3 and were chosen to achieve the highest possible SNR in the 
images and ensure they were comparable to the images acquired with 3He. 
 
Table 5.3 Gas doses for 129Xe acquisitions 
Acquisition 129Xe N2 
RV 1000 0 
RV+1L 750 250 
FRC 1000 0 
FRC+1L 600 400 
TLC 750 250 
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5.2.3 Image analysis 
The parameters TLV, VV and %VV were calculated from all images using the segmentation 
method introduced in Chapter 3 (Figure 5.2). Secondly measures of CV were acquired using 
the method discussed in Chapter 4. CV measures were also generated from the TLV mask as 
in Chapter 4. 
 
Figure 5.2 Workflow of image segmentation and CV metric calculation from the VV mask.(a) Example 
1H anatomical image slice from a 3D data set, (b) Example 3He image slice from a 3D data set, (c) and (d) 
corresponding segmentation slices and (e) example slice of a CV map generated from the 3He image  
5.2.4 Reproducibility and statistical analysis 
As measures of reproducibility between repeated measurements, that is the measurements 
obtained in the healthy volunteers in each imaging session, the coefficient of variation (CoV) 
was calculated [366] along with the percentage difference (%∆ , defined as ((session2-
session1)/session1)*100) and Bland-Altman analysis [367].  
 
Additionally, the voxel-wise Spearman rank correlation coefficient was used to compare 
inflation levels over both sessions, and to compare all inflation levels to FRC+1L for each 
session, that is RV_S1 was registered to FRC+1L_S1 and RV_S2 registered to FRC+1L_S2 
and so on. For this analysis images acquired in session 2 were registered to their 
corresponding image in session 1, that is RV_S2 was registered to RV_S1 and so on. All 
registrations were carried out using the ANTs registration toolbox [84]. Ventilation images 
VDP 
Median CV% 
TLV VV 
0 0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
60% 0% 
(a)	 (b)	
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(e)	
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were registered directly to one another and only voxels within the ventilated volume were 
used in calculating the correlation coefficient. 
 
TLVs calculated from the 1H anatomical images were compared to the volumes from body 
plethysmography. Wilcoxon matched-pairs signed rank tests were carried out to determine if 
there were any significant differences in TLV, VV, %VV and CV metrics between each 
imaging session per inflation level and also between lung volume metrics obtained from MRI 
and body plethysmography for healthy volunteers. Wilcoxon matched-pairs signed rank tests 
were used to evaluate the change in volunteers/patients’ metrics between FRC+1L and TLC. 
Healthy volunteers’ metrics at FRC+1L and TLC were compared to those obtained in patients 
with asthma and CF using Mann-Whitney unpaired t-tests. 
 
Finally, median CV (%) values from the images acquired at RV, RV+1L, FRC and TLC were 
compared to the median CV (%) value from the image acquired at FRC+1L via the mean 
absolute %∆. Here, mean absolute %∆ is defined as: 
 
 ú∆Å(%∆`1) + ú∆Å(%∆`2)2  (5.1) 
where %∆ is defined as, for example: 
 
 •4_»4 − •4_…»• + 1ª•4_…»• + 1ª ×100 (5.2) 
5.3 Results 
Section 5.3.1 discusses the repeatability of quantitative parameters of lung function acquired 
in a small cohort of healthy volunteers. Section 5.3.2 discusses the results of using 
hyperpolarised 129Xe in place of 3He in three of the six healthy volunteers analysed in section 
5.3.1, demonstrating the applicability of using hyperpolarised 129Xe in place of 3He. Section 
5.3.3 compares lung volumes obtained using MRI to those obtained using body 
plethysmography from the healthy volunteers presented in section 5.3.1. Finally, section 5.3.4 
presents the effect of imaging patients at different lung inflation levels. 
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5.3.1 Repeatability in healthy volunteers 
Figure 5.3 shows example images from all healthy volunteers. As can be seen by qualitatively 
evaluating the images, generally ventilation heterogeneity reduces as the volume increases, 
particularly at TLC.  
 
Figure 5.3 Example slices from all 6 healthy volunteers’ datasets (acquired with HP 3He). (a) HV1, (b) 
HV2, (c) HV3, (d) HV4, (e) HV5 and (f) HV6. Red arrows indicate apparent ventilation defects/areas of 
low ventilation present at RV+1L but that appear to fully/partially resolve at higher volumes 
 
TLC FHFRC+1L FHFRC FHRV+1L FHRV FH
RV	 FRC	RV+1L	 FRC+1L	 TLC	
TLC GCFRC+1L GCFRC GCRV+1L GCRV GC
RV	 FRC	RV+1L	 FRC+1L	 TLC	
TLC GNFRC+1L GNFRC GNRV+1L GNRV GNRV	 FRC	RV+1L	 FRC+1L	 TLC	
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Figures 5.4 to 5.7 show plots of the metrics obtained from the images from the 6 HVs 
analysed here. The group mean TLVs at RV+1L and FRC are similar, which is logical 
considering that FRC reduces supine and thus is closer to RV. 
 
 
Figure 5.4 Plot of total lung volume at each inflation level from the 6 healthy adults scanned here. Each 
point represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
 
 
Figure 5.5 Plot of ventilated lung volume at each inflation level from the 6 healthy adults scanned here. 
Each point represents a measurement from a single subject, error bars represent group means and 
standard deviations 
 
Overall, ventilated lung volume (Figure 5.5) appears to track the total lung volume (Figure 
5.4) in these healthy volunteers, whereas %VV (Figure 5.6) highlights that there are 
differences in ventilated lung volume between inflation levels. 
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Figure 5.6 Plot of %VV at each inflation level from the 6 healthy adults scanned here. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
 
Figure 5.7 Plot of median CV at each inflation level from the 6 healthy adults scanned here generated 
using the (a) VV mask and (b) the TLV mask. Each point represents a measurement from a single subject, 
error bars represent group means and standard deviations 
 
Median CV% (Figure 5.7) changed with inflation level; median CV is lowest at TLC and 
highest at RV and RV+1L. Table 5.4 shows the mean CoV, of TLV, VV and %VV, over all 6 
volunteers at each inflation level. Regarding TLV and VV, the most repeatable volumes 
appear to be FRC+1L and TLC. When considering %VV FRC+1L is the most reproducible 
whilst RV has the most variation over all 6 volunteers.  
Table 5.5 shows the mean CoV for all CV metrics generated using both TLV and VV masks, 
where FRC+1L has the lowest CoV in al CV metrics when generated from the VV mask. 
When considering metrics generated from the TLV mask median CV and CVH IQR are most 
repeatable at FRC+1L and CVH skewness and kurtosis are most repeatable at RV+1L. 
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Table 5.4 Mean CoV for TLV, VV and %VV over all volunteers between each session 
Acquisition TLV VV %VV 
RV 3.40 3.05 1.29 
RV+1L 4.13 4.64 0.63 
FRC 4.63 4.64 0.87 
FRC+1L 3.42 3.42 0.38 
TLC 1.19 1.00 0.54 
 
Table 5.5 CV metrics CoV over all volunteers between each session 
 
 
Figure 5.8 shows the Bland-Altman plots for TLV, VV and %VV whilst Figure 5.9 shows the 
Bland-Altman plots for median CV (%), CVH skewness, kurtosis and IQR generated using 
the VV and TLV masks. 
 
Figure 5.8 Bland-Altman plots of (a) TLV, (b) VV and (c) %VV for all 6 volunteers 
 
TLV and VV had Bland-Altman bias± limits of agreement (LOA) of 60ml±420ml and 
40ml±400ml respectively, suggesting almost a litre of change between imaging sessions 
occurs over all 6 volunteers at all inflation levels. %VV had bias±LOA of -0.60%±2.81%. 
Median CV (%) had bias±LOA of 0.14%±1.50% when generated from the VV mask and 
0.16%±1.54%, suggesting very little change in median CV (%) and a moderate change 
in %VV. CVH skewness, kurtosis and IQR also have very little variation when generated 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR 
RV 5.32 9.59 15.16 7.45 
RV+1L 4.62 5.99 10.46 6.46 
FRC 3.99 6.63 11.52 3.95 
FRC+1L 2.74 3.68 5.88 3.03 
TLC 5.46 4.99 7.63 4.19 
TLV metrics 
RV 5.60 7.86 17.71 8.59 
RV+1L 4.74 4.87 10.67 7.26 
FRC 4.16 9.27 17.14 4.52 
FRC+1L 2.72 7.71 15.06 2.97 
TLC 5.52 6.66 14.30 4.50 
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from the VV mask with similar values of bias±LOA seen in the metrics generated from the 
TLV mask when compared to the VV mask suggesting good agreement using both methods. 
 
 
Figure 5.9 Bland-Altman plots of CVH metrics generated from the VV mask (a-d) and TLV mask (e-h). (a) 
Median CV, (b) CVH skewness, (c) CVH kurtosis, (d) CVH IQR, (e) Median CV, (f) CVH skewness, (g) 
CVH kurtosis, and (h) CVH IQR 
 
As can be seen from Table 5.6 there is a clear pattern of increased % change over the two 
sessions, as defined in section 5.2.3, of TLV and VV when compared to %VV. This implies 
that although the volumes measured change between each session the measure of %VV is not 
affected to the same extent.  
 
Table 5.6 %∆ of TLV, VV and %VV over both sessions for all volunteers 
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(e) (f) (g) (h)
 HV1  HV2 
Acquisition TLV VV %VV  TLV VV %VV 
RV 5.04 4.76 -0.26  0.26 1.21 0.95 
RV+1 -7.76 -7.30 0.50  15.79 18.38 2.24 
FRC 5.87 6.82 0.90  10.99 11.45 0.41 
FRC+1 -7.83 -7.41 0.46  -4.06 -4.19 -0.13 
TLC -1.54 0.44 2.01  -1.88 -1.82 0.05 
 HV3  HV4 
Acquisition TLV VV %VV  TLV VV %VV 
RV 1.63 1.16 -0.45  1.67 3.99 2.28 
RV+1 -3.93 -4.17 -0.25  0.50 1.76 1.25 
FRC -0.07 -1.75 -1.68  -5.22 -2.30 3.08 
FRC+1 6.22 5.85 -0.35  -0.24 -1.73 -1.49 
TLC 1.76 2.44 0.66  -2.52 -0.98 1.58 
 HV5  HV6 
Acquisition TLV VV %VV  TLV VV %VV 
RV 1.67 3.99 2.28  -16.95 -11.65 6.27 
RV+1 0.50 1.76 1.25  -5.95 -6.92 -1.03 
FRC -5.22 -2.30 3.08  -14.19 -13.40 0.92 
FRC+1 -0.24 -1.73 -1.49  -5.90 -5.22 0.73 
TLC -2.52 -0.98 1.58  -0.79 -1.05 -0.27 
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Tables 5.7 to 5.8 shows the %∆ of CVH metrics from the VV and TLV masks respectively. 
Table 5.7 %∆ of CVH metrics generated from the VV mask 
 
  
Table 5.8 %∆ of CVH metrics generated from the TLV mask 
 
 
Generally, TLV metrics demonstrate less %∆ between each session when compared to those 
metrics derived from the VV mask. Tables 5.9 to 5.11 shows the results of the voxel-wise 
Spearman correlation of ventilation image signal when considering the inter-session 
correlation and correlation of all inflation levels with FRC+1L for each session respectively. 
 
Table 5.9 Results of the inter-session voxel-wise Spearman correlation 
 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV1  HV2 
RV -15.16 17.33 38.56 -23.96  -0.67 18.54 22.20 1.94 
RV+1L 9.03 -5.59 -14.61 23.17  5.56 1.21 2.14 0.78 
FRC -1.43 2.99 3.30 3.53  -5.00 4.75 7.72 -0.26 
FRC+1L -5.90 -1.89 -3.86 -5.25  6.64 -7.73 -13.18 13.13 
TLC 4.42 5.28 9.34 2.51  -10.44 11.27 17.46 -9.86 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV3  HV4 
RV -10.76 7.09 15.14 -6.78  4.01 22.99 15.92 14.58 
RV+1L -18.22 30.47 50.51 -23.85  0.85 1.02 9.14 0.75 
FRC -13.37 17.19 27.65 -11.3  8.06 -14.21 -20.36 4.55 
FRC+1L 2.43 -2.01 -3.00 0.14  4.90 6.53 12.21 -2.80 
TLC -2.61 19.66 35.69 -2.60  -14.46 -2.99 -4.59 -9.96 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV5  HV6 
RV 3.25 17.93 49.20 -4.11  -8.95 4.66 8.32 -8.87 
RV+1L 3.81 -4.75 -3.83 2.92  0.45 -10.99 -16.46 4.22 
FRC -0.22 4.68 16.03 -8.59  5.08 -12.09 -22.44 4.07 
FRC+1L 4.90 6.52 12.21 -2.80  0.56 9.12 12.25 -1.08 
TLC 5.48 -0.88 -1.53 6.50  7.59 -4.65 -3.20 3.33 
 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV1  HV2 
RV -0.89 0.53 -6.70 -2.27  -10.93 -15.34 -32.49 7.72 
RV+1L 4.96 11.19 20.25 -0.77  -19.19 -4.84 -13.47 36.49 
FRC -5.40 10.57 18.99 0.48  -13.55 5.84 12.95 13.71 
FRC+1L 6.56 -2.51 -0.31 -10.18  2.25 -11.26 -16.48 0.41 
TLC -11.21 -0.28 5.54 13.85  -2.66 13.79 22.26 3.07 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV3  HV4 
RV 4.38 18.64 0.77 -14.25  3.12 15.74 55.23 5.35 
RV+1L 0.79 -0.24 6.11 -0.74  3.72 -12.31 -18.08 -2.56 
FRC 8.30 -6.62 -16.76 -5.49  -0.96 -28.07 -38.81 12.05 
FRC+1L -3.00 -6.50 -18.00 4.54  5.03 0.67 2.53 2.72 
TLC -14.54 -21.19 -39.39 11.69  5.05 1.44 5.40 -4.87 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV5  HV6 
RV -9.15 14.41 42.11 10.37  -16.61 4.53 29.55 39.17 
RV+1L 0.67 -7.22 -12.01 -4.62  9.43 -4.82 -17.46 -19.75 
FRC 5.03 -19.77 -34.89 -4.19  -1.33 -1.45 -7.00 -3.69 
FRC+1L 0.41 36.65 92.16 1.38  -5.92 -11.82 -21.54 5.68 
TLC 7.58 3.96 12.65 -3.13  4.50 15.38 34.95 -2.99 
 
S1 V S2 
Subject RV RV+1L FRC FRC+1L TLC 
HV1 0.88 0.91 0.91 0.89 0.90 
HV2 0.94 0.94 0.97 0.98 0.94 
HV3 0.95 0.97 0.95 0.96 0.91 
HV4 0.95 0.97 0.96 0.95 0.93 
HV5 0.94 0.93 0.95 0.95 0.96 
HV6 0.88 0.92 0.96 0.96 0.95 
Mean(SD) 0.92(0.03) 0.94(0.03) 0.95(0.02) 0.95(0.03) 0.93(0.02) 
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In this cohort of healthy volunteers there was strong correlation between images acquired in 
different sessions, suggesting very little change in the distribution of gas in ventilated regions 
over the two sessions at each inflation level. 
 
Table 5.10 Results of the voxel-wise correlation of all other inflation levels to FRC+1L from the first 
imaging session 
 
 
Table 5.11 Results of the voxel-wise correlation of all other inflation levels to FRC+1L from the second 
imaging session 
 
 
As can be seen from tables 5.10 and 5.11 the image with the highest correlation to FRC+1L is 
FRC, which is logical considering the small inhalation from FRC+1L to FRC. Additionally, 
RV and TLC had good correlations with FRC+1L and, as one would expect from comparing 
the images visually and the different breathing manoeuvre employed prior to imaging, 
RV+1L had a lower correlation with FRC+1L when compared to all other inflation levels. 
 
As an additional measure of repeatability, lung volumes over all volunteers were compared 
via a paired t-test/Wilcoxon matched-pairs signed rank tests (depending on the normality of 
the data). Table 5.12 shows the summary of comparisons. As can be seen all comparisons 
have a p-value >0.1, showing that there is no significant difference between the lung volumes 
over the sessions in this cohort of healthy volunteers.  
 
All V FRC+1L S1 
 
 
 
 
 
 
 
 
 
 
 
Subject RV RV+1L FRC TLC 
HV1 0.80 0.58 0.85 0.68 
HV2 0.86 0.51 0.94 0.71 
HV3 0.84 0.68 0.97 0.80 
HV4 0.83 0.88 0.88 0.70 
HV5 0.78 0.41 0.91 0.68 
HV6 0.82 0.60 0.94 0.85 
Mean(SD) 0.82(0.03) 0.61(0.16) 0.91(0.05) 0.74(0.07) 
All V FRC+1L S2 
 
 
Subject RV RV+1L FRC TLC 
HV1 0.79 0.56 0.89 0.73 
HV2 0.89 0.60 0.97 0.80 
HV3 0.82 0.63 0.95 0.83 
HV4 0.82 0.79 0.87 0.61 
HV5 0.76 0.39 0.88 0.73 
HV6 0.85 0.52 0.92 0.86 
Mean(SD) 0.82(0.05) 0.58(0.13) 0.91(0.04) 0.76(0.09) 
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Table 5.12 P-value comparing TLV, VV and %VV 
 
 
Table 5.13 P-value comparing CVH metrics generated from the VV mask between each session 
Acquisition Median  
CV 
CVH 
skewness 
CVH 
kurtosis 
CVH 
IQR 
RV     0.2162     <0.001     0.0682 <0.001 
RV+1L     0.9579     0.8433     0.7403     0.9458 
FRC     0.6571     0.9649     0.9352     0.8438 
FRC+1L     0.6030     0.9239     0.9152     0.8202 
TLC     0.6115     0.3435     0.3242     0.5377 
 
Table 5.14 P-values comparing CVH metrics generated from the TLV mask between each session 
Acquisition Median 
CV 
CVH 
skewness 
CVH 
kurtosis 
CVH 
IQR 
RV 0.2155 0.3265 0.5609 0.4214 
RV+1L 0.9196 0.3260 0.2407 0.8998 
FRC 0.6182 0.2859 0.2022 0.8438 
FRC+1L 0.6211 0.9860 0.8691 0.9159 
TLC 0.5752 0.5625 0.4375 0.7188 
 
When considering the metrics generated from the VV mask the only significant differences 
were seen with CVH skewness and IQR at RV, whilst for the metrics generated from the TLV 
mask there were no significant differences seen in any metric between any sessions. 
 
The most interesting discovery is that the highest observed CV is at RV+1L with Figure 5.10 
showing an example from HV2. As can be seen at FRC+1L there are few small defects in this 
posterior slice yet at RV+1L there seems to be the appearance of defects and ventilation 
heterogeneity possibly caused by airways which have not reopened after inhalation from RV 
[89]. As discussed by West if only a small inspiration occurs from RV this does not 
sufficiently change the intrapleural pressure, particularly at the base, however it should be 
noted that in this cohort the lack of airway opening seems to occur throughout the lung and 
not only the base.  
Acquisition TLV VV %VV 
RV 0.5655 0.9778 0.2435 
RV+1L 0.7815 0.8883 0.3725 
FRC >0.9999 0.8438 0.4630 
FRC+1L 0.1913 0.1528 0.7022 
TLC 0.5062 0.7846 0.1320 
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Figure 5.10 Example of differences seen in HP 3He images acquired at RV, RV+1L and FRC+1L 
(posterior slices). (a) HP gas image slice acquired at RV, (b) corresponding CV map, (c) HP gas image 
slice acquired at RV+1L, (d) corresponding CV map, (e) HP gas image slice acquired at FRC+1L and (f) 
corresponding CV map generated from the VV mask 
 
Median CV at FRC+1L and RV+1L differed in all volunteers as seen in Figure 5.7. Table 
5.15 shows the mean absolute %∆  of median CV between FRC+1L and all other lung 
volumes.  
 
Table 5.15 Mean absolute %∆ of median CV between FRC+1L and all other lung volumes 
 
 
Two of the six volunteers had very small percentage increases in median CV between 
FRC+1L and RV+1L whilst four had comparatively large increases. Additionally, four of the 
6 volunteers had a greater than 10% increase in median CV at RV when compared to 
FRC+1L whilst two had a less than 10% difference, with HV4 having only a 2.59% change in 
median CV. Median CV at TLC has a greater than 9% difference in all subjects with HV2 and 
HV6 having the greatest differences. This pattern of increased CV in the posterior slices was 
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
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Introduction
Aim
Methods
Results and Discussion
• Lung ventilation imaging with hyperpolarized (HP) gas MRI can be used to derive quantitative 
measures of lung function1
• Lung inflation state has been shown to affect the heterogeneity of lung ventilation images in patients 
with asthma between functional residual capacity (FRC) and total lung capacity (TLC)2
• Increased ventilation heterogeneity has also been observed in elite divers imaged close to residual 
volume (RV) compared to normal controls imaged close to FRC3
• Assessing the effect of lung inflation state on the reproducibility of percent ventilated volume (%VV)1, 
total lung volume (TLV), ventilated volume (VV) and coefficient of variation (CV)4 is an important step 
for better quantification of longitudinal change and intervention response
Conclusions and Future Work
• To evaluate same-session reproducibility of different inflation levels and how they affect quantitative 
measurements of lung ventilation imaging
• This study in healthy volunteers has shown that the most reproducible lung volumes for ventilation imaging 
appear to be FRC+1, RV and TLC
• Imaging the lung at different inflation levels may allow for better understanding of ventilation defect 
presentation and pulmonary function
• Ventilation heterogeneity increases were seen in HVs at low lung volumes
• Future work shall focus on examining these inflation levels in volunteers using hyperpolarized Xenon-129
1Academic Unit of Radiology, University of Sheffield, Sheffield, UK;2Sheffield Children’s Hospital, Sheffield, UK;
• 5 healthy volunteers were assessed twice, volunteers were given ten minutes rest between the two 
imaging sessions – remaining in the scanner throughout
• Images were acquired at five lung volumes (highlighted in red in Figure 1) following the maneuvers 
shown in Figure 1
• A qualified respiratory physiologist gave breathing instructions
MR Imaging
• 3D 3He ventilation images (bSSFP) and same-breath5 1H images (SPGR) were acquired at 1.5T (GE 
HDx, Milwaukee, WI).  Imaging parameters: voxel size = 4x4x5mm, 40-48 slices, 3He: 
TE/TR=0.6/1.9ms, flip angle=10⁰, 1H TE/TR=0.6/1.5ms, flip angle = 5⁰.
• HP 3He dose ranged from 150-200ml depending on the inflation level and was topped up to 1 liter 
with nitrogen
References: [1] Woodhouse et al. J Magn Reson Imaging, 2005, 21(4):365-369; [2] Marshall et al. Proc Americal Thoracic Society
AJRCCM 2013;187:A3744; [3] Muradyan et al. J Appl Physiol 2010 109(6):1969-73; [4] Tzeng et al. J Appl Physiol 2009 106(3):813-
22; [5] Wild et al. NMR Biomed 2011 24(2):130-4; [6] Hughes et al Proc Intl Soc Mag Reson Med 24(2016) 1622; [7] Weir, J Strength
Cond Res 2005 19(1):231-40; [8] West, Respiratory physiology the essentials 8th edition, 2012; [9] Weibel, Morphometry of the
human lung,1963;
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Analysis
• Images were segmented using spatial fuzzy c-means 
thresholding as previously described6, and TLV, VV and 
%VV were calculated 
• Coefficient of variation of 3He signal intensity (CV) maps 
(Figure 2e) were created by:
• Downsampling DICOM images from 256x256xNslices
to 128x128xNslices
• Eroding the proton mask by 1 pixel to account for 
partial volume effects
• Applying a sliding window of 3x3 voxels (centered on 
each voxel within the binary mask corresponding to 
the ventilated volume1)
• Median values of CV (%) were then extracted
• As measures of reproducibility between repeated 
measurements the coefficient of variation (CoV) was 
calculated7
• Wilcoxon matched-pairs signed rank tests were carried 
out to determine if there were any significant differences 
in the metrics listed above between sessions per 
volunteer
%VV 
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Figure 2. Workflow of image segmentation and metric calculation. 
(a) Example 1H anatomical image slice from a 3D data set, (b) Example 3He image slice from a 3D data set, (c)
and (d) corresponding segmentation slices and (e) example slice of a CV map generated from the 3He image
Figure 1. Breathing maneuvers and 
acquisition volumes. RV = residual volume, 
FRC = Functional residual capacity, TLC = 
total lung capacity 
Figure 4. Example of differences seen in HP 3He 
images acquired at FRC+1 and RV+1 (posterior 
slices). 
(a) HP gas image slices acquired at FRC+1, (b) 
corresponding CV map, (c) HP gas image slices
acquired at RV+1 and (d) corresponding CV map
• Table 1 shows the mean CoV
over all 5 volunteers at each 
inflation level. Regarding TLV and 
VV it seems that the most 
reproducible are RV, RV+1 and 
TLC. When considering %VV 
TLC is the most reproducible 
whilst RV+1 has the most 
variation
Inflation Level CoV %
TLV VV %VV Median CV%
RV 1.91 2.16 0.48 4.38
RV+1 1.46 1.51 1.36 2.44
FRC 4.02 3.81 0.58 4.05
FRC+1 4.43 4.95 0.53 7.18
TLC 1.93 2.11 0.22 3.20
Table 1. Mean CoV over all volunteers between each session
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• Figure 3 shows TLV, VV, %VV and Median CV% for all 5 
volunteers and both imaging sessions. As can be seen 
there is a trend of lower %VV, yet higher median CV% at 
lower lung volumes
• Although CoV of the TLV and VV was relatively high 
between sessions the same level of CoV was not seen in 
%VV 
• A reduction in median CV% was seen at TLC compared 
to FRC+1
• Coefficient of variation increased at RV+1, in comparison 
with FRC+1, for all volunteers. This is mainly due to the 
appearance of defects in the dependent part of the lung 
(e.g. Figure 3) – possibly due to airway closure at lower 
lung volumes8
• One limitation of this study is that data was only acquired 
in healthy volunteers. Additionally some of the inflation 
levels may be difficult for patients to obtain, particularly 
those with severe disease due to loss of lung elasticity 
and gas trapping
Figure 3. Scatter plots of (a) TLV, (b) VV, (c) %VV and (d) Median CV% for all 5 volunteers at each inflation level  
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Introducti n
Aim
Methods
Resul s and Discussion
• Lung ventilation imaging with hyperpolarized (HP) gas MRI can be used to derive quantitative 
measures of lung function1
• Lung inflation state has been shown to affect the heterogeneity of lung ventilation images in patients 
with asthma between functional residual capacity (FRC) and total lung capacity (TLC)2
• Increased ventilation heterogeneity has also been observed in elite divers imaged close to residual 
volume (RV) compared to normal controls imaged close to FRC3
• Assessing the effect of lung inflation state on the reproducibility of percent ventilated volume (%VV)1, 
total lung volume (TLV), ventilated volume (VV) and coefficient of variation (CV)4 is an important step 
for better quantification of longitudinal change and intervention response
Co c us ons and Future Work
• To ev luate same-session reproducibility of different inflation levels and how they affect quantitative 
measurements of lung ventilation imaging
• This study in healthy volunteers has shown that the most reproducible lung volumes for ventilation imaging 
appear to be FRC+1, RV and TLC
• Imaging the lung at different inflation levels may allow for better understanding of ventilation defect 
presentation and pulmonary function
• Ventilation heterogeneity increases were seen in HVs at low lung volumes
• Future work shall focus on examining these inflation levels in volunteers using hyperpolarized Xenon-129
1Academic Unit of Radiology, University of Sheffield, Sheffield, UK;2Sheffield Children’s Hospital, Sheffield, UK;
• 5 healthy volunteers were assessed twice, volunteers were given ten minutes rest between the two 
imaging sessions – remaining in the scanner throughout
• Images were acquired at five lung volumes (highlighted in red in Figure 1) following the maneuvers 
shown in Figure 1
• A qualified respiratory physiologist gave breathing instructions
MR Imaging
• 3D 3He ventilation images (bSSFP) and same-breath5 1H images (SPGR) were acquired at 1.5T (GE 
HDx, Milwaukee, WI).  Imaging parameters: voxel size = 4x4x5mm, 40-48 slices, 3He: 
TE/TR=0.6/1.9ms, flip angle=10⁰, 1H TE/TR=0.6/1.5ms, flip angle = 5⁰.
• HP 3He dose ranged from 150-200ml depending on the inflation level and was topped up to 1 liter 
with nitrogen
R ferences: [1] Woodhouse t al. J Magn Reson Imaging, 2005, 21(4):365-369; [2] Marshall et al. Proc Americal Thoracic Society
AJRCCM 2013;187:A3744; [3] Muradyan et al. J Appl Physiol 2010 109(6):1969-73; [4] Tzeng et al. J Appl Physiol 2009 106(3):813-
22; [5] Wild et al. NMR Biomed 2011 24(2):130-4; [6] Hughes et al Proc Intl Soc Mag Reson Med 24(2016) 1622; [7] Weir, J Strength
Cond Res 2005 19(1):231-40; [8] West, Respiratory physiology the essentials 8th edition, 2012; [9] Weibel, Morphometry of the
human lung,1963;
RV
FRC+1 
FRC 
RV RV+1 
TLC 
FRC 
Inhale 1L 
bag 
Inhale 
room air 
Exhale 
E
xh
al
e 
Inhale 1L 
bag 
Exhale 
Analysis
• Images were egme ted using spatial fuzzy c-means 
thresholdi g as previ usly described6, and TLV, VV and 
%VV were calculated 
• Coefficient of variation of 3He signal intensity (CV) maps 
(Figure 2e) were created by:
• Downsampling DICOM images from 256x256xNslices
to 128x128xNslices
• Eroding the proton mask by 1 pixel to account for 
partial volume effects
• Applying a sliding window of 3x3 voxels (centered on 
each voxel within the binary mask corresponding to 
the ventilated volume1)
• Median values of CV (%) were then extracted
• As measures of reproducibility between repeated 
measurements the coefficient of variation (CoV) was 
calculated7
• Wilcoxon matched-pairs signed rank tests were carried 
out to determine if there were any significant differences 
in the metrics listed above between sessions per 
volunteer
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Figure 2. Workflow of image segmentation and metric calculation. 
(a) Example 1H anatomical image slice from a 3D data set, (b) Example 3He image slice from a 3D data set, (c)
and (d) corresponding segmentation slices and (e) example slice of a CV map generate  from the 3He imag
Figure 1. Breathing maneuvers and 
acquisition volumes. RV = re idual volume, 
FRC = Functional residual capacity, TLC = 
total lung capacity 
Figure 4. Example of differences seen in HP 3He 
images acquired at FRC+1 and RV+1 (posterior 
slices). 
(a) HP gas image slices acquired at FRC+1, (b) 
corresponding CV map, (c) HP gas image slices
acquired at RV+1 and (d) corresponding CV map
• Table 1 shows the mean CoV
over all 5 volunteers at each 
inflation level. Regarding TLV and 
VV it seems that the most 
reproducible are RV, RV+1 and 
TLC. When considering %VV 
TLC is the most reproducible 
whilst RV+1 has the most 
variation
Inflation Level CoV %
TLV VV %VV Median CV%
RV 1.91 2.16 0.48 4.38
RV+1 1.46 1.51 1.36 2.44
FRC 4.02 3.81 0.58 4.05
FRC+1 4.43 4.95 0.53 7.18
TLC 1.93 2.11 0.22 3.20
Table 1. Mean CoV over all volunteers between each session
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• Figure 3 shows TLV, VV, %V  and Median V% for all 5 
volunteers and both imaging sessions. As can be seen 
there is a trend of lower %VV, yet higher median CV% at 
lower lung volumes
• Although CoV of the TLV and VV was relatively high 
between sessions the same level of CoV was not seen in 
%VV 
• A reduction in median CV% was seen at TLC compared 
to FRC+1
• Coefficient of variation increased at RV+1, in comparison 
with FRC+1, for all volunteers. This is mainly due to the 
appearance of defects in the dependent part of the lung 
(e.g. Figure 3) – possibly due to airway closure at lower 
lung volumes8
• One limitation of this study is that data was only acquired 
in healthy volunteers. Additionally some of the inflation 
levels may be difficult for patients to obtain, particularly 
those with severe disease due to loss of lung elasticity 
and gas trapping
Figure 3. Scatter plots of (a) TLV, (b) VV, (c) %VV and (d) Median CV% for all 5 volunteers at each inflation level  
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Introduction
Aim
Methods
Results and Discussion
• Lung ventilation imaging with hyperpolarized (HP) gas MRI can be used to derive quantitative 
measures of lung function1
• Lung inflation state has been shown to affect the heterogeneity of lung ventilation images in patients 
with asthma between functional residual capacity (FRC) and total lung capacity (TLC)2
• Increased ventilation heterogeneity has also been observed in elite divers imaged close to residual 
volume (RV) compared to normal controls imaged close to FRC3
• Assessing the effect of lung inflation state on the reproducibility of percent ventilated volume (%VV)1, 
total lung volume (TLV), ventilated volume (VV) and coefficient of variation (CV)4 is an important step 
for better quantification of longitudinal change and intervention response
Conclusions and Future Work
• To evaluate same-session reproducibility of different inflation levels and how they affect quantitative 
measurements of lung ventilation imaging
• This study in healthy volunteers has shown that the most reproducible lung volumes for ventilation imaging 
appear to be FRC+1, RV and TLC
• Imaging the lung at diffe nt inflation levels may allow for better understanding of ventilation defect 
presentation and pulmonary function
• Ventilation heterogeneity incr ases were seen in HVs at low lung volumes
• Future work shall focus on examining these inflation levels in volunteers using hyperpolarized Xenon-129
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• 5 healthy volunteers were assessed twice, volunteers were given ten minutes rest between the two 
imaging sessions – remaining in the scanner throughout
• Images w r  acquired at five lu g v lumes (highlighted in red in Figure 1) following the maneuvers 
shown in Figure 1
• A qualified respiratory physiologist gave breathing instructions
MR Imaging
• 3D 3He ventilation images (bSSFP) and same-breath5 1H images (SPGR) were acquired at 1.5T (GE 
HDx, Milwaukee, WI).  Imaging parameters: voxel size = 4x4x5mm, 40-48 slices, 3He: 
TE/TR=0.6/1.9ms, flip angle=10⁰, 1H TE/TR=0.6/1.5ms, flip angle = 5⁰.
• HP 3He dose ranged from 150-200ml depending on the inflation level and was topped up to 1 liter 
with nitrogen
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Analysis
• Images were segmented using spatial fuzzy c-means 
thresholding as previously described6, and TLV, VV and 
%VV wer  calculated 
• Coefficient of variation of 3He signal intensity (CV) maps 
(Figure 2e) wer  cre ted by:
• Downsampling DICOM images from 256x256xNslices
to 128x128xNsl ces
• Eroding the proton mask by 1 pixel to account for 
partial volume effects
• Applying a sliding window of 3x3 voxels (centered on 
each voxel within the binary mask corresponding to 
the ventilated volume1)
• Median values of CV (%) were then extracted
• As measures of reproducibility between repeated 
measurements the co fficient of variation (CoV) was 
calculated7
• Wilcoxon matched-pairs signed rank tests were carried 
out to determine if there were any significant differences 
in the metrics listed above between sessions per 
volunteer
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Figure 2. Workflow of image segmentation and metric calculation. 
(a) Example 1H anatomical image slice from a 3D data set, (b) Example 3He image slice from a 3D data set, (c)
and (d) corresponding segmentation slices and (e) example slice of a CV map generated from the 3He image
Figure 1. Breathing maneuvers and 
acquisition volumes. RV = residual volume, 
FRC = Functional residual capacity, TLC = 
total lung capacity 
Figure 4. Example of differences seen in HP 3He 
images acquired at FRC+1 and RV+1 (posterior 
slices). 
(a) HP gas image slices acquired at FRC+1, (b) 
corresponding CV map, (c) HP gas image slices
acquired at RV+1 and (d) corresponding CV map
• Table 1 shows the mean CoV
over all 5 volunteers at each 
inflation level. Regarding TLV and 
VV it seems that the ost 
reproducible are RV, RV+1 and 
TLC. When considering %VV 
TLC is the ost reproducible 
whilst RV+1 has the most 
variation
Inflation Level CoV %
TLV VV %VV Median CV%
RV 1.91 2.16 0.48 4.38
RV+1 1.46 1.51 1.36 2.44
FRC 4.02 3.81 0.58 4.05
FRC+1 4.43 4.95 0.53 7.18
TLC 1.93 2.11 0.22 3.20
Table 1. Mean CoV over all volunteers between each session
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• Figure 3 shows TLV, VV, %VV and Median CV% for all 5 
volunt ers and both imaging sessions. As can be seen 
there is a trend of lower %VV, yet higher median CV% at 
lower lung volumes
• Although CoV of the TLV and VV was relatively high 
between sessions the same level of CoV was not seen in 
%VV 
• A reduction in median CV% was seen at TLC compared 
to FRC+1
• Coefficient of variation increased at RV+1, in comparison 
with FRC+1, for all volunteers. This is mainly due to the 
appearance of defects in the dependent part of the lung 
(e.g. Figure 3) – possibly due to airway closure at lower 
lung volumes8
• One limitation of this study is that data was only acquired 
in healthy volunteers. Additionally some of the inflation 
levels may be difficult for patients to obtain, particularly 
those with severe disease due to loss of lung elasticity 
and gas trapping
Figure 3. Scatter plots of (a) TLV, (b) VV, (c) %VV and (d) Median CV% for all 5 volunteers at each inflation level  
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measures of lung function1
• Lung inflation state has b en show  to affect the heterogeneity of lung ventilation images in patients 
with asthma between functional residual capacity (FRC) and total lung capacity (TLC)2
• Increased ventilation heterogeneity has also been observed in elite divers imaged close to residual 
volume (RV) compared to normal controls imaged close to FRC3
• Assessing the effect of lung inflation state on the reproducibility of percent ventilated volume (%VV)1, 
total lung volume (TLV), ventilated volume (VV) and coefficient of variation (CV)4 is an important step 
for better quantification of longitudinal change and intervention respo se
Conclusions and Future Work
• To evaluate same-session reproducibility of different inflation levels and how they affect quantitative 
measurements of lung ventilation imaging
• This study in healthy volunteers has shown that the most reproducible lung volumes for ventilation imaging 
appear to be FRC+1, RV and TLC
• Imaging the lung at different inflation levels may allow for better understanding of ventilation defect 
presentation and pulmonary function
• Ventilation heterogeneity increases were seen in HVs at low lung volumes
• Future work shall focus on examining these inflation levels in volunteers using hyperpolarized Xenon-129
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• 5 healthy volunteers were assessed twice, volunteers were given ten minutes rest between the two 
imaging sessions – remaining in the scanner throughout
• Images were acquired at five lung volumes (highlighted in red in Figure 1) following the maneuvers 
shown in Figure 1
• A qualified respiratory physiologist gave breathing instructions
MR Imaging
• 3D 3He ventilation images (bSSFP) and same-breath5 1H images (SPGR) were acquired at 1.5T (GE 
HDx, Milwaukee, WI).  Imaging parameters: oxel size = 4x4x5mm, 40-48 slices, 3He: 
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Analysis
• Images were segmented using spatial fuzzy c-means 
thresholding as previously described6, and TLV, VV and 
%VV were calculated 
• Coefficient of variation of 3He signal intensity (CV) maps 
(Figure 2e) were created by:
• Downsampling DICOM images from 256x256xNslic s
to 128x128xNslices
• Eroding the proton mask by 1 pixel to account for 
partial volume effects
• App ing a sliding window of 3x3 voxels (centered on 
each voxel within the binary mask corresponding to 
the ventilated volume1)
• Median values of CV (%) were then extracted
• As measures of reproducibility between repeated 
measurements the coefficient of variation (CoV) was 
calculated7
• Wilcoxon matched-pairs signed rank tests were carried 
out to determine if there were any significant differences 
n the metrics listed ab v  between sessions per 
volunte r
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Figure 2. Workflow of image segmentation and metric calculation. 
(a) Example 1H anatomical image slice from a 3D data s t, (b) Example 3He image slice from a 3D data set, (c)
and (d) corresponding segmentation slices and (e) example slice of a CV map generated from the 3He image
Figure 1. Breathing maneuvers and 
acquisition volumes. RV = residual volume, 
FRC = Functional residual capacity, TLC = 
total lung capacity 
Figure 4. Example of differences seen in HP 3He 
images acquired at FRC+1 and RV+1 (posterior 
slices). 
(a) HP gas image slices acquired at FRC+1, (b) 
corresponding CV map, (c) HP gas image slices
acquired at RV+1 and (d) corresponding CV map
• Table 1 shows the mean CoV
over all 5 volunteers at each 
inflation level. Regarding TLV and 
VV it seems that the most 
reproducible are RV, RV+1 and 
TLC. When considering %VV 
TLC is the most reproducible 
whilst RV+1 has the most 
variation
Inflation Level CoV %
TLV VV %VV Median CV%
RV 1.91 2.16 0.48 4.38
RV+1 1.46 1.51 1.36 2.44
FRC 4.02 3.81 0.58 4.05
FRC+1 4.43 4.95 0.53 7.18
TLC 1.93 2.11 0.22 3.20
Table 1. Mean CoV over all volunteers between each session
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• Figure 3 shows TLV, VV, %VV and Median CV% for all 5 
volunteers and both imaging sessions. As can be seen 
there is a trend of lower %VV, yet higher median CV% at 
lower lung volumes
• Although CoV of the TLV and VV was relatively high 
between sessions the same level of CoV was not seen in 
%VV 
• A reduction in median CV% was seen at TLC compared 
to FRC+1
• Coefficie t of var ation increased at RV+1, in comparison 
with FRC+1, for all volunteers. This is mainly due to the 
appearance of defects in the dependent part of the lung 
(e.g. Figure 3) – po sib y due to airway closure at lower 
lung volumes8
• One limitation of this study is that data was only acquired 
in healthy volunteers. Additionally some of the inflation 
levels may be difficult for patients to obtain, particularly 
those with severe disease due to los  of lung elasticity 
nd gas trapping
Figure 3. Scatter plots of (a) TLV, (b) VV, (c) %VV and (d) Median CV% for all 5 volunteers at each inflation level  
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
60% 
0% 
Volunteer FRC+1L  
vs. RV 
FRC+1L  
vs. RV+1L 
FRC+1L  
vs. FRC 
FRC+1L  
vs. TLC 
HV1 12.81 22.78 9.08 9.14 
HV2 6.60 12.34 7.92 34.06 
HV3 35.15 2.41 6.36 14.95 
HV4 2.59 0.92 2.47 13.45 
HV5 14.41 21.64 2.16 14.97 
HV6 18.03 7.73 3.62 24.27 
Mean(SD) 14.93(11.36) 11.30(9.37) 5.27(2.93) 18.37(9.09) 
TLV values 
HV1 15.59 21.98 10.18 8.40 
HV2 6.61 22.51 7.95 34.17 
HV3 36.06 1.90 6.53 14.97 
HV4 2.49 2.43 2.89 13.14 
HV5 14.53 22.28 2.20 14.66 
HV6 19.40 3.08 3.66 24.06 
Mean(SD) 15.78(11.72) 12.36(10.85) 5.57(3.16) 18.23(9.32) 
 
 125 
also seen when taking the median CV of every slice (Figure 5.11), from the images in the first 
imaging session. Additionally, as one would expect in healthy volunteers the pattern of 
change in the CV values calculated from the TLV mask is very similar to those calculated 
from the VV mask. 
 
Figure 5.11 Plots of median CV per slice generated from the VV mask for all 6 healthy volunteers’ images 
obtained with HP 3He during imaging session 1. (a) HV1, (b) HV2, (c) HV3, (d) HV4, (e) HV5 and (f) HV6. 
All inflation levels were acquired using the same imaging volume with the number of slices and field of 
view being kept consistent 
 
As can be seen from Figure 5.11 in five out of the six healthy volunteers there was increased 
median CV, with a steep incline, in the final ten or so posterior slices when comparing 
FRC+1L to RV+1L. High CV values were also seen in the anterior slices, although this may 
be due to less gas reaching this area of the lung due to gravitational dependence as well as 
partial volume effects. These patterns are also seen on the plots when generated from the TLV 
mask metrics (Figure 5.12). 
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Figure 5.12 Plots of median CV per slice generated from the TLV mask for all 6 healthy volunteers’ 
images obtained with HP 3He during imaging session 1. (a) HV1, (b) HV2, (c) HV3, (d) HV4, (e) HV5 and 
(f) HV6. All inflation levels were acquired using the same imaging volume with the number of slices and 
field of view being kept consistent 
 
Figure 5.13 shows a slice-by-slice plot of SNR from all 6 healthy volunteers.  
 
Figure 5.13 Plots of SNR per slice for all 6 healthy volunteers’ images obtained with HP 3He during 
imaging session 1. (a) HV1, (b) HV2, (c) HV3, (d) HV4, (e) HV5 and (f) HV6. All inflation levels were 
acquired using the same imaging volume with the number of slices and field of view being kept consistent 
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As the SNR drops sharply in the most posterior regions this coincides with the increased CV 
in all images. Additionally, the SNR of the anterior and posterior slices is similar in all scans, 
with a general trend of higher SNR in the posterior sections of the lung as one would expect 
due to the gravitational distribution of the gas when a volunteer is supine. Generally, CV 
increases before a noticeable decrease in SNR in the RV+1L images, suggesting this higher 
CV is due to airways not reopening upon inhalation of the 1L bag and not only the reduction 
in SNR. 
5.3.2 Comparison with body plethysmography values 
Figure 5.14 shows a plot of the values of RV, FRC and TLC values measured using MRI and 
body plethysmography (BPleth). To have an accurate comparison to BPleth, TLV masks 
including the major airways needed to be generated as BPleth measures the total compressible 
gas in the thorax. Therefore, following generation of the masks using the method described in 
chapter 3 only minor editing was carried out to ensure no leakage into non-lung areas, with 
the major airways remaining in the mask and contributing to the total lung volume reported in 
this section. 
 
 
Figure 5.14 Plot of lung volumes measured using body plethysmography and MRI. Each point represents 
a measurement from a single subject, error bars represent group means and standard deviations 
 
The values of FRC and TLC as measured using MRI are lower when compared to body 
plethysmography in this healthy cohort. This follows previously reported changes due to 
posture [368-370]. However, the residual volume as estimated by MRI is greater than that 
measured by BPleth, and MRI overestimates FRC compared to BPleth for HV3. Table 5.16 
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shows the difference in volume (L) between body plethysmography and MRI metrics, defined 
as MRI volume – body plethysmography volume. 
 
Table 5.16 Volume difference between MRI derived measures and body plethysmography measures 
 
BP = body plethysmography, S1 = first imaging session, S2 = second imaging session 
 
FRC and TLC from MRI are reduced when compared to body plethysmography with RV 
values being increased. Table 5.17 shows the summary of paired t-test/Wilcoxon matched-
pairs signed rank tests comparing all 6 volunteers’ body plethysmography values to the MRI 
derived metrics. RV and TLC volumes are significantly different from both MRI sessions 
compared to BPLETH whilst FRC values are not. 
 
Table 5.17 P-values comparing Body plethysmography and sessions 1 and 2 (S1/S2) lung volumes 
Volume/Ratio BPleth v S1 BPleth v S2 
RV 0.0074 0.0018 
FRC 0.1910 0.2188 
TLC 0.0039 0.0037 
BPleth = body plethysmography, S1 = first imaging session lung volumes, S2 = second 
imaging session lung volumes 
  
 HV1   HV2  
Lung volume BP S1 S2 S1-BP S2-BP  BP S1 S2 S1-BP S2-BP 
RV 1.57 2.14 2.25 0.57 0.68  1.94 2.31 2.33 0.37 0.39 
FRC 3.44 2.89 3.06 -0.55 -0.38  3.87 3.16 3.5 -0.71 -0.37 
TLC 7.56 6.97 6.87 -0.59 -0.69  6.92 6.39 6.29 -0.53 -0.63 
 HV3   HV4  
Lung volume BP S1 S2 S1-BP S2-BP  BP S1 S2 S1-BP S2-BP 
RV 1.30 1.54 1.56 0.24 0.26  1.42 1.69 1.73 0.27 0.31 
FRC 2.70 3.40 3.39 0.70 0.69  2.63 2.21 2.11 -0.42 -0.52 
TLC 6.84 6.43 6.53 -0.41 -0.31  6.40 6.09 5.97 -0.31 -0.43 
 HV5   HV6  
Lung volume BP S1 S2 S1-BP S2-BP  BP S1 S2 S1-BP S2-BP 
RV 1.95 2.63 2.69 0.68 0.74  1.84 2.85 2.41 1.01 0.57 
FRC 4.95 3.76 3.64 -1.19 -1.31  4.35 4.17 3.59 -0.18 -0.76 
TLC 8.51 7.76 7.88 -0.75 -0.63  8.32 7.17 7.11 -1.15 -1.21 
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5.3.3 Results of multiple inflation analysis using hyperpolarised 
129Xe 
Figure 5.15 shows example slices from ventilation images acquired with 3He and 129Xe from 
all volunteers.  
 
Figure 5.15 Example slices from all five inflation levels in all three healthy volunteers scanned with both 
HP 3He and HP 129Xe. a(i) HV2 3He, a(ii) HV2 129Xe, b(i) HV3 3He, b(ii) HV3 129Xe, c(i) HV6 3He and 
c(ii)HV6 129Xe 
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As can be seen the SNR of the 129Xe images is generally slightly lower than that of the 3He 
images particularly at the RV and RV+1L images, a pattern seen in all three volunteers. 
Additionally, there are more apparent defects appearing at RV+1L when using 129Xe when 
compared to 3He. Following analysis of the RV images acquired in HV3 it became apparent 
the coil was not receiving in the posterior right section due to almost complete disappearance 
of the right lung. Due to this the metrics acquired at RV using 129Xe were considered 
unreliable and hence could not be compared to those values acquired with 3He. 
 
Figure 5.16 shows the (a) SNR change of all images acquired using 3He and 129Xe for the 
three volunteers analysed here and (b) the distribution of the SNR of images acquired using 
both gases. As can be seen 129Xe SNR is generally lower for all acquisitions. 
 
 
Figure 5.16 Plots comparing the SNR from each session using 129Xe and 3He for the three volunteers 
analysed using both gases. (a) the SNR change for 3He and 129Xe and (b) Plots comparing the SNR from 
each session. Each point represents a measurement from a single subject, error bars represent group 
means and standard deviations 
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Table 5.18 shows the coefficient of variation analysis results of TLV, VV and %VV. Note 
that HV3 data was excluded from CoV analysis at RV. %VV is highly reproducible at all 
inflation levels with TLC having the lowest CoV. TLC also has the best repeatability in terms 
of TLV and VV. 
Table 5.18 Mean CoV over all volunteers between each session 
Acquisition TLV VV %VV 
RV 3.33 1.34 3.98 
RV+1L 2.19 2.26 1.16 
FRC 5.88 4.80 1.49 
FRC+1L 6.88 6.00 3.18 
TLC 1.97 1.91 0.62 
 
Table 5.19 CV metrics CoV over all volunteers between each session 
Acquisition Median  
CV 
CVH  
skewness 
CVH  
kurtosis 
CVH  
IQR 
RV 9.37 9.27 12.25 5.41 
RV+1L 7.60 10.91 14.33 8.02 
FRC 2.86 10.12 10.83 4.86 
FRC+1L 3.74 7.75 10.10 4.02 
TLC 4.62 9.51 10.30 3.21 
TLV values 
RV     6.73     5.76     7.60 4.89 
RV+1L     6.41     9.35    18.14 6.96 
FRC     3.02    14.77    19.11 5.57 
FRC+1L     3.88    34.39    41.91 4.28 
TLC     4.48    12.84    38.73 2.94 
 
Figure 5.17 shows Bland-Altman plots of TLV, VV and %VV. When compared to the Bland-
Altman plots shown in Figure 5.8 it is clear that the intersession agreement of the metrics 
obtained using 129Xe is poorer than the agreement of the metrics obtained when using 3He. 
 
Figure 5.17 Bland-Altman plots of (a) TLV, (b) VV and (c) %VV for all 3 volunteers 
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Figure 5.18 shows the Bland-Altman plots of CVH metrics generated using the VV (a-d) and 
TLV mask (e-h). Generally, the agreement of these metrics is good with the IQR, as one 
would expect, being very reproducible across sessions. However, the TLV mask CVH 
skewness and kurtosis’ reproducibility is substantially lower than that of the VV mask values.  
 
Figure 5.18 Bland-Altman plots of CVH metrics generated from the VV mask (a-d) and TLV mask (e-h). 
(a) Median CV, (b) CVH skewness, (c) CVH kurtosis, (d) CVH IQR, (e) Median CV, (f) CVH skewness, (g) 
CVH kurtosis, and (h) CVH IQR 
 
Table 5.20 shows the %∆ over both sessions for TLV, VV and %VV derived from 129Xe and 
3He ventilation-weighted and 1H anatomical images in HV2, HV3 and HV6.  
 
Table 5.20 Comparison of %∆ of TLV, VV and %VV calculated using 129Xe and 3He datasets 
 
 
Table 5.21 shows the %∆ of all CV metrics generated using both the VV and TLV masks.  
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(e) (f) (g) (h)
HV2 129Xe  HV2 3He 
Acquisition TLV VV %VV  TLV VV %VV 
RV -7.30 -8.04 -0.80  0.26 1.21 0.95 
RV+1L -8.95 -9.87 -1.01  15.79 18.38 2.24 
FRC 1.16 3.23 2.04  -1.88 -1.82 0.05 
FRC+1L 3.37 2.34 -1.00  10.99 11.45 0.41 
TLC -1.67 -2.92 -1.27  -4.06 -4.19 -0.13 
HV3 129Xe  HV3 3He 
Acquisition TLV VV %VV  TLV VV %VV 
RV NA NA NA  1.63 1.16 -0.45 
RV+1L -0.84 4.15 5.04  -3.93 -4.17 -0.25 
FRC -7.10 -2.60 4.85  1.76 2.44 0.66 
FRC+1L -4.62 -6.57 -2.05  -0.07 -1.75 -1.68 
TLC 2.63 2.50 -0.13  6.22 5.85 -0.35 
HV6 129Xe  HV6 3He 
Acquisition TLV VV %VV  TLV VV %VV 
RV -8.03 0.89 9.69  -14.19 -13.40 0.92 
RV+1L 1.19 -0.66 -1.83  -5.90 -5.22 0.73 
FRC -7.57 -5.92 1.79  -0.79 -1.05 -0.27 
FRC+1L -17.16 -10.66 7.84  -16.95 -11.65 6.27 
TLC 3.98 2.70 -1.23  -5.95 -6.92 -1.03 
 
 133 
Table 5.21 %∆ of CVH metrics generated from the VV and TLV masks 
 
 
Figure 5.19 shows plots of TLV, VV and %VV calculated using 129Xe and 3He for HV2, HV3 
and HV6 for sessions 1 and 2. %VV is generally lower when measured using 129Xe compared 
to 3He.  
 
 
Figure 5.19 Plots of TLV, VV and %VV 129Xe and 3He datasets. (a) TLV, (b) VV and (c) %VV. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
FG shows plots of median CV when generated from the VV mask (a) and the TLV mask (b) 
using both HP 129Xe and 3He. Median CV is generally increased in images acquired with HP 
129Xe when compared to HP 3He. 
 
Figure 5.20 Plots of median CV generated from the (a) VV mask and (b) TLV mask. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV2 VV metrics  HV2 TLV metrics 
RV -11.84 -3.36 -7.45 -10.43  -13.77 -18.65 -27.77 0.41 
RV+1L 10.48 -11.56 -10.48 12.33  -6.19 -13.15 -23.99 -7.28 
FRC 7.31 20.66 16.98 15.95  -1.54 13.84 10.50 3.39 
FRC+1L -1.94 17.82 23.08 3.20  -0.02 38.99 79.54 3.06 
TLC -4.35 38.13 41.46 4.36  -12.63 -30.31 -51.47 -5.18 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV3 VV metrics  HV3 TLV metrics 
RV NA NA NA NA  NA NA NA NA 
RV+1L -6.02 -0.32 -2.36 -7.19  11.23 -14.38 -34.03 9.87 
FRC -1.77 14.79 21.87 2.08  -4.19 9.73 -8.85 -5.71 
FRC+1L -0.19 8.85 9.80 2.07  -12.21 44.37 31.02 -13.38 
TLC -13.00 2.82 1.11 -5.95  -1.22 -9.84 -48.21 -2.73 
Acquisition Median CV CVH skewness CVH kurtosis CVH IQR  Median CV CVH skewness CVH kurtosis CVH IQR 
HV6 VV metrics  HV6 TLV metrics 
RV 7.03 -14.38 -14.97 8.79  -16.5 -7.79 4.32 -21.9 
RV+1L 16.04 -28.83 -38.29 16.14  10.71 -9.62 -8.32 13.40 
FRC -1.95 -9.94 -10.06 -3.73  7.23 50.68 89.51 15.54 
FRC+1L -10.50 8.39 13.69 -11.21  -3.37 125.05 177.49 0.80 
TLC 1.11 5.68 8.63 -3.17  -4.22 8.76 -27.22 4.47 
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Figure 5.21 shows scatter plots comparing TLV, VV and %VV acquired with 129Xe and 3He.  
 
 
Figure 5.21 Scatter plots comparing (a) TLV, (b) VV and (c) %VV generated from images acquired with 
129Xe and 3He 
 
TLV and VV have strong correlations whilst %VV is poorly correlated. One possible cause 
for this was the requirement of registration to calculate %VV from the 129Xe and 1H 
anatomical images which may introduce error as discussed by Horn et al. in their paper 
discussing ventilation volume percentage calculation [66]. The poor correlation of %VV may 
be expected as it has previously been shown that any airway obstruction or even partial 
obstruction is present causing lower signal, and thus lower %VV, due to the poorer diffusivity 
of the xenon gas compared to helium [60].  
 
Figure 5.22 shows scatter plots of median CV generated from both the VV and TLV masks. 
Median CV (%) will differ due to the generally lower SNR of the 129Xe images compared to 
the 3He images as was shown in chapter 4. What is interesting to note is that the correlation of 
median CV when generated from the TLV mask is slightly higher than the correlation of 
median CV generated from the VV mask in these healthy volunteers. 
 
 
Figure 5.22 Scatter plots comparing (a) median CV generated from the VV mask and (b) median CV 
generated from the TLV mask from images acquired with 129Xe and 3He 
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5.3.4 The effect of inflation level on MRI-based measures of lung 
function demonstrated in patients with CF and asthma 
Figure 5.23 shows plots of all metrics analysed in the cohorts presented at both FRC+1L and 
TLC generated from the VV mask. As can be seen VDP in both the patients with CF and 
asthma cohorts is higher than that seen in the HV cohort (Figure 5.23c). Additionally, CV 
metrics follow the same patterns as those discussed in Chapter 4.  
 
 
Figure 5.23 Plots of all metrics at both inflation levels analysed for all cohorts generated from the VV 
mask. (a) Median CV%, (b) VDP, (c) CVH skewness, (d) CVH kurtosis and (e) CVH IQR. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations. 
 
Figure 5.24 shows the plots of all CV metrics generated using the TLV mask at FRC+1L and 
TLC. When considering the CVH kurtosis measured using the TLV mask the patients with 
asthma values become more widely spread when compared to the CVH kurtosis measured 
using the VV mask. It should be noted however that five of the six patients are very well 
grouped with only one patient having markedly different values at FRC+1L to the rest of the 
group and only two patients having different values at TLC to the rest of the group. 
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Figure 5.24 Plots of all CV metrics analysed at both inflation levels analysed for all cohorts generated 
from the TLV mask. (a) Median CV%, (b) VDP, (c) CVH skewness, (d) CVH kurtosis and (e) CVH IQR. 
Each point represents a measurement from a single subject, error bars represent group means and 
standard deviations. 
 
Figure 5.25 shows example images at FRC+1L and TLC from the HV, patients with CF and 
asthma groups. As can be seen there is a decrease of ventilation heterogeneity as assessed 
visually with some defects resolving at TLC in the patients’ images. 
 
 
 
Figure 5.25 Example slices from datasets acquired at FRC+1L and TLC. a(i) healthy volunteer FRC+1L, 
a(ii) healthy volunteer TLC, b(i) CF FRC+1L, b(ii) CF TLC, c(i) asthma FRC+1L and c(ii) asthma TLC 
 
This is further evidenced by the reduction in VDP at TLC in four out of six of the patients 
with CF and all six of the patients with asthma (Figure 5.26), however even with this 
reduction at TLC the VDP seen in both CF and patients with asthma is higher than that seen 
in the HVs at TLC. Increased VDP at TLC in some healthy volunteers is due to coil 
sensitivity effects at the diaphragm (e.g. see TLC images of HV1 and HV6, Figure 5.3). 
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Figure 5.26 Change in VDP for all cohorts analysed 
 
When considering CV metrics generated from the VV mask, CVH skewness increased in five 
out of the six healthy volunteers from FRC+1L to TLC, whilst it increased in all CF patients 
and five of the six patients with asthma (Figure 5.27) suggesting a shift of the peak location of 
the histogram towards 0 at TLC as confirmed by comparing histograms (Figure 5.28) from 
the datasets shown in Figure 5.25. When considering CVH skewness generated using the 
TLV mask all subjects demonstrated increased skewness at TLC when compared to FRC+1L. 
 
 
Figure 5.27 CVH Skewness change from FRC+1L to TLC for all cohorts generated from the (a) VV mask 
and (b) TLV mask 
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Figure 5.28 Example histograms for the datasets shown in Figure 5.25. (a) healthy volunteer, (b) patient 
with CF and (c) patient with asthma histograms generated from the VV mask. As shown in Figure 5.27 
the pattern is the same for metrics generated using the TLV mask 
 
CVH kurtosis followed the same pattern as skewness, increasing at TLC when compared to 
FRC+1L, in four out of the six healthy volunteers, all six CF patients and five of the six 
patients with asthma (Figure 5.29) when generated from the VV mask. When considering the 
metrics generated from the TLV mask one healthy volunteer has a marked increase of kurtosis 
at TLC compared to FRC+1L, whilst all other subjects have moderate increases as seen in the 
metrics generated from the VV mask. 
 
Figure 5.29 CV Kurtosis change from FRC+1L to TLC for all cohorts from the (a) VV mask and (b) TLV 
mask 
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CVH IQR (Figure 5.30) decreased in five of the six healthy volunteers and decreased in all 6 
of the patients with CF and all 6 of the patients with asthma, this suggests a tighter grouping 
of values of CV at the higher inflation level when generated from the VV mask. When 
considering the metrics generated from the TLV mask the patterns were the same. 
 
 
Figure 5.30 CV IQR change from FRC+1L to TLC for all cohorts from the (a) VV mask and (b) TLV 
mask 
 
Marked decreases in four of the six CF patients and two of the six patients with asthma CVH 
IQR values suggest a drastic alteration in the distribution of the gas within the lung possibly 
due to improved ventilation in areas affected by mucus plugging in the patients with CF and 
possible airway opening due to increased pressure in the patients with asthma. Table 5.22 
shows the results of comparing the metrics obtained at FRC+1L to TLC in all cohorts 
analysed. As can be seen there is a significant difference in all CV metrics in patients with CF, 
whilst for patients with asthma only CVH IQR is significantly different. Patients with asthma 
are the only group to display a significant difference in VDP. Median CV is the only metric to 
significantly change from FRC+1L to TLC for the HA group. 
 
Table 5.22 Wilcoxon matched-pairs results of comparing metrics at FRC+1L and TLC in all cohorts 
analysed using CV metrics generated from both the VV and TLV masks 
Metric HA CF  Asthma 
VDP 0.4375 0.1562 0.0312 
Median CV 0.0312 0.0312 0.0625 
CVH skewness 0.0938 0.0312 0.1562 
CVH kurtosis 0.0938 0.0312 0.1562 
CVH IQR 0.0625 0.0312 0.0312 
TLV values 
Median CV 0.0312 0.0312 0.0625 
CVH skewness 0.0312 0.0312 0.0312 
CVH kurtosis 0.0312 0.0312 0.0312 
CVH IQR 0.0625 0.0312 0.0312 
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Table 5.23 shows the results of the Kruskal-Wallis test comparing healthy volunteers to the 
patient cohorts. When considering the metrics generated from the VV mask the difference in 
metrics at TLC between the healthy volunteers and patients with asthma became more 
significant in four of the six metrics, with a decreased significance in VDP when compared to 
those results obtained at FRC+1L. All metrics were more significantly different between 
healthy volunteers and patients with CF at FRC+1L when compared to those at TLC. When 
considering the metrics generated from the TLV mask the difference between median CV at 
TLC between the healthy volunteers and patients with asthma became more significant when 
compared to FRC+1L, as did CVH skewness and kurtosis although these metrics could not 
distinguish the groups. CVH IQR became less significantly different. Median CV and CVH 
IQR were more significantly different between healthy volunteers and patients with CF at 
FRC+1L when compared to those at TLC whilst CVH skewness and kurtosis became more 
significantly different at TLC when compared to FRC+1L. 
 
Table 5.23 Results of the Kruskal-Wallis test comparing healthy volunteers to the patient cohorts 
 
 
When comparing the VV and TLV mask generated CV metrics ability to differentiate the 
patients with asthma and healthy adult groups at FRC+1L median CV was less significantly 
different using the TLV mask when compared to the VV mask metrics, whereas CVH 
skewness and kurtosis are unable to differentiate the groups using the TLV mask, although 
CVH IQR is significantly different where it is not using the VV mask. At TLC, median CV is 
more significantly different as is CVH IQR, although neither the VV mask or TLV mask 
generated IQR can differentiate the groups at TLC. When considering the healthy adults and 
CF group median CV is slightly more significantly different at FRC+1L using the TLV mask 
when compared to the VV mask, however CVH skewness, kurtosis and IQR are less 
significantly different, with the same pattern persisting at TLC. 
Metric FRC+1L asthma TLC asthma FRC+1L CF TLC CF 
VDP 0.0070 0.0137 0.0116 0.0257 
Median CV 0.0099 0.0024 0.0049 0.1032 
CVH skewness 0.0299 0.0137 0.0013 0.0257 
CVH kurtosis 0.0463 0.0221 0.0007 0.0161 
CVH IQR 0.0611 0.1168 0.0009 0.0034 
TLV metrics 
Median CV 0.0116 0.0049 0.0041 0.0908 
CVH skewness >0.9999 0.8981 0.1032 0.0401 
CVH kurtosis >0.9999 0.4684 0.0463 0.0132 
CVH IQR 0.0463 0.0908 0.0013 0.0049 
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5.4 Discussion 
The finding of increased ventilation heterogeneity at lower lung volumes, specifically RV+1L, 
in healthy volunteers is interesting indicating partial airway closure in certain lung fields. This 
was mostly seen in the posterior section of the lung, consistent with the gravitational 
dependence of the lung in the supine position [371, 52]. The volume inhaled was 1L, which is 
similar to the volumes used by Muradyan et al. [363] in their experimentation, and the results 
seen here are very similar to those seen in this paper, with a patchier distribution of 
ventilation quantified by the increased CV at RV+1L when compared to FRC+1L.  
 
Notice that at all inflation levels the lung has high CV towards the anterior portion, however 
in four out of six of the volunteers the posterior portion of the lung shows the highest CV. 
However, it should be noted that the higher CV seen at RV+1L is caused by the fact that this 
is the only image acquired from RV. This was done as the dependence of the metrics on 
inflation level was a secondary objective of the study with the prime objective being 
repeatability of metrics at different inflation levels. Were this experiment to be redesigned all 
images would be acquired from RV with the aid of spirometric gating. An additional 
limitation is the separate-breath acquisition of the anatomical and 129Xe scans requiring 
registration between them to calculate %VV. As noted by Horn et al. [66] registration will 
introduce some error into the calculation of %VV and this may be particularly problematic in 
this study due to the participants being asked to inhale to the highest and exhale to the lowest 
volumes possible. Additionally, the lower diffusivity of xenon compared to helium may cause 
lower %VV values and in combination with lower SNR this may lead to the poorer 
repeatability of the %VV derived from xenon when compared to helium [60]. The increased 
median CV at all lung volumes is most likely due to the decreased SNR of the 129Xe images.  
 
The closing volume of healthy lungs is also a key point to consider when reviewing the results 
of this study, as it is known that with aging the lung becomes less elastic and hence the 
volume at which airway closure begins will increase, with airway closure occurring at FRC 
around 45 years of age [372]. Additionally, with some of the volunteers here being occasional 
or former smokers there may be some detrimental effect on the airways from this past activity, 
although there was still a change in ventilation heterogeneity at different lung inflation levels 
seen in the never smokers (HV5 and HV6). 
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By carrying out imaging acquisitions in patients at different inflation levels the fixed or 
temporally reversible nature of focal ventilation defects may be understood more clearly. 
Indeed, as seen in the patients with CF and patients with asthma at TLC there was decreased 
VDP in some patients suggesting resolution of defects by increasing the pressure in the 
airways with the deep inspiration. However, it is noted that not all defects resolved and there 
was a clearer improvement in ventilation homogeneity at TLC in the severe CF patients 
compared to the milder patients. Additional work to co-register high-resolution CT images of 
the airways and identify the cause of defects is needed in order to draw concrete conclusions 
on the cause of some defects resolving and others not in this cohort of patients. 
 
The comparatively large between session CoV in TLV and VV derived from MR images and 
smaller between session CoV seen in measures of %VV further confirm the body of evidence 
[58, 60, 63, 66] that this measure is a robust global metric of lung ventilation. The good inter 
scan repeatability of %VV also suggests that it is a good candidate marker of lung ventilation 
change in response to treatment. However, the relatively large between session CoV seen in 
the median coefficient of variation of signal intensity suggests this measure of image texture 
may be less reliable as a global index of ventilation heterogeneity. It is possible that 
normalisation of the image, such as conversion to fractional ventilation values [326], may 
improve the repeatability of a normalised CV metric.  
 
The differences between body plethysmography and MRI derived FRC and TLC are as one 
would expect to see from the literature due to the different postures adopted for each test 
[368-370]. However increased measures of RV when using MRI when compared to BPLETH 
(measured using BPLETH, supine RV is lower than sitting RV [373]) may be caused by the 
confounding factors of MRI segmentation e.g. inclusion of small vessels which will take up a 
higher proportion of the total lung volume at RV, discussed in more detail in the discussion 
section of chapter 3. 
 
Generating CV metrics over the total lung volume mask following the method of Tzeng et al. 
[326] rather than over the ventilated volume mask yielded similar CVH metrics in most of the 
healthy volunteers and generally less reproducible metrics over two sessions. In addition, 
these metrics generally became less significantly different when comparing healthy adults to 
patients at FRC+1L and TLC, suggesting that from this specific group of data generating 
metrics over the ventilated volume mask is optimal for separation of health from disease. 
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5.5 Conclusion 
This work has shown that although TLV and VV may vary relatively largely between imaging 
acquisitions there is little effect on the quantitative ratio of lung function (%VV) often used in 
the pulmonary MRI community in these healthy volunteers. Additionally, this work has 
shown that even in healthy volunteers, increased ventilation heterogeneity is seen at lower 
lung volumes, using both 3He and 129Xe. Patients with CF and asthma imaged at FRC+1L and 
TLC showed some resolution of ventilation defects at TLC with decreased ventilation 
heterogeneity also clearly seen and quantified using CV. This indicates that imaging patients 
over a range of inflation levels and with different gas inhalation/exhalation manoeuvres may 
allow for better understanding of ventilation defects and pulmonary mechanics.  
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CHAPTER 6. QUANTITATIVE 
MEASUREMENT OF THE VENTILATION-
PERFUSION RATIO USING HP GAS AND 
DCE-1H LUNG MRI 
6.1 Introduction 
The primary function of the lung is to facilitate gas exchange. Gas exchange is affected by 
changes in ventilation (V) and perfusion (Q) and pulmonary diseases may directly or 
indirectly affect the V/Q ratio due to issues such as thickening of the alveolar-capillary walls 
and reduced blood flow [374, 81, 64, 375] resulting in areas of shunt and wasted ventilation 
as shown in Figure 2.2. V/Q matching allows oxygen uptake and carbon dioxide excretion to 
occur most efficiently, as these are both passive mechanisms that depend on the concentration 
gradients over the alveolar-capillary barrier [376]. Therefore, if a detrimental change in 
ventilation occurs, a decrease in V/Q, poor alveolar ventilation and also removal of oxygen 
from the alveolus outweighing the delivery to it occurs. These changes cause a reduction in 
the partial pressure of oxygen whilst the partial pressure of carbon dioxide is increased. 
Additionally, if areas of the lung are poorly perfused, an increase in V/Q, the delivery of 
oxygen will increase relative to its removal, and the amount of carbon dioxide delivered back 
to the alveolus from the blood will decrease, with alveolar partial pressure of oxygen 
increasing and the partial pressure of carbon dioxide reducing.  
 
Measurement of the V/Q ratio and quantification of gas exchange is a key area of research 
within the MR community as many diseases may affect both V and Q, for example recent 
work has shown that there is a vascular component (Q) involved in airway remodelling in 
asthma [361, 377, 378] as well as the well-known airways obstruction (V). Kelly et al. [379] 
have recently demonstrated that in asthma hypoxic pulmonary vasoconstriction (HPV) is not 
the only mechanism behind perfusion redistribution in asthma suggesting that multimodal 
imaging is necessary to truly understand this complex disease. There has also been evidence 
of perfusion defects present in patients with CF [380, 381]. Identification of perfusion defects 
in patients with COPD and emphysema is important, particularly if they are being considered 
for procedures such as lung volume reduction surgery. It is therefore important for the 
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development of image processing workflows allowing the combination of multimodal 
imaging techniques including HP gas MRI, DCE-1H MRI and possibly CT [256] to improve 
the current understanding of ventilation and perfusion in respiratory diseases. The next 
section of this chapter discusses previous methods for analysing V/Q relationships in the lung. 
6.1.1 Review of PFT and imaging methods to analyse V/Q in the 
lung 
To date only small patient numbers have been used in the attempt to quantify V/Q with HP 
gas and DCE-1H MRI [95]. However quantification of regional V/Q with Positron Emission 
Tomography (PET) has been explored [97, 382-384], and the MIGET pulmonary function test 
has been demonstrated to provide highly valuable information on the V/Q ratio within the 
lung [385, 8]; albeit without regional information. The most commonly employed method for 
imaging V/Q in the clinic is V/Q scintigraphy [9, 12], followed by V/Q SPECT [27, 28, 162, 
204, 386], whilst it is also possible to measure V/Q with dual-energy CT [163, 387, 164, 25]. 
There have been other methods to measure V/Q using MR imaging including the work of 
Henderson et al. [52] which combined specific ventilation (SV) imaging using oxygen 
enhanced 1H MRI and ASL imaging simultaneously to calculate the V/Q ratio whilst HP gas 
MRI has also been combined with ASL to calculate V/Q [388, 56, 389]. 
6.1.1.1 Multiple Inert Gas Elimination Technique 
Wagner developed the MIGET technique [385, 390] and analysis method in the mid 1970s. 
The MIGET technique [385] is based on the work of three different groups from which the 
V/Q equations approximated for oxygen and carbon dioxide were derived [8], which led to 
the realisation that the partial pressures of oxygen and carbon dioxide (PO2 and PCO2 
respectively) are set by the local V/Q ratio for given boundary conditions, with the effects of 
V/Q matching on these quantities being discussed in the introduction to this chapter. The 
MIGET technique is based on applying these equations to inert gases. Due to the nature of 
these inert gases it is known that the fraction of the gas retained is a function of the blood-gas 
partition coefficient and the V/Q ratio. This has been researched extensively [8], with the 
most well-known work coming from Kety [391] and Farhi [392, 393]. The MIGET technique 
is invasive, as it requires venous injection of a mix of six inert gases, of variable solubility, 
and saline. The method also requires extraction of systemic and pulmonary blood to monitor 
gas retention and excretion. In addition, the levels of expired gas are analysed. Following the 
collection of these samples gas chromatography is used to analyse the levels of gas present 
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and the data are analysed using the MIGET algorithms, which use a least squares fitting 
algorithm to find the best fit to the theoretical excretion and retention (from the equations) 
and the actual data (from the samples). The limitations of this technique are mainly theoretical 
as stated by Wagner [8]. However, the major practical limitations are the inherent 
invasiveness of drawing blood and the technique’s ability to only provide whole lung 
measurements of V/Q. 
 
With the desire for regional information and reduced invasiveness, V/Q analysis using 
imaging methods is particularly attractive. With established clinical perfusion imaging 
methods based on scintigraphy it is necessary for the injection of an ionizing contrast agent. 
The improved spatial resolution of MRI over nuclear scintigraphy and SPECT for assessment 
of vasculopathy [386] makes MR perfusion imaging combined with HP gas ventilation even 
more attractive in comparison to these techniques. 
6.1.1.2 Nuclear scintigraphy 
VQ scintigraphy is a well-established method and is still used widely in clinical practice since 
its introduction some 40 years ago. The inhalation of a gas contrast agent is used for 
ventilation imaging and intravenous administration of a 99T labelled contrast agent is required 
for perfusion imaging [9, 12] with the radiation captured by a gamma camera. 
 
During a SPECT V/Q scan the patient will inhale a radioactive inert gas or a labelled aerosol 
such as 99mTc-diethylenetriaminepentaacetic acid [27, 29] whilst the perfusion scan is usually 
carried out following the ventilation scan using 99mTc-macroaggregated albumin [29, 386]. 
V/Q SPECT is currently the preferred clinical screening test for chronic thromboembolic 
pulmonary hypertension [386] and has also been used in the analysis of patients with COPD 
[394]. SPECT provides improved visualisation of V/Q over scintigraphy as it allows for 3D 
imaging. Although both of these methods are well known in the clinic the radiation dose is an 
issue, particularly for longitudinal studies, as is the poor spatial resolution and lack of 
structural information. 
6.1.1.3 Position emission tomography  
PET has proven potential for measuring regional V/Q [395, 97, 396]. The method described 
in [97] is based on the kinetics of the tracer used (13NN), which has advantages over MRI 
since both V and Q are measured with the same tracer. For this work Melo et al. began 
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imaging sheep at apnoea following the injection of a bolus of the tracer for sixty seconds. 
They then resumed ventilation of the animal and analysed the washout of the tracer and based 
on the low solubility of their tracer in blood and tissues could estimate regional perfusion 
based on the radioactivity measured during apnoea. Ventilation was then estimated by taking 
the inverse of the time constant of their model. A limitation of PET is the spatial resolution 
but the temporal resolution of the tracer kinetics is high. The ionising nature of PET does not 
allow for longitudinal studies and although it provides functional information it is limited in 
its ability to deliver structural information, an area where MRI has been proven to be sensitive 
and capable [38, 176, 34, 208, 397].  
6.1.1.4 CT 
Dual energy CT is an emerging field and a recent publication demonstrated the feasibility of 
combined V/Q imaging [160] in patients with suspected pulmonary embolism (PE). To 
acquire the V scan an inhalation of radio-dense xenon is used to differentiate from tissue and 
for the Q scan an injection of iodinated contrast is used and the images are acquired in a 
single breath hold. The clear advantage of dual energy CT over MR is the increased image 
resolution, however again this is an ionising imaging modality, exposing patients to a 
significant amount of radiation when compared to SPECT or nuclear scintigraphy [398, 399]. 
6.1.1.5 Oxygen enhanced 1H MRI 
The method proposed by Henderson et al. [52] builds on some of their previous work [400, 
371, 44] by incorporating quantifiable ASL imaging with specific ventilation (SV) imaging. 
The SV image is acquired in cycles of breathing room air and 100% oxygen with a single 
slice 1H MRI acquisition. The volume of fresh gas in the voxels is then estimated, since 
oxygen changes the _z within the lung appreciably. This method builds upon previous studies 
[401-405, 44, 406], however with this method there are disadvantages. One key disadvantage 
is the basic registration method employed, where data is discarded if the movement in the 
lung is too large, which could lead to erroneous values in the final analysis. Furthermore, the 
SNR of the resulting images is low, although it does employ 1H MRI, which is readily 
available for use in many medical institutions. An additional assumption is that the changes 
seen assume a constant perfusion input with all signal change being the result of changes in 
O2 and ventilation, though this may not be the case in reality. Results with SV are promising, 
but clear and convincing comparisons to HP gas MRI have not yet been presented. Recent 
work by Sa et al. [407] compared the results from this methodology to the MIGET technique. 
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Close correlation of measures of the V/Q ratio were observed between the MRI and MIGET 
methods, and it was suggested that this non-contrast methodology is suitable for use in clinic 
[407]. However, the fact that only one slice of the lung is analysed and the lengthy acquisition 
time are clear disadvantages of this method. 
6.1.1.6 Free-breathing 1H MRI 
Recent work has focused on non-contrast enhanced methods to measure V and Q with 1H 
MRI using a methodology termed Fourier decomposition (FD) MRI [179-182, 184, 185]. To 
derive parametric maps from these images requires analysis of the signal change observed 
during inspiration and expiration, this can be separated from changes in signal intensity based 
on the cardiac pulsatility. These physiological processes can then be spectrally retrieved from 
the timeseries data and used to generate ventilation and perfusion weighted images [180]. 
Bauman et al. [180] compared FD MRI to nuclear medicine methods of SPECT and CT in 
porcine lung and found qualitative agreement between the techniques. A study comparing 
DCE-1H MRI and perfusion-weighted FD MRI [181] in patients with CF determined that 
perfusion-weighted FD MRI provides equivalent diagnostic information to DCE-1H MRI. 
Lederlin et al. [182] displayed good reproducibility of V and Q images derived from FD MRI 
in healthy volunteers suggesting that this may be a useful technique in future, particularly in 
patients with renal failure or small children. Kjorstad et al. [183] also developed a method to 
quantify perfusion using FD MRI which produced results comparable to other published 
methods, whilst Capaldi et al. compared ventilation images acquired using FD MRI to 3He 
ventilation images [408] where they found a strong relation between FD MRI and 3He 
ventilation images for COPD but not in bronchiectasis. Voskrebenzev et al. acquired images 
in two healthy volunteers and patients with CTEPH, COPD and CF [187]. This study did not 
compare the ventilation and perfusion weighted images acquired using the FD MRI technique 
to any other imaging technique. 
6.1.1.7 Hyperpolarised gas PO2 mapping 
The method described by Rizi et al. [57] and Wild et al. [409] measures the regional alveolar 
partial pressure of oxygen within the lung (PAO2) by building on previous methods in which 
the oxygen-dependent decay of HP 3He signal is described [410], and essentially the method 
developed allowed the conversion of regional PAO2 to regional V/Q measurements. To 
measure this HP 3He was mixed with N2 and pure O2 gas and this mixture was injected into 
pig lungs and imaged at breath hold. One drawback to be seen from this method is that it 
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requires two scans to be carried out to differentiate between RF induced depolarisation and O2 
induced _z decay, this is done by comparison of the two scans. Due to the model used to 
calculate this regional V/Q numerous sources of error can be introduced although from the 
results obtained it seems to match well with the literature [411, 412]. Although this study 
provided promising results the necessity of two HP gas scans and the complex model and 
analysis mean that it is not particularly feasible to include in everyday clinical use. However 
recent studies have acquired these images in the same breath-hold in human subjects [413, 64] 
meaning that this method could be adapted and used more frequently in the clinical research 
setting.  
6.1.1.8 Dissolved phase 129Xe MRI 
Recent work with gaseous and dissolved phase 129Xe MR imaging may be used to measure 
the regional gas exchange within the lung [80]. The results obtained in reference [97] show 
that prior to any embolism or bronchoconstriction that V/Q ratios are narrow and unimodal 
and these distributions become wider and bimodal after bronchoconstriction. The use of 
dissolved phase xenon for assessment of perfusion however relies on the fact that the lungs 
need to be ventilated in order to deliver xenon to the capillaries via alveolar gas exchange, the 
technique therefore shows perfusion where there is VQ matching but will be less effective at 
demonstrating a true picture of absolute perfusion. 
6.1.1.9 Combined HP gas and DCE-1H MRI 
Crémillieux et al. [388] were among the first to display the possibility of combining DCE-1H 
MRI and 3He MRI and demonstrate the possibility of acquiring these types of images in rats. 
Lipson et al. [56] demonstrated the usefulness of acquiring V and Q images in humans in a 
small study using ASL and 3He V images whilst Rizi et al. also acquired images in healthy 
volunteers [414]. Their qualitative analysis of the images again showed that these imaging 
modalities are sensitive to pulmonary disease and have improved resolution over the current 
gold standards in the clinic. However, the clear drawback here is the lack of quantitative 
analysis in comparison with the nuclear medicine methods, this is one of the key challenges in 
calculating V/Q with MRI. Marshall et al. [68, 415] developed a method to combine the 
information from 3He MRI and DCE-1H MRI to analyse the V/Q ratio in asthmatic patients in 
response to bronchodilator (BD) and also in patients with CTEPH before and after pulmonary 
endartorectomy [68].  
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In the work presented here quantitative ventilation [326] and perfusion metrics [83, 205] were 
generated from HP 3He ventilation-weighted and DCE-1H images which have been co-
registered. The aim of this work was to compare metrics developed using these co-registered 
images from patients with asthma and COPD to healthy volunteers. 
6.2 Quantitative perfusion analysis theory 
As stated in chapter 2, section 2.4.2 tracer kinetic theory is often used to quantify pulmonary 
perfusion in terms of the primary hemodynamic parameters of pulmonary blood flow (PBF), 
pulmonary blood volume (PBV) and mean transit time (MTT). PBF, PBV and MTT are 
derived based on the kinetic theory of tracers in stationary or linear systems [416, 47, 144, 
417, 202, 418]. By assuming a closed one-compartment model there is an assumption that the 
tracer will have negligible leakage into the extracellular space during the first pass [144]. 
Additionally, this model assumes conservation of volume of the tracer entering and exiting 
the system at a constant flow. There are numerous other models that can be used to examine 
pulmonary perfusion which can be used depending on the acquisition length and temporal 
resolution with a list found in table 3 of reference [205]. 
 
To obtain the aforementioned parameters it is necessary to know how the tracer behaves as it 
first enters the pulmonary vascular system and then how it behaves as it passes through the 
system and also to convert from signal intensity to contrast agent concentration. The initial 
behaviour in pulmonary perfusion is described by the arterial input function (AIF) where a 
region of interest (ROI) is usually drawn in the main pulmonary artery to extract a curve 
representing the passage of the bolus through the artery. To convert signal in a voxel to 
contrast agent concentration it is necessary to have the _z measurements from the same voxel 
pre, during and post contrast administration. Contrast concentration is proportional to the 
relaxation rate at time o (defined as 1/_z) minus the relaxation rate at time zero divided by the 
relaxivity of the contrast agent being used [419]: 
 
Using this and a signal-formation model based on the sequence applied (in this work a 3D 
SPGR sequence was used which spatially matches the subsequent DCE time resolved imaging 
sequence) it is possible to calculate the _z at each time point for all voxels in the lung and 
 CA t = 	 1_z(o) − 1_z,RÇz = 	 1Çz 	»z − »z,R (6.1)  
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convert the signal intensity to the contrast agent concentration. The first step is to estimate _z,R by acquiring images pre-contrast administration. The method used here was the variable 
flip angle method [420] with three different flip angles of 2, 10 and 30 degrees. Note that 
other _z  mapping methods such as inversion recovery [421] and the Look-Locker method 
[422, 423] are available and the inversion recovery method is seen as the gold standard, whilst 
recent developments have also allowed the use of ultra-fast modified look-locker SSFP 
imaging to measure _z [424]. 
 
By fitting each voxel in the three flip angle maps using equation 6.2 and the Levenberg-
Marquardt non-linear least squares fitting algorithm values of baseline _z (_z,R) and proton 
spin density (cR) can be extracted [420, 425]. 
 
To enable measurement of _z,R and cR the sequence TR must be kept constant and this will 
then result in a curve characterized by _z [145] with each point on the curve defined at each 
flip angle measured. To extract the values of _z,R and cR this equation can also be linearized 
and solved in the form of equation 6.3: 
 
Where  $ is XY9ä 9| . Where the _z,R (equation 6.4a) and cR (equation 6.4b) are defined by 
the slope (F) and y-intercept (∆) values obtained [145]: 
 
 
Following determination of these values, the _z,R and cR maps will need to be registered to 
the dynamic acquisition in order to convert signal intensity to contrast agent concentration. 
This is dependent on the sequence used and the conversion algorithm used is shown below. 
Relaxivity (Çz) of the Gd agent used here was assumed to be 5.2 L/mmol sec-1 as shown in the 
Gadovist™ (Bayer Schering Pharma, Germany) data sheet. The dynamic contrast enhanced 
 ÜBáàâ = cR 1 − XY9ä 9|1 − XY9ä 9| ∙ cos(k)	sin(k) (6.2)  
 ÜBáàâsin(k) =  $ ÜBáàâtan k .cR(1 −  $) (6.3) 
 _z,R = 	 −_»ln(F) (6.4a) 
 cR = 	 ∆1 − F (6.4b) 
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sequence TR was 2.297ms and the flip angle was 30o. Gadovist was administered at 
0.05ml/kg at a rate of 4ml/s with a saline flush of 20ml/s. This dose was used over the 
recommended 0.2ml/kg as in some cases patients were scanned twice on the same day and 
hence it was necessary to remain within local hospital dosing rules. Secondly at higher 
concentrations the relationship between signal intensity and contrast agent concentration is 
non-linear [426, 419] and this would impact the analysis methodology introduced in this 
section. Of course the need to measure pre-contrast _z  is determined by the relationship 
between the relative signal enhancement and contrast concentration – if this relationship is 
non-linear then the approach of normalising the signal time-course to the baseline signal time-
course acquisition, as Nikolaou et al. [213] amongst others have used, would not be 
appropriate. To assess this relationship for the specific sequence parameters used here the 
approach of Schabel et al. was used [428], where relative signal enhancement is calculated by 
equation 6.5: 
 
 
Where Oz,R = expY9ä∙ä|,œ , Oz = expY9ä∙ä| , Og,R = expY96∙ä~,œ∗ , Og = expY96∙ä~∗ , where »z,R 
and »z  are defined as in equation 6.1 and »g,R∗ = z9~,œ∗  and »g∗ = z9~∗ . Relaxation rates were 
assumed to scale linearly with contrast agent concentration [428] and thus »z = 	»z,R +Çz ∙ •∏  and »g= 	»g,R + Çg ∙ •∏ . Çz  was set to 5.2 L/mmol-1sec-1 and Çg  was set to 6.1 
L/mmol-1sec-1. For both the simulations in Figures 6.1 and 6.2 _g,R∗  was estimated as 1.4ms 
with a _z,R of lung and blood set as 1200ms, with the range of contrast concentrations being 
the same. 
 
As is done in most work the  _g∗ component is ignored thus for the simulations to determine _z  dependence this was done [428]. For simulations, the _z  of lung tissue and blood was 
defined as an equispaced vector ranging from 200ms to 2500ms and contrast agent 
concentration (CA) was defined as an equispaced vector (with the same number of points as 
the _z vector) ranging from 0 mmol/litre to 10 mmol/litre. Figure 6.1 shows a plot of the 
percentage signal enhancement against a range of _z values for a number of contrast agent 
concentrations (a) and for a fixed contrast agent concentrations of 1 to 5mmol/litre (b). As can 
be seen there appears to be increased _z dependence at higher contrast agent concentrations 
with a CA of 10 mmol/litre causing anywhere from 5% to 70% enhancement depending on 
∆``R = 	 (Oz − 1)(Oz,R cos k − 1)(Oz,R − 1)(Oz cos k − 1)	 OgOg,R − 1 (6.5) 
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the _z . These simulations show that measurement of pre-contrast _z  is a necessary step, 
particularly in the lung where there is a large range of _z values. 
 
 
Figure 6.1 Simulated curves of relative signal enhancement as a function of concentration of contrast 
agent. (a) Varying #$ and contrast agent concentration and (b) Varying #$ and fixed contrast agent 
concentrations between 1 and 5mM 
 
Additionally, not including the _g∗ effects may be detrimental to the calculation, particularly 
in the lung due to the low	_g∗ , as discussed in Chapter 2, compared to other organs. For 
simulation of the effect of including/excluding this effect equation 6.5 was used with and 
without the _g∗ component to generate the curves in Figure 6.2. Figure 6.2 demonstrates that 
in the case of the flip angle used in this work (30o) there is little difference in the percentage 
signal enhancement when considering/not including the _g∗ effects with an average error of 64% 
over the range of contrast concentrations used in simulation, meaning that on average 
excluding the _g∗ leads to a 64% overestimation in percentage signal enhancement. Although 
this value seems large, when considering the percentage increase at a low concentration value 
of 1 mmol/litre this causes a 500% change in signal and thus 64% is negligible, as is proven 
by the near overlap in Figure 6.2, suggesting that it is reasonable to exclude the _g∗ component 
as has been done in previous publications [46, 144]. 
 
Figure 6.2 Simulated curves showing the effect of including/excluding the #&∗  component (a) over a large 
range of contrast concentrations and (b) an enhanced view of concentrations of 0-5 mmol/litre 
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Equations 6.6-6.11 show the way in which the contrast concentration was found [430]. Note 
that ` here refers to the dynamic acquisition signal intensity. 
 
 
 
 
 
 
Where •∏ will be in units of mmol/litre. The next stage of quantitative perfusion analysis is to 
extract the parameters PBF, PBV and MTT. Before applying any modelling techniques the 
data is smoothed via fitting to a Gamma-variate function [431, 82]: 
 
 
Where –G is a constant scale factor, k and — are scale parameters; o is time after injection and ∏_ is the appearance time of the contrast in the voxel being considered. Following the fitting 
of every voxels concentration-time curves the closed compartment model described in detail 
by Ostergaard et al. [83] can be used where the indicator dilution theory provides the 
fundamental method for volume calculation. The CA concentration in a lung voxel is defined 
by [46]: 
 
Where ⨂ is the convolution operator, •7”‘ is the concentration of the CA in the AIF (acquired 
from a region similar to the region of interest shown in Figure 2.13) at time o and » is the 
residue function, defined as the fraction of contrast agent concentration remaining in the lung 
after time o [83, 432, 46]. PBF is usually taken as the maximum value of the result of the 
deconvolution of the •∏®’í÷ and •∏7”‘ concentration-time curves [83].  
∏ = 	` o − `(0)cR sin(k)  (6.6) 
π = 	 1 − XY9ä 9|,œ1 − cos k (XY9ä 9|,œ) (6.7) 
• = 	 1 − (∏ + π)1 − cos k (∏ + π) (6.8) 
»1{ = 	− 1_» ln(C) (6.9) 
»1R = 	 1_z,R (6.10) •üëoÇúÅo	◊üë◊XëoÇúoùüë	 •∏ = 	»1{ − »1R	Çz	  (6.11) 
•∏®’í÷ o = 	–G(o − ∏_)ÿXY({Y79)Ÿ  (6.12) 
•∏®’í÷ o = 	Sπ…(•∏7”‘ o ⨂» o ) (6.13) 
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Deconvolution is a complex procedure and there are different methods that may be used, 
however the most commonly used method of deconvolution in perfusion analysis was applied 
in this work, singular value decomposition (SVD) [83, 433, 434]. The SVD method of 
estimating PBF from contrast enhanced MRI data involves solving a matrix equation formed 
from [83]: 
 
Which can be represented in matrix form as equation 6.15: 
 
 
Where où  and T  denote the time of the ù th acquisition and total number of acquisitions 
respectively. ∆_  is the sampling time of the dynamic acquisition and the matrix •∏7”‘  is 
generated from the sampled values of the AIF over time [435]: 
 
⁄ = •∏7”‘[o1] 0 0 … 0•∏7”‘[o1 + ∆_] •∏7”‘[o1] 0 … 0⋮ ⋮ ⋱ ⋱ ⋮⋮ ⋮ ⋱ 0•∏7”‘[o1 + (T − 1)∆_] •∏7”‘[o1 + (T − 2)∆_] … … •∏7”‘[o1]  
 T is the number of samples used to generate the AIF (the number of time frames in the 
dynamic acquisition) and o1 is the time at which sampling started. »:<; (fi) and •∏{ÉGG’fl (‡) 
are Tx1 vectors representing the residue function multiplied by the PBF and ∆_  and the 
contrast agent in the region of interest respectively. The aim is then to solve the matrix 
equation ‡ =	⁄fi for the value of fi. Using the SVD methodology the inverse of ⁄ can be 
calculated as: 
 ·É	are the diagonal elements of ‚ and „9 is the transpose of „. 
 
This is possible as the SVD methodology expresses the matrix ⁄  as the product of the 
orthogonal matrix „, the diagonal matrix ‚ with a positive or zero element and the transpose 
of the orthogonal matrix ‰ [436].  
•∏®’í÷ o = 	Sπ…∆_	 •∏7”‘ où 	» oÂ − où´É™z  (6.14) 
»:<; = 	 1∆_ •∏7”‘Yz •∏{ÉGG’fl (6.15) 
⁄Y$ = ‰ nùúû(1/·É) „9 (6.16) 
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Note that it is possible to estimate functions for the residue function, for example a box 
function [83, 433], however these estimates may lead to a deconvolution with increased noise 
and affect the value of PBF found. For this work the residue function was assumed to have a 
value of 1 at the initial sampling time-point and was not estimated by any of the functions 
listed in [83, 433]. The matrix fi can then be estimated by: 
The values in the diagonal matrix ‚ are usually thresholded by removing any values less than 
a threshold, typically this threshold is set around 20% of the largest singular values [437], to 
try and reduce the noise in the deconvolution. The maximal value of the matrix fi is then 
taken as the PBF [433]. 
 
The PBV is then given by the time integrated concentration-time curve of the voxel of interest 
within the lung normalised by the time integrated concentration-time curve of the pulmonary 
artery: 
And from the central volume theorem [431, 83] the MTT can be calculated by simply 
dividing the PBV by PBF: 
 
At this point the values returned are not in the standard reporting measures of ml/100ml for 
PBV and ml/100ml/min for PBF [199, 426, 438, 439, 200, 201, 191, 418, 203, 206]. PBV will 
be a dimensionless fraction whilst PBF will be in units of 1/time following deconvolution. 
When expressing these values, it is important to consider the density of the lung tissue and the 
haematocrit factor [83, 208, 419], however it should be noted that in much of the previous 
literature of DCE in lungs these values are not used to calculate PBV and PBF. 
 
It is known that the concentration of the contrast agent will be reduced in tissue capillaries 
(•{¡) when compared to the intravascular space (•ÉÁ) [440] and can be defined by equation 
6.20 [431]: 
fi = ‰ nùúû(1/·É) („9‡) (6.17) 
Sπ4 = 	 •∏®’í÷ o 	noËR •∏7”‘(o)	noËR = È (6.18) 
c__ = 	Sπ4Sπ… (6.19) 
•{¡ = 	È. •ÉÁ (6.20) 
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Where È will be a fraction between 0 and 1 [441].  
 
From the principle of conservation of mass, the amount of contrast agent input to a system 
must equal the amount leaving the system as defined by equation 6.21 [431, 441]:  
Where … is the flow per unit volume. By combining equations 6.20 and 6.21 È is defined as 
fractional blood volume (equation 6.22):  
Therefore to calculate PBV in units of ml/100ml of tissue the fraction È must be multiplied by 
the hematocrit factor (ÍÎ) (the difference between hematocrit in the artery and capillaries 
(equation 6.23a), usually not reported as it close to unity) divided by the tissue density 
(equation 6.23b) [442]. 
Whilst PBF is given by equation 6.23c [441] : 
 
This means that whereas È is a dimensionless unit, PBV is the volume of blood per unit mass 
of tissue and PBF is the flow of blood per unit mass of tissue over time. Also, it should be 
noted that in many cases È  and PBV are used interchangeably within the literature and 
particular care must be taken when reporting these values. Therefore prior to deconvolution it 
is important to transform the CA values from mM/litre to the correct units for flow. This 
transformation is accomplished by firstly converting the CA values to grams/ml by; (1) 
multiplying the CA values by the weight of the gadolinium chelate and (2) dividing by 1000. 
The second stage is to convert the mass into a volume by using a lung tissue density estimate 
… •¿Ö{flÖq o 	no = … •ÉÁ o 	no	{R 	{R  (6.21) 
È = 	 •{ÉGG’fl o 	no{R •ÉÁ(o)	no{R  (6.22) 
ÍÎ = 	 1 − Í¿Ö{flÖq1 − Í¡¿ÆÉ®®¿Öq (6.23a)  
Sπ4 = 	ÍÎe È (6.23b) 
•{ÉGG’fl = 	 eÍÎ . Sπ…. •7”‘(o)⨂» o  (6.23c) 
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(0.2 g/cm3 at inspiration for example) and applying the factor of 100 to get to the standard 
reporting values. 
6.3 Materials and methods 
6.3.1 Participant selection 
To evaluate the V/Q mapping image-processing workflow developed, patient and normal 
subject imaging data was used. Four patients with asthma (denoted A-), five patients with 
COPD (denoted COPD-) and three healthy volunteers (denoted HV-) were scanned for this 
study. Patients with asthma underwent imaging pre and post administration of a 
bronchodilator to assess response to treatment. Subject demographics and PFTs are given in 
Table 6.1. 
Table 6.1 Patient and volunteer demographics 
 
* GINA – global initiative for asthma score [443]; ** % predicted; - data not available; NA – 
not applicable 
6.3.2 Imaging 
6.3.2.1 1H anatomical and 3He ventilation-weighted imaging 
Patients with asthma underwent multi-slice 2D spoiled gradient echo HP 3He ventilation 
imaging following inhalation of 350ml 3He mixed with 650ml N2 from FRC. Prior to the 3He 
scan a 1H anatomical image at the same inflation level as the 3He scan was acquired. For 
COPD patients and healthy volunteers three-dimensional 1H anatomical (SPGR) and HP 3He 
ventilation-weighted (bSSFP) images were acquired during the same breath hold following 
Patient Age Gender GINA*/GOLD FEV1_base** FEV1_post** 
HV1 35 F NA 98.2 NA 
HV2 42 M NA 107.2 NA 
HV3 40 F NA 99.9 NA 
A1 60 F 4 110.3 115.1 
A2 44 M 4 79.6 83.9 
A3 52 F 4 90.1 90.0 
A4 60 M 4 44.2 50.3 
COPD1 61 M - - NA 
COPD2 69 F - - NA 
COPD3 57 M - - NA 
COPD4 59 F - 48.9 NA 
COPD5 67 F - 43.9 NA 
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the methods in [73, 66]. HP gas ventilation-weighted images were acquired followed 
immediately by 1H anatomical images. Patients inhaled 200mL HP 3He mixed with 800mL 
N2 from FRC prior to the scan. Imaging parameters can be seen in Table 6.2. 
 
Table 6.2 Imaging parameters for the sequences used in this work. TR = Repetition time, TE = echo time, 
FA = flip angle. Note that slice number and field of view (FOV) were adjusted per patient to ensure full 
lung coverage 
 
6.3.2.2 Variable flip angle imaging for T1 mapping 
All subjects had three-dimensional SPGR images acquired at flip angles of 2, 10 and 30 
degrees during inspiratory breath-hold to estimate _z and proton spin density of the lungs pre 
contrast adminstration (_z,R and cR). TR and TE were kept constant at 2.85ms and 0.9ms 
respectively. Bandwidth was ±62.5 kHz, with an acquisition matrix of 200x80 and a slice 
thickness of 4mm [144].  
6.3.2.3 DCE-1H imaging 
DCE-1H perfusion-weighted images were acquired following all HP gas images so as not to 
affect the contrast of the ventilation-weighted images. DCE-1H perfusion-weighted images 
were acquired during inspiratory breath-hold using a 3D spoiled gradient echo sequence with 
full lung coverage with an acquisition matrix of 200x80 and 36 time-frames of ~0.5s each 
[216, 214] following injection of 0.05ml/kg gadolinium contrast agent (Gadovist) at 4ml/s 
with 20ml saline flush. TR was 2.2ms, TE was 0.8ms and FA was 30°. 
6.3.3 Image analysis 
Figure 6.3 describes the co-registration and basic analysis steps used in this work. Briefly 
perfusion time-course images were co-registered to the initial time point of the dynamic 
acquisition to reduce motion artifact error in the quantitative pulmonary perfusion analysis. 
Following this, all dynamic contrast enhanced images are co-registered to the _z-weighted 
image acquired using a flip angle of 2° to allow for conversion of signal intensity to contrast 
Acquisition Sequence TR 
(ms) 
TE 
(ms) 
FA 
(o) 
Bandwidth  
(kHz) 
Matrix size 
(frequency x phase) 
FOV 
(cm) 
Voxel size 
(mm) 
Slice thickness 
(mm) 
Slices 
1H (2D) SSFP 2.4 0.7 50 167 128x64 32-42 2.3x3.5-3.2x4.9 10 16-24 
3He (2D) SPGR 3.6 1.1 8 62.5 128x102 32-42 2.3x1.8-3.2x2.5 10 16-24 
1H (3D) SPGR 1.5 0.6 5 167 100x100 40-48 4x4-4.8x4.8 5 46-50 
3He (3D) SSFP 1.9 0.6 10 167 100x80 40-48 4x3.2-4.8x3.8 5 46-50 
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agent concentration. Following registration of the dynamic contrast enhanced images and the _z-weighted image, quantitative pulmonary perfusion analysis is carried out to estimate the 
pulmonary blood volume. The pulmonary blood volume map and peak signal enhancement 
image are then indirectly registered to the same image space as the ventilation image. This 
registration is accomplished by registering the first time point of the dynamic contrast 
enhanced acquisition (which has been co-registered to the _z-weighted image) to the same-
breath 1H anatomical image and applying the transform to the peak signal enhancement image 
and pulmonary blood volume map. Finally, the fractional ventilation and VQ metrics, 
discussed next, are derived. 
 
 
Figure 6.3 Basic representation of the workflow used to analyse V and Q images. Example slices from (a) #$-weighted image used in #$ mapping, (b) peak signal enhancement image, (c) Pulmonary blood volume 
map, (d) fused ventilation-weighted and 1H anatomical image and (e) Fractional ventilation map 
6.3.3.1 Ventilation image analysis 
Ventilation-weighted images were quantified using the method developed by Tzeng et al. 
[326], where the signal intensity of the ventilation image is converted to a fraction of gas in 
the voxel using equation 6.24: 
 FV = 	 1`É,Ì,Z × É`,Ì,Z4ÁÓpfl® (6.24)  
 
Where FV is the fractional ventilation, É`,Ì,Z  is the signal intensity at voxel location ù, Â, ], É`,Ì,Z  is the total signal including airways and 4ÁÓpfl®  is the volume of the voxel. 1H 
anatomical images were registered to ventilation-weighted images using the method presented 
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in chapter 3, section 3.2.7 to compute %VV using the segmentation method described in 
chapter 3. 
6.3.3.2 T1 mapping _z  mapping was carried out following the variable flip angle method described in [144]. 
Images were registered using masked registration, that is masking out everything but the lung 
parenchyma and then registering these masked images, after which the deformation field was 
applied to the unmasked data. To calculate _z,R and cR images were then passed into a Matlab 
function to fit every voxel using a non-linear least squares Levenberg-Marquardt algorithm 
[430, 47, 420, 144].	_z,R and cR images were subsampled to the same number of slices as the 
DCE-1H acquisition. 
6.3.3.3 DCE-1H image analysis 
The DCE-1H time series images were registered to the _z-weighted image acquired with a flip 
angle of 2°. Following registration signal intensity was converted to contrast agent 
concentration and pulmonary blood volume (PBV) was calculated by fitting a gamma-variate 
to every voxel’s concentration-time curve [431, 82, 83, 444, 46] as outlined in section 6.2 and 
applying the deconvolution methodology to estimate values of PBF and MTT, and using 
equation 6.19 PBV was defined as MTT*PBF. Finally, the quantitative PBV map, as well as _z and cR maps were registered to the ventilation image space, and as with the DCE-1H to _z 
registration, ventilation images were subsampled to the same number of slices as the DCE-1H 
acquisition. As in reference [442] PBV was multiplied with a factor Ô to account for lung 
density at the level of inspiration during scanning. For this work Ô = 0.2g/cm3 was used, 
based on lung density measurements acquired from CT at inspiration [445]. Major blood 
vessels were segmented from the peak signal enhancement image by setting a threshold value 
by drawing an ROI in any vessel clearly seen in the lung followed by manual editing to 
ensure no parenchyma was removed. 
 
The region of interest for the calculation of the AIF was manually drawn in the pulmonary 
artery. First DCE-1H images were reviewed to assess at which time point and slice the 
pulmonary artery was most clearly seen. Second a region of interest was drawn using the 
Matlab command roipoly. Finally, all voxels greater or equal to the 95th percentile within the 
region of interest were used from every time point to construct the AIF. 
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6.3.3.4 V and Q metrics 
Dividing the fractional ventilation image by the PBV map generated V/Q ratio maps. 
Additionally, measures of percent ventilated volume (%4ÁÓ® ), percent perfused volume 
(%8ÁÓ®) and percent ventilated and perfused volume (%V∩Q) were calculated. %8ÁÓ® was 
calculated by first manually segmenting the whole lung from the peak signal enhancement 
image, generated by taking the maximum signal intensity over time for every voxel in the 
DCE-1H images that were registered to the ventilation image. Following this the image was 
thresholded to calculate the perfusion defect area, this defect area was then subtracted from 
the whole lung perfusion mask to give the perfused volume (8ÁÓ®). The threshold was defined 
by drawing an ROI in an area of noise and calculating the standard deviation over two slices 
(equation 6.25):  
 
 oℎÇXÅℎü≠n = 2(FXúë(ëüùÅX»Òz + ëüùÅX»Òg)) (6.25) 
 
Any voxel, within the whole lung perfusion mask, in the peak signal enhancement image with 
an intensity lower than the threshold was defined as perfusion defect. 
 
%8ÁÓ® is then defined by equation 6.26: 
 %8ÁÓ® = 8ÁÓ®_ª4 ×100% (6.26) 
 
Where the TLV is defined as the registered 1H anatomical image lung volume.  
 
%V∩Q is defined by equation 6.27: 
 %4 ∩ 8 = 4 ∩ 8_ª4 ×100% (6.27) 
 
In addition to these metrics wasted ventilation (WV) and shunt were also defined using the 3-
compartment model discussed by Peterson and Glenny [81] equations 6.28-6.31 
 
 `ℎÚëo	¨ü≠ÚFX	 `ℎÁÓ® = 8ÁÓ® ∩ 44 ∩ _ª4 (6.28) 
 
 %`ℎÚëo = `ℎÁÓ®_ª4 ×100% (6.29) 
   
 ÛúÅoXn	¨Xëoù≠úoùüë	¨ü≠ÚFX	 Û4ÁÓ® = 4ÁÓ® ∩ 8ÁÓ® ∩ _ª4 (6.30) 
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 %Û4ÁÓ® = Û4ÁÓ®_ª4 ×100% (6.31) 
 
In addition to these metrics histograms were generated to assess the overlap of the FV and 
PBV histograms. To allow this analysis the ranges of the data needed to be made equal, this 
was done by normalising the PBV image to the minimum and maximum values of the FV 
image. Second both images were divided by their mean value and histograms generated using 
100 bins. The location of the bin centres from the FV image were then used to generate the 
PBV image histogram. This normalisation process allowed for the area of the overlap to be 
calculated along with the mutual information (MI) of the histograms. 
6.4 Results 
6.4.1 Healthy volunteers 
Table 6.3 shows the results of each of the aforementioned V and Q metrics for the three 
healthy volunteers. %VV are high as one would expect in healthy volunteers and is in line 
with previously reported results [66]. %8ÁÓ® is also high but slightly lower than %VV in two 
out of the three volunteers, though this may be due to slight registration errors at the periphery 
of the lung. %V∩Q is above 90% for all three volunteers, as one would expect.  
 
Table 6.3 Healthy volunteer V and Q metrics 
Patient %‰Ùıˆ %˜Ùıˆ %V∩Q 
HV1 98.20 93.90 93.32 
HV2 94.49 94.15 90.85 
HV3 98.02 94.29 93.31 
 
Figure 6.4 shows an example FV, PBV and V/Q image from HV1. Both the FV and PBV 
maps are homogeneous with little heterogeneity seen in the V/Q map.  
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Figure 6.4 Example slices from a healthy volunteers (a) FV map, (b) PBV map and (c) V/Q map 
 
Table 6.4 shows the mean values for PBV, FV and V/Q for each of the volunteers. Fractional 
ventilation values are similar to those estimated in healthy volunteers using the multiple 
breath washout technique [67]. It should also be noted that the mean V/Q ratio in two out of 
three of these healthy volunteers is higher than the reported range of 0.8-1.2 [376], although 
this could be due to the gravitational effect of the volunteers being supine and reduced 
ventilation and perfusion seen in the anterior slices, exemplified in the axial view of FV and 
PBV maps shown in Figure 6.5 , note that these are from the same volunteer shown in Figure 
6.4. This pattern of increased PBV and FV towards the posterior section of the lung is 
representative of all volunteers analysed. 
 
Table 6.4 Mean values of PBV, FV and V/Q for the three healthy volunteers 
Patient Mean PBV 
(ml/100ml) 
Mean FV 
 
Mean V/Q 
 
HV1 3.72 0.25 2.34 
HV2 6.47 0.23 1.21 
HV3 5.41 0.22 1.99 
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Figure 6.5 Example axial slices from a HV1s FV and PBV maps. (a) FV slice and (b) PBV slice 
 
Figure 6.6 shows the FV and PBV histograms for all three healthy volunteers whilst Table 6.5 
shows the overlap area and mutual information (MI) values.  
 
 
Figure 6.6 FV and PBV histograms from all three healthy volunteers. (a) HV1, (b) HV2 and (c) HV3. The 
inset on each graph is the FV and PBV histograms plotted on a log x axis 
 
Table 6.5 MI and overlap area of histograms for healthy volunteers 
Patient MI Overlap area 
HV1 0.50 4164 
HV2 0.48 1927 
HV3 0.51 4018 
 
Pulmonary blood volume in these healthy volunteers is slightly lower than previously 
reported values in healthy volunteers [46], however slight differences in deconvolution 
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methodology and image registration will affect the values calculated from the fitted 
concentration-time curves. Additionally, the breath-hold at which the image is acquired will 
affect the perfusion parameters. When comparing our results and the study in [46] it is worth 
noting that in that work the contrast agent concentration was not calculated using _z,R and cR 
maps as there is no mention of the method used to convert the signal intensity to contrast 
agent concentration. In these healthy volunteers, it is clear that there is still some V/Q 
mismatch even after normalization of the data. However, there is a good level of overlap in 
the histograms as exemplified in Figure 6.6.  
6.4.2 Patients with asthma – pre and post bronchodilator 
administration 
Figure 6.7 shows image examples from a patient with asthma with a good ventilation 
response to bronchodilator.  
 
Figure 6.7 Example images from an asthmatic (A1) pre and post bronchodilator administration. (a) FV 
pre, (b) PBV pre, (c) V/Q pre, (d) FV post, (e) PBV post and (f) V/Q post 
 
As can be seen in Figure 6.7 there is clearly a perfusion deficit in the base of the lung, with 
little improvement following the administration of the bronchodilator, this is likely due to 
hypoxic vasoconstriction and the pulmonary vasculature not responding to the increased lung 
ventilation on the time course of the post bronchodilator scan [446, 447, 98, 448]. Table 6.6, 
Figure 6.8 and Table 6.7 shows the V and Q metrics for the asthmatic patients pre and post 
bronchodilator administration, note that no statistical tests were carried out due to the small 
patient numbers. 
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Table 6.6 Asthmatic V and Q metrics pre and post bronchodilator 
 
 
Figure 6.8 Change in %‰Ùıˆ, %˜Ùıˆ and %V∩Q pre and post bronchodilator. (a) %‰Ùıˆ, (b) %˜Ùıˆ and 
(c) %V∩Q 
 
%4ÁÓ® shows increased in all patients, whilst %8ÁÓ® increased in two patients and decreased 
in the remaining two. %V∩Q increases in all four patients. Table 6.7 shows the mean values 
for PBV, FV and V/Q for each of the asthmatic patients pre and post administration of the 
bronchodilator. The %VV values seen in these patients is slightly higher than previously 
reported values [63] however the difference in analysis methods may be a cause of this 
difference. 
Table 6.7 Mean values of PBV and FV for the asthmatic patients 
 
 
Patient %!!"# %!!"# %V∩Q 
A1pre 90.81 87.84 82.02 
A1post 94.43 87.01 84.91 
A2pre 81.99 88.01 76.41 
A2post 84.31 85.65 78.7 
A3pre 95.28 75.36 74.91 
A3post 96.74 90.62 90.1 
A4pre 83.89 79.13 69.09 
A4post 84.33 92.31 80.65 
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Mean V/Q 
 
A1pre 9.09 0.17 0.77 
A1post 7.72 0.14 0.63 
A2pre 6.52 0.17 2.29 
A2post 8.18 0.30 3.27 
A3pre 8.26 0.17 1.57 
A3post 9.56 0.23 1.11 
A4pre 7.04 0.15 1.20 
A4post 6.52 0.19 1.32 
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Mean PBV over the whole lung increased post bronchodilator administration in two of the 
four asthmatics and decreased in the remaining two (Figure 6.9a). Mean fractional ventilation 
decreased in one subject (A1), and increases in patients A2, A3 and A4 increased (Figure 6.9), 
with a marked increase seen in patient A2. Mean V/Q increases in two patients (A2, A4) and 
decreases in the remaining two (A1, A3) suggesting an improvement in matching of V and Q 
for A1 and A3 and a worsening for A2 and A4.  
 
 
Figure 6.9 Change in PBV, FV and V/Q pre and post bronchodilator. (a) FV, (b) PBV and (c) V/Q 
 
Figure 6.10 shows example axial slices from patient A1. Following administration of the 
bronchodilator there is almost no gravitational gradient seen in the FV images whilst PBV is 
much patchier and more heterogeneously distributed when compared to the healthy volunteer 
shown in Figure 6.5. 
 
Figure 6.10 Example axial slices form patient A1. (a) FV pre, (b) FV post, (c) PBV pre and (d) PBV post 
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Figure 6.11 shows FV and PBV histograms for patients with asthma pre and post 
administration of a bronchodilator whilst Table 6.8 shows the overlap area and mutual 
information (MI) values. For this cohort of asthmatics there is slight improvement in the 
overlap of the histograms assessed visually although the overlap area metric does not 
represent this in one out of the four patients with asthma. MI between the FV and PBV 
histograms improves in three out of the four asthmatics, including A1 and A2 where there is a 
decrease in the overlap area of the histograms.  
 
 
Figure 6.11 Example FV and PBV histograms for all patients with asthma. (a) A1 pre BD, (b) A1 post BD, 
(c) A2 pre BD, (d) A2 post BD, (e) A3 pre BD, (f) A3 post BD, (g) A4 pre BD and (h) A4 post BD. The inset 
on each graph is the FV and PBV histograms plotted on a log x axis 
 
 
 
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 0.5 1 1.5 2 2.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 1 2 3 4 5 6
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
100 101 102
FV or PBV
0
2
4
6
Fr
eq
ue
nc
y (
pe
rc
en
t)
100 101 102
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
100 101 102
FV or PBV
0
1
2
3
4
Fr
eq
ue
nc
y (
pe
rc
en
t)
100 101 102
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
100 101 102
FV or PBV
0
2
4
6
8
Fr
eq
ue
nc
y (
pe
rc
en
t)
100 101 102
FV or PBV
0
1
2
3
4
Fr
eq
ue
nc
y (
pe
rc
en
t)
100 101 102
FV or PBV
0
2
4
6
8
Fr
eq
ue
nc
y (
pe
rc
en
t)
100 101 102
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y (
pe
rc
en
t)
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
( )	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
1
2
3
4
5
6
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 1 2 3 4 5 6 7
FV or PBV
0
1
2
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5 4
FV or PBV
0
1
2
3
4
5
6
7
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
0 0.5 1 1.5 2 2.5 3 3.5
FV or PBV
0
0.5
1
1.5
2
2.5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
(a)	 (b)	
(c)	 (d)	
(e)	 (f)	
(g)	 (h)	
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
FV or PBV
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Fr
eq
ue
nc
y 
(p
er
ce
nt
)
FV
PBV
 170 
Table 6.8 MI and overlap area of histograms for patients with asthma 
Patient MI Overlap area 
A1pre 0.31 303 
A1post 0.35 747 
A2pre 0.27 1192 
A2post 0.33 446 
A3pre 0.33 582 
A3post 0.31 730 
A4pre 0.28 1179 
A4post 0.34 1826 
6.4.3 Patients with COPD 
Figure 6.12 shows example images from a patient with COPD. This patient has a large 
amount of ventilation defects with some areas of reduced perfusion, with a heterogeneous 
V/Q map with large areas of high V/Q seen.  
 
 
Figure 6.12 Example slices from a patient with COPD (COPD3) (a) FV map, (b) PBV map and (c) V/Q 
map 
 
Table 6.9 shows the V and Q metrics from the patients with COPD. There is lower %V∩Q 
seen in this group of COPD patients compared to that seen in asthma, due to the increased 
number of defects seen in both the ventilation and perfusion images in the COPD patients 
when compared to the patients with asthma. 
Table 6.9 COPD V and Q metrics 
Patient %‰Ùıˆ %˜Ùıˆ %V∩Q 
COPD1 80.36 72.04 64.10 
COPD2 80.14 65.00 55.80 
COPD3 54.26 68.63 41.26 
COPD4 68.50 70.00 51.80 
COPD5 84.80 74.44 66.81 
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%VV for these patients is within the range of previously reported values [58, 290]. Table 6.10 
shows the mean PBV, FV and V/Q values from the patients with COPD. PBV is within 
previously reported values [449]. Mean V/Q is markedly increased in these COPD patients 
when compared to both asthmatic patients and healthy volunteers. One cause for this is the 
clearer mismatch in areas that are both ventilated and perfused compared to the healthy 
volunteers and patients with asthma. Additionally, the increased heterogeneity within 
ventilated lung contributes to these much higher mean V/Q values. 
 
Table 6.10 Mean values of PBV, FV and V/Q for the patients with COPD 
Patient Mean PBV 
(ml/100ml) 
Mean FV Mean V/Q 
COPD1 7.71 0.09 48.98 
COPD2 6.31 0.14 22.97 
COPD3 4.26 0.15 13.15 
COPD4 4.87 0.13 64.88 
COPD5 5.94 0.12 20.67 
 
Figure 6.13 shows example axial slices of FV and PBV from patient COPD3. This patient has 
a similar perfusion gravitational gradient to the healthy volunteer, although this may simply 
be due to tissue destruction in the anterior portion of the lung.  
 
 
Figure 6.13 Example axial slices from patient COPD3s FV and PBV maps. (a) FV slice and (b) PBV slice 
 
Figure 6.14 shows the FV and PBV histograms of all patients with COPD whilst Table 6.11 
shows the overlap area and MI of these histograms. As can be seen the MI values are 
particularly small in these patients, partially due to the lack of perfused and ventilated tissue 
and the very different distributions seen in FV and PBV. 
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Figure 6.14 Example FV and PBV histograms for all patients with COPD. (a) COPD1, (b) COPD2, (c) 
COPD3, (d) COPD4 and (e) COPD5. The inset on each graph is the FV and PBV histograms plotted on a 
log x axis 
 
Table 6.11 MI and overlap area of histograms for patients with COPD 
Patient MI Overlap area 
COPD1 0.09 48.98 
COPD2 0.14 22.97 
COPD3 0.15 13.15 
COPD4 0.13 64.88 
COPD5 0.12 20.67 
 
These histograms follow the same pattern of high frequency of low PBV values and a broader 
spread of FV values when compared to healthy volunteers. Figure 6.15 shows the V and Q 
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metrics of all three cohorts analysed. COPD patients have the highest variance in values of all 
three cohorts. 
 
 
Figure 6.15 V and Q metrics for all cohorts analysed. (a) %‰Ùıˆ, (b) %˜Ùıˆ and (c) %V∩Q. Each point 
represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
Figure 6.16 shows the estimated percentages of shunt and wasted ventilation using the 
aforementioned techniques. As can be seen healthy volunteers have the lowest levels of shunt 
and wasted ventilation whilst patients with COPD have the highest values for these metrics. 
One interesting finding is the reduced value of shunt and wasted ventilation following 
administration of the bronchodilator to the patients with asthma. 
 
 
Figure 6.16 %Shunt and %WVvol obtained from all cohorts analysed. (a) %Shunt and (b) %WVvol. Each 
point represents a measurement from a single subject, error bars represent group means and standard 
deviations 
 
Figure 6.17 shows plots of mean FV, PBV and V/Q as well as the mutual information and 
overlap area for all cohorts analysed. Healthy volunteers have the higher mean FV but lower 
mean PBV. Population means for the patients with asthma have a trend of improvement in all 
metrics following administration of the bronchodilator. 
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Figure 6.17 Plots of mean FV, PBV and V/Q along with MI and overlap area for all cohorts analysed. (a) 
FV, (b) PBV, (c) V/Q, (d) MI and (e) overlap area 
 
Table 6.12 shows the results of statistical comparisons (p-values) of all metrics derived. All 
groups were compared to the healthy volunteer group via the Kruskal-Wallis test and the 
patients with asthma were then compared pre and post administration of the bronchodilator 
via a Wilcoxon matched-pairs signed rank test, the results of which are shown in Table 6.13. 
 
Table 6.12 P-values from the Kruskal-Wallis multiple comparisons test comparing patient groups to 
healthy volunteers 
Comparison % ˘¯˙˚ %¸˘˙˚ %V∩Q %WVvol %Shunt 
HV vs. Apre 0.3260 0.2215 0.1627 >0.9999 0.8443 
HV vs. Apost 0.7001 0.6477 0.8139 >0.9999 >0.9999 
HV vs. COPD 0.0073 0.0017 0.0017 0.1970 0.0710 
Comparison FV* PBV* V/Q ratio* MI Overlap area 
HV vs. Apre 0.5064 0.0906 >0.9999 0.1616 0.3414 
HV vs. Apost >0.9999 0.0635 >0.9999 0.8118 0.4464 
HV vs. COPD 0.0091 >0.9999 0.2056 0.0016 0.0017 
*Mean over whole lung 
Table 6.13 Wilcoxon matched-pairs signed rank test results 
Comparison % ˘¯˙˚ %¸˘˙˚ %V∩Q %WVvol %Shunt 
Apre vs. Apost 0.1250 0.6250 0.1250 0.3750 0.6250 
Comparison FV* PBV* V/Q ratio* MI Overlap area 
Apre vs. Apost 0.2500 0.8750 >0.9999 0.2500 0.8750 
*Mean over whole lung 
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As can be seen from Table 6.12 the only significant differences were seen between healthy 
volunteers and COPD patients’ values of  %4ÁÓ®, %8ÁÓ®, %V∩Q, %Shunt, FV, MI and 
overlap area. No significant differences were found between any metrics when comparing the 
patients with asthma pre and post bronchodilator. 
6.5 Discussion 
The main aim of this work was to develop and validate the proposed workflow however a 
limitation is the small numbers of healthy volunteers and patients analysed meaning a 
statistical significance cannot be derived and general conclusions may not be derived from the 
results presented. 
 
Patients with COPD had lower %V∩Q than patients with asthma suggesting poorer matching 
of ventilation and perfusion in this small cohort of COPD patients than in the cohort of 
patients with asthma. %V∩Q improved in three of the four patients with asthma analysed and 
dropped by less than 1% in the remaining patient following administration of a bronchodilator. 
 
Lower PBV was seen in the healthy volunteers when compared to some of the patients with 
asthma and COPD. One possible reason for this could be the difference in inspiration level as 
the volumes were not controlled for the DCE-1H and _z-mapping acquisitions and it has been 
shown that PBV increases at expiration compared to inspiration [199]. %8ÁÓ® changed in all 
four patients with asthma following administration of a bronchodilator, with an increase seen 
in two and a decrease seen in the other two. One possible reason for the decrease may be the 
change in inspiration level, with the patient being able to take a larger breath in following 
administration of the bronchodilator. The increase may be caused by minor vasodilation 
effects of the bronchodilator [450] or simply that the breath hold was better held during the 
DCE-1H acquisition meaning less motion induced errors are seen. 
 
Perfusion defects occurred in the same regions of the lung as ventilation defects in most 
patients with asthma (Figure 6.7) and COPD (Figure 6.12), and in some cases in areas where 
there was no apparent ventilation defect. The patient exemplified in Figure 6.7 shows an 
example of HPV causing reduced perfusion in the base of the lung, which remains even after 
administration of a bronchodilator and increased ventilation in this area of the lung suggesting 
that reversing the effects of HPV may be more difficult in asthma than simply oxygenating 
previously hypoxic areas of the lung due to possible vascular remodelling caused by chronic 
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hypoxia. This may help in the treatment of asthma and COPD by demonstrating that 
although %VV improves with treatment the vascular component of the disease may require 
more treatment or be beyond treatment due to the constriction that has taken place and 
possible destruction of the capillary bed, due to the time between the acquisition of the 
ventilation and perfusion images. 
 
Another limitation is the lack of reproducibility data however Ingrisch et al. [206] 
demonstrated that in healthy volunteers PBV was fairly reproducible with moderate ICC, 
although PBF had a low ICC whilst other studies have shown good reproducibility of DCE-
1H MRI [451-453] in patients with cancer. 
 
This method is not without its drawbacks as there are still the time consuming manual stages 
of segmentation of the first time-point of the DCE-1H acquisition and the thresholding to 
determine the vessels and areas of perfusion deficit. Additionally, manual selection of the 
region of interest for the AIF will introduce a source of error into measurements between 
observers, due to the possibility of selecting different slices and region of interest sizes. 
However, the combination of V and Q metrics seems to provide improved difference in the 
patients with asthma pre and post administration of a bronchodilator and also provides good 
grouping of the healthy volunteers. The grouping of the patients with COPD does not improve. 
6.6 Conclusion 
A semi-automated workflow for quantitative evaluation of co-registered ventilation and 
perfusion images was developed and tested in a small cohort of healthy volunteers and 
patients with asthma and COPD. The method allows for voxel-by-voxel comparison of 
ventilation and perfusion whilst also allowing for novel metrics such as percentage ventilated 
and perfused lung to be examined. 
 
Differences were seen between the healthy volunteers and the two patient cohorts analysed, 
although no statistical significance was found when comparing the healthy volunteers and 
patients with asthma. Increased numbers are needed to determine if this method can be used 
in conjunction with standard measures of the ventilation-perfusion ratio and if the metrics 
derived are capable of differentiating health from disease or detecting improvement following 
intervention in patients. 
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CHAPTER 7. CONCLUSIONS AND FUTURE 
WORK 
7.1 Summary of the thesis and conclusions 
This thesis investigated image-processing methods for quantitative evaluation of multinuclear 
magnetic resonance images of the lung. Three distinct analysis pipelines were developed and 
their utility in patients and healthy volunteers was demonstrated. 
 
Chapter 3 introduced a semi-automatic segmentation method for lung MRI using a Spatial 
Fuzzy C-means methodology.  This method reduced inter-observer differences when 
compared to the standard manual method and also provided more similar segmentations to the 
manual method than the well-known K-means method. Its utility was demonstrated in a small 
number of patients with diverse disease and also demonstrated on images acquired with both 
hyperpolarised 3He and 129Xe. 
 
Chapter 4 investigated the use of the coefficient of variation of signal intensity histogram 
metrics in separating health from disease. Histogram metrics were used to differentiate 
healthy controls from patients and compared to the gold standard of ventilation defect percent 
and the standard global metric of median CV. In one case the CV histogram metrics were able 
to differentiate health from disease where VDP could not. In addition, the effect of sequence 
parameters, SNR, kernel size, dimensionality and gas used were investigated with the effect 
on CV metrics shown. 
 
Chapter 5 made use of the segmentation software and the coefficient of variation of signal 
intensity to assess the effect of lung inflation level on quantitative metrics of lung function 
derived from hyperpolarised gas MRI. Six healthy volunteers were scanned to assess the 
repeatability of lung volumes and metrics whilst the effect of inflation level was also 
investigated in a small cohort of patients with asthma and cystic fibrosis. It was shown that 
although lung volumes may vary between sessions the quantitative measure of lung function 
(%VV) is very reproducible between sessions. Additionally, it was shown that %VV changes 
in disease when imaged at total lung capacity compared to functional residual capacity plus 1 
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litre, which may lead to better understanding of the nature of focal defects in patients with 
asthma and cystic fibrosis. 
 
Chapter 6 discussed the development of a workflow for quantitative analysis of the 
ventilation-perfusion ratio using MRI. A workflow was developed to co-register 
hyperpolarised gas and DCE-1H MRI to allow for a voxel-by-voxel comparison of 
quantitative metrics of ventilation and perfusion. Metrics were also developed using the co-
registered images to analyse the severity of perfusion defects and the extent to which 
ventilation and perfusion are matched. This workflow was demonstrated on a small cohort of 
patients and volunteers. 
7.2 Future work 
Chapter 3 
Further automation via addition of a vesselness filter and algorithm to automatically 
determine the optimum number of clusters to use in the Spatial Fuzzy C-means algorithm are 
the main areas to improve the methodology presented in chapter 3. Addition of a vesselness 
filter can be accomplished using the method developed by Frangi et al. [314] whilst 
determining the optimal number of clusters will require experimentation based on the 
distribution of signal intensity values within the lung. 
 
Chapter 4 
Developing a method to denoise the HP gas images and attempt to minimise the effect of 
noise on CV values is a key step to improve the reliability and sensitivity of the CV based 
metrics. Increased numbers of healthy volunteers imaged with both HP 129Xe and 3He are 
needed to determine normal values for each of the CV metrics presented. Additionally, 
increased numbers of patients with a range of pulmonary disease are needed to carry out the 
same simulations and comparisons of kernel size and dimensionality as was done for HP 3He. 
 
Chapter 5 
Increasing the numbers of healthy volunteers and patients with different inflation levels is a 
key aspect of future work to ensure that the pattern of airway closure at lower lung volumes is 
seen in a cohort with a wider age range. Additional patient data may also allow for clearer 
understanding of what defects in different diseases are. A final stage of this work would be to 
add in a registration of high-resolution CT and proton anatomical images to the same space as 
the HP gas images to determine why certain defects resolve and others do not. 
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Chapter 6 
Increased patient numbers analysed using the fully quantitative pipeline to show that the 
metrics developed may be useful in assessing patients, whilst more healthy volunteers are 
needed to determine a normal range for the metrics developed. Combining multiple breath 
washout MRI [69, 70] and free-breathing DCE-1H MRI [203, 206] and comparing the output 
to that obtained from static breath hold images to determine if any changes are seen in the 
metrics developed is an interesting project and could allow for improved patient comfort for 
scanning if a free-breathing DCE-1H MRI can be implemented. Finally comparing the metrics 
developed using HP 129Xe and DCE-1H to those obtained using HP 3He and DCE-1H MRI is 
an important development. 
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